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Summary 
 
Pseudomonas aeruginosa is an opportunistic pathogen that will initiate infection upon local or 
general impairment of the host immune system. As the number of people receiving 
immunosuppression and invasive treatments rises, P. aeruginosa infections are increasingly 
prevalent. P. aeruginosa is intrinsically resistant to many antibiotics but is also able to acquire 
additional resistance mechanisms, giving rise to strains unsusceptible to nearly all available 
antibiotics. However, even in the absence of detectable resistance, infections are often 
difficult to treat. A major factor responsible for treatment failure is the presence of persister 
cells, phenotypic variants of the wild type insensitive to the action of bactericidal agents. 
Upon withdrawal of the antibiotic, persisters revert to regular cells and regrow into a 
susceptible population, causing relapse of infection. They prolong the stay of the pathogen in 
the human body in the presence of antibiotics, leading to an increased probability of 
developing resistance. Targeting these persisters will greatly improve treatment.  
Mechanisms underlying formation of P. aeruginosa persister cells are not fully understood. 
To obtain more insight into the mechanistic basis of persister formation in P. aeruginosa, a 
screening was conducted prior to this work to identify genes involved in fluoroquinolone 
tolerance in this pathogen. In a first part of this thesis, we follow up on this previous research 
by characterizing the newly identified gene named dnpA (de-N-acetylase involved in 
persistence). We demonstrate that dnpA is a bona fide persistence gene, since the persister 
level of the dnpA mutant after fluoroquinolone treatment is strongly reduced but increases 
upon overexpression of dnpA in the wild-type strain. Despite its genomic localization in the 
conserved lipopolysaccharide (LPS) core oligosaccharide biosynthesis gene cluster, no 
obvious role in LPS biosynthesis was demonstrated. A transcriptome analysis indicates that 
DnpA affects the expression of genes involved in surface-associated processes. In support of 
these results, we demonstrate that DnpA is inserted in the inner membrane. Additionally, our 
experiments reveal that correct transmembrane insertion of DnpA, but not membrane 
association per se, is needed to exert its effect on fluoroquinolone tolerance in P. aeruginosa.  
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It is becoming clear that several mechanisms are involved in the formation of persister cells, 
making rational design of an anti-persister therapy difficult. In a second part of this thesis, a 
new research line was initiated in which a top-down approach was used to identify 
compounds that, in combination with conventional antibiotics, reduce the persister fraction of 
P. aeruginosa. We identified three distinct compound families with anti-persister properties. 
Based on a structure activity relationship analysis, the two most promising molecules, named 
SPI001 and SPI002, each belonging to a different compound family, were selected for 
additional experiments. Both compounds are able to reduce the persister fraction of P. 
aeruginosa in combination with mechanistically different antibiotics. Importantly, they also 
show activity against other relevant Gram-negative and Gram-positive pathogens. Further 
characterization of SPI001 reveals biological activity against different pseudomonal clinical 
isolates as well as the ability to improve activity of additional classes of antibacterial agents. 
In addition, we provide evidence that this compound exerts its cidal effect by acting on the 
bacterial membrane. Our results show that SPI001 has the potential to be developed for use in 
an anti-persister therapy.  
The work presented in this thesis contributes to the development of an anti-persister therapy, 
which prevents relapse of infection, and thus positively affects patients’ outcome. 
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Samenvatting 
 
Pseudomonas aeruginosa is een opportunistische pathogeen die infectie kan veroorzaken in 
personen waarin het immuunsysteem geheel of gedeeltelijk is verzwakt. Door een stijging in 
zowel het aantal personen met een onderdrukt immuunsysteem als patiënten die invasieve 
ingrepen ondergaan, zijn P. aeruginosa infecties meer en meer voorkomend. Deze pathogeen 
is intrinsiek resistent tegen vele verschillende klassen van antibiotica en verwerft bovendien 
ook gemakkelijk bijkomende resistentiemechanismen. Hierdoor zijn er reeds stammen 
beschreven die ongevoelig zijn voor bijna alle courant gebruikte antibacteriële middelen. Ook 
indien geen resistentie tegen het gebruikte antibioticum wordt vastgesteld zijn pseudomonale 
infecties vaak moeilijk te behandelen. Een belangrijke factor hiervoor verantwoordelijk is de 
aanwezigheid van persistorcellen, fenotypische varianten van het wildtype die ongevoelig zijn 
voor de bactericidale werking van antibiotica. Na daling van de antibioticumconcentratie op 
de plaats van infectie kunnen deze cellen ontwaken en groeien ze uit tot een gevoelige 
populatie, waardoor de infectie terug opflakkert. Op deze manier verlengen persistorcellen de 
tijd die de bacterie doorbrengt in de gastheer in aanwezigheid van antibiotica, wat de kans op 
ontwikkeling van resistentie verhoogt. Gericht inwerken op deze persistorcellen zal daarom 
de behandeling van infecties aanzienlijk verbeteren.  
De mechanismen die verantwoordelijk zijn voor de vorming van persistorcellen in P. 
aeruginosa zijn nog niet volledig begrepen. Daarom werd eerder in onze onderzoeksgroep een 
screening uitgevoerd ter identificatie van genen betrokken in tolerantie tegen fluorchinolonen 
in P. aeruginosa. In het eerste deel van deze thesis wordt verder gewerkt op dit voorgaand 
onderzoek door een nieuw geïdentificeerd gen, dat dnpA werd genoemd (de-N-acetylase 
betrokken in persistentie), verder te karakteriseren. We tonen aan dat dnpA een bona fide 
persistentiegen is doordat overexpressie van het dnpA allel zorgt voor een stijging in het 
aantal persistorcellen terwijl een dnpA insertiemutant een lagere persistorftractie vertoont ten 
opzichte van het wildtype. Ondanks zijn genomische ligging in de geconserveerde 
lipopolysacharide (LPS) kern oligosacharide biosynthese cluster kon geen duidelijke rol 
worden vastgesteld voor DnpA in LPS synthese. Een transcriptoomanalyse impliceert dat 
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DnpA genen beïnvloedt die betrokken zijn in oppervlakte-gerelateerde processen. Deze 
resultaten worden verder ondersteund door onze observatie dat DnpA aanwezig is in de 
binnenmembraan van P. aeruginosa. Verder duiden onze experimenten erop dat correcte 
insertie van DnpA in de membraan, en niet zozeer membraanassociatie op zich, noodzakelijk 
is om zijn rol in fluorchinolonentolerantie te vervullen.  
Het wordt steeds duidelijker dat verschillende overlappende mechanismen betrokken zijn in 
de vorming van persistorcellen, hetgeen de ontwikkeling van een doelwitgericht 
antipersistormiddel moeilijk maakt. In een tweede deel van deze thesis wordt een nieuwe 
onderzoekslijn opgestart met als doel kleine moleculen te identificeren die, in combinatie met 
conventionele antibiotica, de persistorftractie van P. aeruginosa doen dalen. We 
identificeerden drie verschillende componentfamilies die over zulke antipersistoractiviteit 
beschikken en op basis van een structuuractiviteitsanalyse werden de twee meest belovende 
componenten geselecteerd voor verdere testen. Deze componenten, SPI001 en SPI002, elk lid 
van een andere componentfamilie, zijn in staat om de persistorfractie significant te verlagen in 
combinatie met verschillende klassen van antibiotica. Bovendien vertonen ze ook anti-
persistoractiviteit op andere klinisch relevante Gram-negatieve en positieve bacteriën. Nadere 
karakterisatie van SPI001 toont aan dat deze component ook actief is op klinische isolaten van 
P. aeruginosa en dat het de biologische activiteit van bijkomende klassen van antibacteriële 
middelen verbetert. Verdere experimenten wijzen erop dat SPI001 inwerkt op de bacteriële 
membraan. Onze resultaten tonen aan dat SPI001 het potentieel bezit voor verdere 
ontwikkeling tot een anti-persistortherapie.  
Het werk in deze thesis draagt bij tot de ontwikkeling van een therapie gericht tegen 
persistorcellen. Op deze manier wordt de heropflakkering van infectie voorkomen hetgeen 
een gunstige invloed heeft op de gezondheid van de patiënt. 
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Chapter 1 
The Gram-negative opportunistic pathogen 
Pseudomonas aeruginosa  
 
1.1 Introduction 
1.1.1 History of the genus Pseudomonas 
Pseudomonas aeruginosa was first isolated by Gessard in 1882 from blue-green colored 
wound bandages (Gessard, 1984) and named Bacillus pyocyaneus (Silvestre & Betlloch, 
1999). After more than a decade, Walter Migula proposed the genus Pseudomonas, which he 
defined as ‘Cells with polar organs of motility. Formation of spores occurs in some species 
but it is rare’ (Migula, 1894). As a type species, he proposed Pseudomonas pyocyanea, which 
was later renamed to P. aeruginosa. However, he never provided a clarification for his choice 
of the name ‘Pseudomonas’. Taxonomists interpreted the name as a derivation from the Greek 
words ‘pseudes’ (false) and ‘monas’ (unit). False would refer to the variability in morphology 
of these organisms (Silvestre & Betlloch, 1999). However, Palleroni suggested that Migula 
named Pseudomonas after a nanoflagellate called ‘Monas’. Cells of Pseudomonas resembled 
those of this nanoflagellate both in size and motility, which resulted in the name false 
‘Monas’ (Palleroni, 2010). ‘aeruginosa’ is derived from the Latin name for copper rust, 
referring to the blue-green appearance of this bacterium (Silvestre & Betlloch, 1999; 
Palleroni, 2010). This color results from the production of the soluble pigment pyocyanine.  
Because of the broad description by Migula, a large number of unrelated organisms were 
assigned to this genus. In 1984, over 100 species were classified as Pseudomonas as listed in 
Bergey’s Manual of Systemic Bacteriology (Palleroni, 1984; Peix et al., 2009). Later on, 
based on sequencing and comparison of 16S rRNA, 5 different rRNA groups were defined 
(Palleroni et al., 1973). Currently, all members of Group II-V have been moved to other 
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genera such as Burkholderia and Ralstonia (Anzai et al., 2000). rRNA Group I or 
Pseudomonas sensu stricto, contains the remaining Pseudomonas species with P. aeruginosa 
as type species. This group is divided into 8 different subgroups including P. aeruginosa, P. 
fluorescens, P. putida, P. stutzeri, P. syringae, P. chlororaphis, P. pertucinogena and incertae 
sedis.  
 
1.1.2 Characteristics of Pseudomonas aeruginosa 
P. aeruginosa is a non-spore forming, Gram-negative rod-shaped γ-Proteobacterium 
measuring 0.5 to 0.8 µm by 1.5 to 3.0 µm. Most strains contain a single polarly inserted 
flagellum which is used for motility. This bacterium grows aerobically but is capable of using 
nitrate or arginine as a final electron acceptor in the absence of oxygen, allowing anaerobic 
growth (Vander Wauven et al., 1984; Haas et al., 1992). Because of its remarkable 
adaptability to a variety of environments, P. aeruginosa is present in diverse ecological niches 
such as soil, water, plants and animals (Rahme et al., 1995; Mahajan-Miklos et al., 2000). P. 
aeruginosa synthesizes 2-aminoacetophenone (2-AA), producing a fruity, grape-like smell. 
This characteristic, along with the fact that this bacterium produces the blue colored soluble 
pigment pyocyanin, greatly helps in identifying an unknown colony as P. aeruginosa. 
The complete genome of the widely used laboratory strain P. aeruginosa PAO1, a wound 
isolate (Holloway, 1955), was sequenced and published in 2000 (Stover et al., 2000). The 
genome has a high G+C content (66.6 %) and consists of 6.3 million base pairs. The presence 
of 5,570 predicted open reading frames reflects the genetic complexity of the P. aeruginosa 
genome underlying the capability of this bacterium to grow in different ecological niches. At 
the moment, complete genome sequences of 30 additional P. aeruginosa strains are publicly 
available.1  
P. aeruginosa can be part of the normal human microbial flora. For instance, this bacterium is 
present in the intestine of 10-15 % of healthy persons (White, 1971) and in about 2 % , P. 
aeruginosa is found in moist regions of the skin such as the external ear, armpits and 
anogenital regions (Hojyo-Tomoka et al., 1973). However, P. aeruginosa is an opportunistic 
                                               
1
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pathogen that will initiate infection upon local or general impairment of the immune system 
(Bergan, 1981). 
 
1.2 Pseudomonas aeruginosa as a human pathogen 
P. aeruginosa causes community-acquired infections (CAI) but is especially known to cause 
healthcare-associated infections (HAI). CAI include skin infections, ear infections, keratitis 
and in rare cases pneumonia. In the latter case, patients almost always suffer from a general or 
local immune deficiency (Williams et al., 2010). HAI caused by P. aeruginosa are often life-
threatening and, since the number of people receiving immunosuppression and invasive 
treatments increases, are increasingly prevalent. Below, some examples of CAI and HAI are 
described.  
 
1.2.1 Community-acquired Pseudomonas infections 
1.2.1.1 Microbial keratitis 
Microbial keratitis is a corneal infection that can result in severe vision loss due to scarring of 
the cornea. Several factors increase the incidence of microbial keratitis, with the most 
common ones being ocular surface disease, ocular trauma, contact lens wear, systemic 
diseases and ocular surgery (as reviewed in Stapleton & Carnt (2012)). The major preventable 
predisposing factors include ocular trauma and wearing contact lenses (Bourcier et al., 2003; 
Keay et al., 2006). The latter induces physiological changes to the corneal cells, lowering 
resistance to bacterial infection (as reviewed in Stapleton & Carnt (2012)).  
P. aeruginosa is the most common cause of contact lens-associated microbial keratitis (Cheng 
et al., 1999). This bacterium is often resistant to contact lens disinfectant fluid and grows as 
biofilms in lens storage materials. In addition, P. aeruginosa is capable of adhering to and 
colonizing lens materials during wear. Adherence to the lens surface is mediated by the cell-
associated structures pili and flagella, but also depends on the hydrophobic character of the 
bacterial cell surface (Dutta et al., 2012). Initiation and maintenance of infection relies on the 
production of extracellular and cell-associated virulence factors (Willcox, 2007). 
Pseudomonas produces several proteins, such as ExoS, ExoU, elastase, alkaline protease and 
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protease IV, that severely destruct the corneal cells. Importantly, excessive induction of host 
immune response greatly contributes to the destruction of the cornea.  
Two phenotypic distinct corneal isolates, cytotoxic and invading strains respectively, have 
been detected (Fleiszig et al., 1996). The phenotypic difference between those two strains 
depends on the presence of genes encoding the type III secreted virulence factors ExoS, 
ExoT, ExoU and ExoY. The cytotoxic strains typically lack the gene encoding ExoS (Fleiszig 
et al., 1997) and are responsible for acute infection, hereby causing corneal edema (Cole et 
al., 1998). The invasive strains do not produce ExoU (Fleiszig et al., 1997) and enter the 
corneal cells, where they survive and replicate without killing the host cells (Fleiszig et al., 
1994; Fleiszig et al., 1995). These invasive strains also cause severe keratitis resulting in 
corneal ulceration (Cole et al., 1998).  
 
1.2.1.2 Primary cutaneous infections  
In healthy persons, Pseudomonas is capable of causing several cutaneous manifestations. The 
most important local predisposing factors are hyperhydration and destruction of the stratum 
corneum, the upper layer of the epidermis. This stratum corneum is the first line of defense 
against infection because of its dryness and the presence of sphingosines, lipids that possess 
antimicrobial properties (Silvestre & Betlloch, 1999). The prognosis of these skin infections 
in healthy persons is good, while in immunosuppressed people, the outcome is poor.   
Common infections are folliculitis and the ‘green nail syndrome’. Folliculitis is an infection 
and subsequent inflammation of hair follicles. Typically, in healthy persons, this disease is 
self-limiting and disappears within 7 to 10 days (Silvestre & Betlloch, 1999). The ‘green nail 
syndrome’ or ungual infection results from the capability of P. aeruginosa to digest keratin 
(Lin et al., 2009), the structural component of hair, nails and the outer layer of the epidermis. 
This infection is characterized by the green coloration of the nail fold which is reflected in the 
name. Most patients are cured within a few months, but in rare cases, removal of the affected 
nail is necessary (Silvestre & Betlloch, 1999). P. aeruginosa is also associated with toeweb 
infections. When feet are exposed to a hot and humid environment, the thick layer of stratum 
corneum is affected, facilitating the growth of P. aeruginosa.  
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1.2.1.3 Otitis externa 
Acute otitis externa is an inflammation of the external ear canal, primarily caused by bacterial 
infection (Schaefer & Baugh, 2012). The most common predisposing factors are excessive 
moisture and trauma. As it is often caused by water left in the ear canal after swimming, this 
infection is also known as ‘swimmer’s ear’. P. aeruginosa, together with Staphylococcus 
aureus and Staphylococcus epidermidis, is the most common isolated pathogen in acute otitis 
externa (Roland & Stroman, 2002). Otitis externa sets off with itch, oedema, a sensation of 
fullness and, upon progression of the infection, with pain. This acute infection can become 
chronic upon inadequate treatment or when allergies or chronic dermatologic conditions are 
present (Ong & Chee, 2005; Schaefer & Baugh, 2012). In rare cases, P. aeruginosa invades 
the surrounding soft tissue and bone, which is called malignant otitis externa. This condition 
is potentially life-threatening and affects most frequently elderly, immunocompromised 
persons and diabetic patients (Hobson et al., 2014).  
 
1.2.2 Healthcare-associated infections  
P. aeruginosa is a major cause of severe nosocomial infections (ECDC, 2013; Magill et al., 
2014), and is associated with a high percentage of morbidity compared to other bacteria 
(Harbarth et al., 2002; Osmon et al., 2004). In Europe, P. aeruginosa is the fourth most 
isolated microorganism in HAI, accounting for 8.9 % of all isolated bacteria. It is the 
predominant organism found in respiratory tract infections, the most common HAI. 
Furthermore, P. aeruginosa resides in the top five organisms isolated from surgical site (7.6 
%), urinary tract (8.4 %), bloodstream (6.1 %) and gastrointestinal tract (2.5 %) infections 
(ECDC, 2013). In addition, burn wound patients are highly susceptible to acute or chronic 
superinfection with P. aeruginosa (Altoparlak et al., 2004). Infections often initiate as 
localized lesions but can spread into deeper tissue, eventually resulting in life-threatening 
sepsis (Church et al., 2006).  
P. aeruginosa is capable of growing in a wide variety of environments, including specific 
niches within the hospital. It is capable of forming biofilms, multicellular structures of cells 
embedded in a self-produced extracellular matrix in which bacteria are more tolerant against 
the bactericidal action of antibacterial agents (Costerton et al., 1999; Romling & Balsalobre, 
2012). In this way, P. aeruginosa often persists within hospital equipment, forming a 
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reservoir of bacteria that may cause infection outbreaks. For example, P. aeruginosa biofilms 
in the hand hygiene sink drains of intensive care units served as a source for a severe outbreak 
of P. aeruginosa infection in the Toronto General Hospital (Toronto, Canada) (Hota et al., 
2009). In this specific case, 12 out of 36 infected patients died as a consequence of infection.  
Several other cases have been reported in which for example contaminated hand lotion (Becks 
& Lorenzoni, 1995), nebulizers (Cobben et al., 1996), surface cleaning equipment (Engelhart 
et al., 2002), medical equipment (Silva et al., 2003), mouth swabs (Iversen et al., 2007) and 
even contaminated bottled water (Eckmanns et al., 2008) served as the source of infection.  
P. aeruginosa is the dominant organism isolated in lung-associated infections (ECDC, 2013). 
Acute respiratory infections are mainly the result of trauma, for example after intubation or 
smoke inhalation. In many cases, P. aeruginosa can grow and form biofilms on the 
endotracheal tubes itself, forming a reservoir of bacteria that can initiate infection in the 
intubated patient (Adair et al., 1999). On the other hand, chronic infections develop if the 
immune system of the patient is weakened, such as in patients receiving immunosuppression, 
immune deficient persons and the elderly. The classic example of chronic pseudomonal lung 
infections are the ones present in the cystic fibrosis lung (as discussed in the next section). 
Furthermore, chronic lung infections are also highly associated with people suffering from 
chronic bronchiectasis and obstructive pulmonary disease (COPD). COPD develops as the 
result of chronic inflammation of the lung, mostly because of chemicals present in cigarette 
smoke (Provinciali et al., 2011). Approximately 4-15 % of COPD patients get infected by P. 
aeruginosa, with the signs of infection being either acute or chronic (Williams et al., 2010).  
 
1.2.3 Special case: pseudomonal infection of the cystic fibrosis lung  
Cystic fibrosis (CF) is a recessive hereditary disorder caused by mutation of the CF 
transmembrane conductance regulator (CFTR), and is most common in North European 
populations. Over 1800 mutations in the CFTR have been identified2 with the absence of 
phenylalanine at position 508 (∆F508) accounting for almost 70 % of all mutations observed 
in North European and North American CF patients (Lyczak et al., 2002; O'Sullivan & 
Freedman, 2009). Mutation of CFTR, a cAMP-dependent chloride ion transporter, results in 
malfunction or loss of epithelial transport of chloride. In addition, CFTR also has other 
                                               
2
 Cystic Fibrosis Foundation. Cystic Fibrosis Foundation patient registry 2012 annual data report. 2013 
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regulatory roles such as inhibition of sodium transport (Ismailov et al., 1996) and is involved 
in bicarbonate-chloride exchange (Smith & Welsh, 1992). This CFTR dysfunction leads to the 
accumulation of thick, dehydrated mucus in all exocrine glands, resulting in several clinical 
manifestations associated with CF.  
The majority of CF patients is born with or develop pancreatic insufficiency within the first 
year of life, resulting in vitamin deficiency and malnutrition. Currently, the life expectancy of 
CF patients is over 40 years3, but at the time CF was first recognized, they only survived a 
few months because of malnutrition (Anderson, 1938). Nowadays, patients receive pancreatic 
enzyme replacement therapy (Borowitz et al., 2002). As the patient ages, the pancreas 
undergoes autolysis, eventually leading to insulin insufficiency and carbohydrate intolerance 
(Elder et al., 2007). In addition, the thickened intestinal secretions lead to intestinal 
obstruction and blocked bile ducts. In male CF patients, mutation of CFTR results in 
abnormalities of the reproductive system. They lack the vas deferens, resulting in infertility 
(Quinzii & Castellani, 2000). Presently, the most life-threatening clinical manifestation of CF 
patients is situated at the respiratory system. Because of the dehydrated and thickened airway 
surface liquid present in the CF lung, mucociliary clearance is impaired (Hartl et al., 2012), 
facilitating bacterial colonization. Typically, soon after birth, lungs are colonized with S. 
aureus and/or Haemophilus influenza. Infection by these bacteria damages the epithelial cells, 
facilitating the attachment of P. aeruginosa, which in time becomes the dominant bacterial 
species present in the CF lung (Folkesson et al., 2012). P. aeruginosa adapts to the CF lung 
environment by switching to a mucoid phenotype, reducing the expression of virulence 
factors and by adaptation of metabolic pathways to the lung environment. The concentrated 
airway mucus also likely promotes formation of microcolonies and biofilms (Matsui et al., 
2006). In this way, infections caused by P. aeruginosa persist and become chronic (Hogardt 
& Heesemann, 2013). In addition to the continuous damage caused by the bacteria, the 
presence of P. aeruginosa leads to immune-mediated inflammation, which further damages 
the lung tissue resulting in decreased lung function. It was shown that patients who remain 
clear of P. aeruginosa have a significantly better survival rate (Konstan et al., 2007). 
Consequently, early detection and eradication of infections is highly recommended.    
 
                                               
3
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1.3 Current treatment problems 
Nosocomial infections with P. aeruginosa are often caused by strains resistant to one or more 
classes of antibiotics (ECDC, 2013). The low number of potent new anti-pseudomonal drugs 
in late stages of clinical development (see Section 1.4.1) makes effective treatment very hard 
and, in some cases, nearly impossible. Some infections are difficult to eradicate despite the 
absence of detectable resistance against the used antibiotic of the isolated strains (Mulcahy et 
al., 2010). The latter may be explained by the formation of biofilms, in which cells are more 
tolerant to antibiotics, and the presence of persister cells. Persisters are suspected to be the 
major culprit of relapse of infection, giving rise to persistent and even chronic infections. 
Lingering, untreatable infections caused by multi-drug resistant strains prolong the hospital 
stay of patients and significantly contribute to morbidity and mortality. It is estimated that in 
2007, HAI caused by resistant strains resulted in 2.5 million extra hospital days in the 
European Union, Iceland and Norway and in addition, were responsible for 25,000 death 
cases (ECDC, 2009). Below, the mechanisms of antibiotic resistance and factors underlying 
the difficult treatment of infections caused by non-resistant strains are discussed.  
 
1.3.1 Antibiotic resistance 
P. aeruginosa is intrinsically resistant to a number of antibiotics and has the remarkable 
ability to quickly and easily acquire additional resistance mechanisms, giving rise to strains 
resistant to nearly all antibiotics. As new anti-pseudomonal drugs are not expected to be 
introduced on the market soon (Bassetti et al., 2013; Pendleton et al., 2013), infections may 
become untreatable. Furthermore, the absence of good treatment options of bacterial 
infections, including those caused by Pseudomonas, makes important medical interventions 
such as chemotherapy and invasive surgery impossible, since they rely on protection of the 
patient offered by antibiotics. Currently, old drugs such as polymyxins, although reported as 
nephro- and neurotoxic (Ryan et al., 1969; Koch-Weser et al., 1970), are increasingly used as 
a last resort in treatment of critically ill patients (Nation & Li, 2009; Boisson et al., 2013). In 
the following paragraphs, mechanisms underlying intrinsic resistance and strategies that P. 
aeruginosa uses to obtain resistance against additional antibiotics are described.  
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1.3.1.1 Intrinsic antibiotic resistance 
P. aeruginosa is intrinsically resistant to a number of antibiotics, resulting from an interplay 
between different mechanisms, encoded by the genetic make-up of this bacterium 
(Breidenstein et al., 2011). The low overall membrane permeability reduces the entrance rate 
of antibiotics in the bacterial cell. Antibiotics that manage to cross the outer membrane and 
enter the bacterial cell are extruded by the action of efflux pumps or are degraded by 
chromosomally encoded inactivating enzymes.  
 
Outer membrane impermeability 
The outer membrane of Gram-negatives is highly impermeable for large hydrophobic and 
hydrophilic molecules. Even diffusion of small molecules is restricted and uptake of nutrients 
occurs via specific porins (Nikaido, 2003). Small hydrophilic antibiotics such as the ß-lactams 
and quinolones usually diffuse across the outer membrane, mostly through small aspecific 
porin channels (Nikaido, 2003; Delcour, 2009). The major porin protein in P. aeruginosa is 
OprF (Hancock et al., 1979) forming large pores in the outer membrane (Bellido et al., 1992). 
Despite the fact that the number of OprF proteins is similar to that of the major Escherichia 
coli porin protein, the P. aeruginosa outer membrane is 100 times less permeable for 
hydrophilic solutes as compared to E. coli (Yoshimura & Nikaido, 1982). This reduced rate of 
antibiotic influx is explained by the observation that P. aeruginosa contains a very limited 
number of open channel porins (Nikaido, 2003). The small size of the other porins such as 
OprD and OprB further prevents diffusion of antibiotics across the outer membrane (Nikaido, 
2003; Breidenstein et al., 2011). Entrance of lipophilic molecules via diffusion through the 
outer membrane is significantly reduced by the presence of the lipopolysaccharide (LPS) 
leaflet (Plesiat & Nikaido, 1992).  
 
Efflux pumps 
Antibiotics that manage to cross the bacterial membranes are extruded by the action of efflux 
pumps. In Gram-negative bacteria, efflux pumps mainly belong to the resistance-nodulation-
division (RND) family which operates as a tripartite system containing a periplasmic 
membrane fusion protein, an outer and an inner membrane protein (Poole, 2004). The genome 
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of P. aeruginosa encodes 12 RND systems, but only seven of them have been characterized. 
These include MexAB-OprM (Poole et al., 1993; Li et al., 1995), MexCD-OprJ (Poole et al., 
1996), MexEF-OprN (Kohler et al., 1997), MexGHI-OprD (Aendekerk et al., 2002; Sekiya et 
al., 2003), MexJK-OprM/OpmH (Chuanchuen et al., 2002; Chuanchuen et al., 2005), 
MexVW-OprM (Li et al., 2003) and MexXY-OprM (Mine et al., 1999). MexGHI-OprD 
contains an additional small integral membrane protein MexG, of which the function is 
unknown (Aendekerk et al., 2002). The most important pumps in terms of antibiotic 
resistance are MexAB-OprM, MexCD-OprJ, MexEF-OprM and MexXY-OprM, which have 
been identified in clinical isolates and are known to export clinically relevant antibiotics. All 
efflux pumps export a preferential set of substrates with MexAB-OprM showing the broadest 
substrate range, exporting antibiotics (ß-lactams, aminoglycosides, fluoroquinolones, 
macrolides, tetracyclines, chloramphenicol, novobiocin, lincosamides, glycylcyclines, 
trimethoprim) and non-antibiotic compounds (crystal violet, acriflavin, ethidium bromide, 
sodium dodecyl sulfate and triclosan). For an overview of the substrates of each independent 
efflux pump see for instance Kumar & Schweizer (2005) or Poole (2007). MexAB-OprM, 
MexXY-OprM and MexHI-OprM/H are involved in intrinsic resistance of P. aeruginosa, 
others such as MexCD-OprJ and MexEF-OprN are not expressed during growth under normal 
laboratory conditions. 
 
Chromosomally encoded ß-lactamases 
The chromosome of P. aeruginosa contains two genes that code for ß-lactamases, ampC and 
poxB. AmpC is a member of the class C ß-lactamases, and is linked to the intrinsic resistance 
of P. aeruginosa against ß-lactams (Lodge et al., 1990; Poole, 2011). PoxB belongs to the ß-
lactamases class D (Kong et al., 2005), and its activity is only detected in strains lacking 
AmpC activity (Poole, 2011). AmpC is usually present in low levels but production may 
increase upon induction by the presence of a number of ß-lactams (Livermore & Yang, 1987). 
Interestingly, although they serve as a substrate for AmpC, monobactams, piperacillin and a 
number of cephalosporins do not induce production of this ß-lactamase (Poole, 2011). 
Therefore, resistance depends on mutational derepression of AmpC. Interestingly, AmpC 
activity is not inhibited by clinically used ß-lactamase-inhibitors such as clavulanic acid, 
sulbactam and tazobactam (Nordmann & Guibert, 1998). The presence of extended spectrum 
AmpC variants has been reported among clinical isolates (Rodriguez et al., 2009).  
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1.3.1.2 Acquired antibiotic resistance 
P. aeruginosa has a remarkable capacity to acquire additional resistance mechanisms to 
multiple classes of antibiotics (as reviewed by Strateva & Yordanov (2009) and Breidenstein 
et al. (2011)). To this end, it uses two different mechanisms, mutational resistance and 
horizontal gene transfer, which are described below.  
 
Mutational resistance 
Additional resistance can be acquired by mutation of antibiotic target genes. This is most 
common for quinolone resistance, where specific point mutations in genes encoding DNA 
gyrase or topoisomerase IV confer resistance to this class of antibiotics (Jacoby, 2005). The 
main target of quinolones in Gram-negatives is DNA gyrase, but high levels of resistance are 
usually obtained when mutations in both enzymes are present. These point mutations occur in 
the active site of these enzymes, also called the quinolone-resistant-determinative region 
(Yoshida et al., 1990; Yoshida et al., 1991), and lead to lower binding affinity for the 
quinolones. 
Mutational resistance can also be obtained by mutations in non-target genes. Typically, these 
mutations enhance the intrinsic resistance already present in the bacterium. For example, 
partial derepression of the chromosomally encoded ß-lactamase AmpC is achieved by 
mutation of its negative regulator ampD (Langaee et al., 2000). Constitutive hyperexpression 
of ampC is realized when additional mutations occur in the two AmpD homologues AmpDh2 
and AmpDh3 (Juan et al., 2006). Another example is provided by mutational inactivation of 
efflux pump repressors. As a consequence, genes encoding efflux pumps are overexpressed 
leading to increased resistance towards several antibiotic classes. For instance, mutation of 
mexZ, which is the most frequently reported mutation identified in CF clinical isolates (Smith 
et al., 2006), results in the overexpression of the MexXY-OprM pump, conferring resistance 
to aminoglycosides, fluoroquinolones and the cephalosporin cefepime (Muller et al., 2011). 
Lastly, carbapenem resistance is obtained when mutational alteration or loss of OprD occurs, 
accompanied with expression of AmpC (Livermore, 1992). 
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Horizontal gene transfer 
P. aeruginosa can acquire DNA elements containing resistance genes through horizontal gene 
transfer by means of conjugation, transformation or transduction. This mechanism mainly 
affects aminoglycoside and ß-lactam resistance. Some examples are listed below.  
The major mechanisms by which P. aeruginosa acquires additional resistance against ß-
lactams is by horizontal transfer of plasmids encoding ß-lactamases. Based on their nucleotide 
and amino acid sequence, ß-lactamases are classified into four different classes, A-D. 
Members of all four classes have been identified in P. aeruginosa strains (extensively 
reviewed by Strateva & Yordanov (2009)). 
Aminoglycoside resistance genes obtained by horizontal gene transfer encode aminoglycoside 
modifying enzymes (AMEs) or 16S rRNA methylases. AMEs include aminoglycoside 
phosphoryltransferases, aminoglycoside adenylyltransferases and aminoglycoside 
acetyltransferases that transfer a phosphate, adenyl or acetyl group, respectively, to the 
aminoglycoside antibiotic (as reviewed in Ramirez & Tolmasky (2010)). 16S rRNA 
methylases methylate, as the name suggests, 16S rRNA hereby interfering with the binding of 
aminoglycosides to the 30S ribosomal unit. This results in high-level resistance to the 
clinically used antibiotics amikacin, gentamicin and tobramycin (as reviewed in Doi & 
Arakawa (2007)). Examples of such enzymes are RmtA, RmtB, RmtD and ArmA.  
Plasmid-encoded genes can also contribute to quinolone tolerance. For instance, the qnr genes 
encode proteins that bind DNA gyrase and topoisomerase IV hereby lowering the amount of 
enzyme that can bind to DNA and preventing quinolones to enter the cleavage complexes 
formed by these enzymes (Tran et al., 2005a; Tran et al., 2005b). The aac(6’)-Ib-cr protein is 
capable of acetylating fluoroquinolones, thus decreasing drug activity (Robicsek et al., 2006). 
Lastly, plasmids may contain genes encoding additional efflux pumps such as OqxAB, 
QepA1, and QepA2 (Yamane et al., 2007; Cattoir et al., 2008).  
 
1.3.2 Recurrent infections 
Even in the absence of genome-encoded resistance against the used antibiotic, treatment of P. 
aeruginosa infections remains challenging. Incomplete eradication of acute P. aeruginosa 
populations leads to relapse of infection, and, upon adaptation of P. aeruginosa to the host 
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environment, infections may become chronic. Furthermore, upon continuous presence of this 
bacterium in the host environment, the probability of acquiring additional resistance 
mechanisms increases, hereby contributing to the development of untreatable multi-drug 
resistant strains (Cohen et al., 2013). 
Several factors may contribute to the incomplete eradication of acute P. aeruginosa 
infections. First of all, P. aeruginosa is capable of altering its gene expression and/or protein 
expression upon sensing antibiotic stress. This phenomenon, known as adaptive resistance, is 
transient and the bacterium reverts back to its initial antibiotic sensitive state when the 
antibiotic disappears (Fernandez et al., 2011). Secondly, the presence of a small fraction of 
persister cells, phenotypic variants of the wild type insensitive to the action of bactericidal 
agents, prevents total clearance of the bacterial population upon antibiotic treatment (Spoering 
& Lewis, 2001). As P. aeruginosa primarily infects immunocompromised persons, the 
immune system is not capable of removing this small remaining fraction of cells, hereby 
providing a reservoir of bacteria capable of causing relapse of infection.  
Chronic infections are often associated with biofilm formation, multicellular structures of 
bacteria embedded in a self-produced extracellular matrix (Costerton et al., 1999). Bacterial 
cells within biofilms are more tolerant to antibiotic treatment compared to free-living cells, 
making treatment more difficult. Examples of P. aeruginosa biofilm-associated infections 
include CF lung infection, chronic wound infection, catheter-associated urinary tract 
infection, chronic otitis media and contact lens-related keratitis (Romling & Balsalobre, 
2012).  
 
1.3.2.1 Adaptive resistance 
Adaptive resistance is a transient phenomenon in which bacteria alter their gene expression 
and/or protein synthesis in response to changing environmental conditions. When the 
environmental trigger disappears, bacteria usually revert back to their initial antibiotic 
susceptible state. This temporary state allows the bacterium to cope with, for instance, a 
sudden increase in antibiotic concentration (Fernandez et al., 2011).  
An example of adaptive antibiotic resistance is the response of bacteria to cationic peptides 
such as polymyxins. The presence of this antibiotic induces the expression of the LPS 
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modification operon arnBCADTEF-PA3559 (Fernandez et al., 2010). This gene cluster is 
responsible for adding 4-amino-4-deoxy-L-arabinose to the phosphate group of lipid A, 
thereby increasing tolerance to cationic antimicrobial peptides (Moskowitz et al., 2004). 
Additional examples include the induction of the chromosomally encoded ß-lactamase AmpC 
by the presence of ß-lactams or upregulation of the genes encoding the MexXY-OprM efflux 
pump in the presence of aminoglycosides. In addition, adaptive resistance to antibiotics is not 
always triggered by the presence of antibiotics. For instance, social behavior such as the 
formation of biofilms or swarming induces the expression of genes involved in antibiotic 
resistance (as reviewed in Fernandez et al. (2011)).  
 
1.3.2.2 Biofilm tolerance  
Several factors contribute to the increased tolerance of biofilm-associated bacteria compared 
to planktonic cultures. A number of independent studies showed that penetration of 
aminoglycosides in biofilms was slower compared to that of fluoroquinolones (Hoyle et al., 
1992; Yasuda et al., 1993; Kumon et al., 1994; Suci et al., 1994; Vrany et al., 1997). 
Together with the observations that aminoglycosides were bound by alginate (Nichols et al., 
1988; Hatch & Schiller, 1998), it was hypothesized that the negatively charged biofilm matrix 
binds the positively charged aminoglycosides, slowing down diffusion of these antibiotics 
within the biofilm. A study carried out by Walters et al. (2003) indicated that the slower 
penetration of aminoglycosides does not explain the observed antibiotic tolerance of biofilms. 
Instead, limitation of oxygen, which results in lower metabolic activity of cells deeper in the 
biofilm, appeared to be an important factor contributing to biofilm tolerance. This is 
confirmed by the observation of the presence of different cell populations within the biofilm 
(Werner et al., 2004). Due to diffusion, cells residing close to the substratum receive less 
oxygen and nutrients, resulting in a lower metabolism compared to cells located at the biofilm 
surface. Antibiotic tolerance of the biofilm was attributed to the presence of these 
metabolically-quiescent, slow-growing cells which are less susceptible to the action of 
antibiotics. However, this mechanism cannot explain the higher tolerance of biofilms to 
quinolones, since this class of antibiotics is capable of killing non-growing planktonic cells 
(Brooun et al., 2000). Another mechanism that is believed to contribute to biofilm tolerance is 
the induction of adaptive resistance mechanisms. For instance, biofilm mode of growth 
induces expression of genes involved in synthesis of periplasmic glucans that bind 
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aminoglycosides (Mah et al., 2003). In addition, genes PA1874-1877, encoding a biofilm-
specific efflux system, are induced, resulting in increased resistance to tobramycin, 
gentamicin and ofloxacin (Zhang & Mah, 2008). At the beginning of the 21st century, it was 
observed that biofilms, just like planktonic cultures, contain a small fraction of persister cells 
(Spoering & Lewis, 2001). The presence of these antibiotic-insensitive cells is currently seen 
as a major culprit for the multi-drug tolerant character of a biofilm (see Chapter 2).  
In addition to the high tolerance against antibiotics, the mutation frequency and horizontal 
gene transfer in biofilms is higher compared to planktonic cultures (Molin & Tolker-Nielsen, 
2003; Driffield et al., 2008), hereby increasing the rate of resistance development. 
 
1.3.2.3 Adaptation of Pseudomonas to the host environment 
Upon initial infection of the CF airway, P. aeruginosa undergoes several adaptations that 
ultimately result in chronic colonization of the CF lung (Hogardt & Heesemann, 2013). 
During this adaptation process, P. aeruginosa hypermutator phenotypes emerge, creating 
multiple subclonal variants of the initial colonizing strain, thereby enhancing long-term 
survival within changing environmental conditions. Changes are triggered by the lung 
environment and occur at the morphological, genetic and physiological level. The resulting 
chronic P. aeruginosa isolates are less inflammatory and cytotoxic compared to the initial 
colonizing isolates.  
 
Hypermutator phenotype 
Within the chronically infected CF lung, P. aeruginosa hypermutators are extremely 
prevalent (Oliver et al., 2000). These strains possess an increased mutation rate due to defects 
in DNA repair systems. P. aeruginosa possesses different DNA repair systems that are 
involved in replacement of wrongly inserted nucleotides into the DNA and in prevention of 
recombination events between non-identical DNA sequences (Jolivet-Gougeon et al., 2011). 
Members of the methyl-directed DNA mismatch repair (MMR) are most frequently mutated, 
while mutations in a second DNA repair system, 8-oxo-2-deoxyguanosine, are less reported 
among isolates from the CF lung. The MMR system involves the mutS, mutL and uvrD genes, 
with mutS the most commonly affected gene among CF isolates (Ciofu et al., 2010). The 
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presence of hypermutators is correlated with a poorer lung function in CF patients (Ferroni et 
al., 2009). This might be explained by the fact that the presence of hypermutators is correlated 
to an increased resistance rate (as reviewed by Oliver & Mena (2010)). As a consequence, 
isolates from the CF lung are more resistant compared to isolates obtained from other sources 
(Henwood et al., 2001). More recently, evidence was provided that hypermutators also affect 
the genetic adaptation of P. aeruginosa to the CF lung, resulting in more recalcitrant strains, 
negatively affecting the clinical outcome of CF patients (Oliver & Mena, 2010).   
 
Adaptations 
To establish a chronic infection in the CF lung, P. aeruginosa undergoes changes at the 
morphological level. Chronic infections are marked by the presence of mucoid strains that 
overproduce the exopolysaccharide alginate. These isolates are more difficult to eradicate and 
are associated with increased tissue damage leading to deterioration of lung function 
(Hoffmann et al., 2005). Overproduction of alginate is often the result of mucA inactivation as 
a response to oxidative stress (Mathee et al., 1999). This leads to overexpression of 
AlgT/AlgU, an alternative sigma factor that induces expression of AlgD and several 
regulatory proteins, resulting in increased alginate levels (Ramsey & Wozniak, 2005). Mucoid 
isolates are better protected against stresses from the CF lung environment such as reactive 
oxygen species, antibiotics, antibodies and phagocytosis. A second phenotype detected in CF 
lungs is the occurrence of small colony variants (SCV) of which the presence in CF airways 
correlates with poor lung function and antibiotic therapy (Haussler et al., 1999; Haussler, 
2004). These variants display several characteristics that differ from their parental phenotype 
including a slower growth rate, resistance to antibiotics, increased biofilm formation and 
reduced motility. In the absence of antibiotics, they revert back to the wild type morphotype 
(Proctor et al., 2006). Evidence is present that intracellular levels of the second messenger 
cyclic di-GMP (c-di-GMP) (Hengge, 2009) play a role in switching to the SCV phenotype 
(Starkey et al., 2009). Specifically, it was shown that the tripartite signaling system YfiBNR, 
which controls c-di-GMP levels in P. aeruginosa, is involved in the generation of SCV. In 
response to yet unknown signals, YfiN produces c-di-GMP which targets exopolysaccharide 
synthesis, thereby leading to generation of SCV (Malone et al., 2010). A follow-up study 
showed that several causal adaptive mutations in P. aeruginosa SCV were mapped to the 
yfiBNR locus. Some isolates harboured both activating and inactivating mutations, pointing to 
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the alternation between favorable and non-favorable lung environments for SCV throughout 
the course of infection (Malone et al., 2012). 
Adaptation to the CF lung is marked by changes in the expression of virulence factors. 
Several of them are switched off or produced in lesser amount to reduce recognition by the 
immune system and to lower energy costs associated with maintaining production of these 
factors (Hoboth et al., 2009). For instance, chronic CF isolates lack the cell-associated 
virulence factors pili and flagella, mainly resulting from mutations of the rpoN gene 
(Mahenthiralingam et al., 1994). Reduction in expression of several other virulence factors 
results from mutational inactivation of the quorum sensing (QS) transcriptional regulator 
lasR, a mutation very commonly found among chronic CF airway isolates (Smith et al., 
2006). Recently, it was shown that exposure of a mutS-deficient strains to 2-AA, a QS 
regulated molecule, caused accumulation of lasR mutations (Kesarwani et al., 2011). In 
addition, cytotoxicity is severely reduced in chronic CF isolates, resulting from the absence of 
expression of the type III secretion system (Jain et al., 2004).   
In the CF lung, P. aeruginosa experiences various nutritional stresses and encounters a 
significantly lower oxygen tension, which results in metabolic adaptations. Several studies 
show that P. aeruginosa uses amino acids and fatty acids and TCA intermediates which are 
present in the nutrient-rich CF sputum, to support its growth in this environment (as reviewed 
by Hogardt & Heeseman (2013)). Analysis of sequential isogenic isolates obtained during 
chronic pulmonary infections further supported these results and, in addition, indicated that P. 
aeruginosa adapts to the micro-aerobic niches present in the CF lung (Hoboth et al., 2009; 
Oberhardt et al., 2010). Increased expression over time was observed for genes with a role in 
amino acid biosynthesis and metabolism, central carbon and energy metabolism and fatty acid 
and phospholipid metabolism. Decreased expression was observed for genes encoding 
cytochrome oxidases, generally expressed under aerobic conditions, and genes necessary for 
catabolism of aromatic compounds. Furthermore, expression of anaerobic and micro-aerobic 
respiration and the anaerobic arginine deaminase pathway was detected, supporting adaptation 
to the micro-aerobic niches present in the CF airway.  
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1.4 Novel treatment strategies 
Incomplete eradication of acute infections leads to relapse and eventually, the infection can 
become chronic. Such infections not only seriously hampers the patients’ outcome but also 
increase the cost associated with the prolonged hospital stay (ECDC, 2009). Old antibiotics 
like polymyxins, despite their toxic side effects, are currently used as a last option to treat 
critically ill patients (Nation & Li, 2009; Boisson et al., 2013). A recent report of the World 
Health Organization on the prevalence of antimicrobial resistance revealed that a high level of 
resistance is found in all regions of the world4, underlining the importance of finding new 
antibacterial agents.  
Resistance develops soon after the introduction of a new antibiotic on the market. In case of 
daptomycin, resistance was observed within one year (Dolgin, 2010). Therefore, in addition to 
new antibiotics, novel treatment strategies are needed that slow down the rate of resistance 
development and completely eliminate the bacterial population, preventing an infection from 
becoming chronic. A good strategy entails combining different antibiotics or using a 
combination of an antibiotic with a compound targeting non-essential processes such as 
virulence, biofilms or persister cells. In addition, treatment strategies such as immunization, 
immunotherapy and phage therapy could be an alternative to deal with P. aeruginosa 
infections. 
 
1.4.1 Novel antibiotics  
To efficiently develop new antibacterials, reliable screening platforms need to be established 
(Lewis, 2013). These should focus on preventing rediscovery of existing antibiotic classes, 
incorporate rules describing the penetration of compounds through the bacterial cell envelope 
and explore new natural sources. Below, a brief history of antibiotic discovery is given, 
followed by two paragraphs that discuss possible new sources and approaches to increase 
discovery of new antibiotic classes. Finally, an overview is provided of anti-pseudomonal 
drugs currently under clinical development.  
 
                                               
4
 WHO (2014) Antimicrobial resistance: global report on surveillance 
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1.4.1.1 History 
Between 1940 and 1962, about 20 different antibiotic classes were introduced on the market, 
with most of them discovered by screening soil-derived actinomycetes. Resistance to these 
antibiotics did emerge, but given the high number of newly identified antibiotics, it was 
believed that the battle against infectious diseases was won. However, since the 1960s, only a 
few new classes of antibiotics have been approved, and problematically, they lack activity 
against Gram-negative bacteria (as reviewed by Coates et al. (2011) and Lewis (2013)). In the 
1990s it became clear that the low number of newly discovered antibiotics could no longer 
overcome the increasing incidence of multi-drug resistant strains, rendering some infections 
untreatable by clinically approved antibiotics. Consequently, the pharmaceutical industry 
invested in new platforms for drug discovery, mainly based on the screening of synthetic 
compounds against targets identified by genomics. These screening efforts did not yield any 
drug with a reasonable spectrum of activity. One of the major issues was, despite the 
detection of in vitro activity against the target, the difficult penetration of the bacterial cell 
envelope (Payne et al., 2007). These unsuccessful and costly endeavors caused the 
pharmaceutical industry to leave the field of antibacterial drug discovery.  
 
1.4.1.2 Alternative sources 
In the golden era of antibiotic discovery, soil-derived organisms were screened for 
antibacterial agents leading to the identification of about 20 different antibiotic classes. 
However, after some time, known compounds were rediscovered upon which this platform 
was abandoned. Sequencing the genome of Streptomyces coelicolor revealed that this 
organism has a far bigger potential of producing bioactive substances than the number of 
secondary metabolites known to be produced under standard laboratory conditions (Bentley et 
al., 2002; Challis, 2014). An intriguing new strategy consists of looking into these silent 
operons. One of the first companies to explore this option was Ecopia Biosciences which, by 
varying the growth conditions, discovered several new secondary metabolites including a 
novel antibacterial agent (Banskota et al., 2006). Another approach consists of cloning the 
silent operons into a host strain for production (Baltz, 2010) or altering expression in the 
original producing strain (Komatsu et al., 2010; Gomez-Escribano & Bibb, 2011). Large-
scale induction of such operons could provide a new platform for antibiotic discovery.  
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Natural products from marine sources seem to be chemically more diverse compared to 
terrestrial products, making oceans a good but yet underexplored niche for new antimicrobial 
agents (Kong et al., 2010). Exploration of this niche has revealed the presence of numerous 
secondary metabolites, mainly produced by bacteria. Recently, several secondary metabolites 
produced by a coralline algal-associated Pseudoalteromonas strain (Tebben et al., 2014) and 
two new antibacterials produced by a marine Streptomyces strain (Mondol & Shin, 2014) 
showing activity against P. aeruginosa were described, pointing to the promising potential of 
oceans and seas as antibacterial drug source. In addition, unculturable bacteria from different 
niches, unable to grow under standard laboratory conditions, proved to be very promising 
sources of novel secondary metabolites. For example, by exploring soil DNA, several 
genomic regions encoding antibacterial compounds were discovered (Gillespie et al., 2002). 
NovoBiotic Pharmaceuticals has developed a technology to grow unculturable organisms in 
the lab (Kaeberlein et al., 2002) which it currently uses for antibiotic drug discovery. Using 
this technique, novel candidate antibiotics against S. aureus were discovered (Peoples et al., 
2008).  
In the 1990s, the pharmaceutical industry switched to synthetic chemical libraries as a 
potential source of new antibacterial drugs. However, screening of these libraries did not yield 
a substantial number of promising lead compounds (Payne et al., 2007). To improve drug 
discovery, more diverse libraries should become available. Another strategy proven to be 
successful is the use of libraries that were initially meant for other screening purposes. For 
instance, screening of a library of ATP-mimicking molecules resulted in the identification of a 
new class of antibacterial agents (Miller et al., 2009).  
Another alternative source of antibacterial compounds is provided by so-called ‘repurposing’ 
compound libraries. These collections contain for instance compounds that have no major 
safety issues but failed in clinical trials, were no longer commercially favorable, or have 
patents that are about to expire. These libraries offer the advantage that toxicity, 
pharmacological and pharmacodynamical properties have already been tested (Allarakhia, 
2013).  
 
Chapter 1                                    The Gram-negative opportunistic pathogen Pseudomonas aeruginosa 
21 
 
1.4.1.3 Improved screening platforms 
In addition to find new sources for new antibiotics, it is important to develop reliable 
screening platforms which increase the chance of drug discovery. A very important parameter 
for discovery of drugs targeting Gram-negatives, and in particular P. aeruginosa, is the ability 
to penetrate the Gram-negative outer membrane (Lewis, 2013). A possibility is to determine a 
set of penetration parameters based on common properties of molecules that seem to penetrate 
the outer membrane effectively. Such an empirical approach worked really well in the past to 
define a set of parameters important for orally bioavailable compounds (Lipinski et al., 2001). 
Based on these results, existing compound libraries can be re-evaluated. Some 
physiochemical properties that negatively affect outer membrane permeation are already 
known. For instance, comparison of 147 antibacterial active compounds revealed that drugs 
active against Gram-negatives usually are < 600 Da, hydrophilic (reflected by a low partition 
coefficient) and polar (O'Shea & Moser, 2008). In addition, presence of uncommon metal 
atoms improves penetration of the outer membrane. An example of such an antibiotic is 
AN3365, a boron-containing leucyl-tRNA-synthetase inhibitor, discussed in Section 1.4.1.3 
(Sutcliffe, 2011).  
To prevent rediscovery of existing classes of antibiotics, a so-called ‘counterscreening’ can be 
carried out in which the compounds are analyzed by mass and nuclear magnetic resonance 
spectrometry to filter out existing molecules (Silver, 2011; Lewis, 2013).   
 
1.4.1.4 Pipeline overview 
A range of new antibacterials with activity against Gram-negatives has entered clinical trials, 
but most of them show only modest in vitro activity against P. aeruginosa (Bassetti et al., 
2013; Pucci & Bush, 2013). These new antibacterial agents mostly belong to familiar classes 
of antibiotics such as quinolones, aminoglycosides, tetracyclines, ß-lactams in combination 
with ß-lactamase inhibitors and polymyxins. In addition, two compounds with a new mode of 
action have been developed, both acting on the membrane. Agents with reported in vitro anti-
pseudomonal activity are listed in Table 1.1 along with their current status and identifier or 
reference of the indicated clinical trial. The available chemical structures are shown in Figure 
1.1.  
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Several new quinolones were developed with the majority of them showing improved in vitro 
activity against Gram-positives but rather modest activity against P. aeruginosa (Pucci & 
Bush, 2013). Nemonoxacin (Adam et al., 2009) and zabofloxacin (Park et al., 2006) display 
comparable activity to that of moxifloxacin, with a minimal inhibitory concentration which 
inhibitied 90 % of the tested isolates (MIC90) of 32 and 64 µg mL-1  respectively. Delafloxacin 
showed a comparable result to ciprofloxacin with an MIC90 of 0.25 µg mL-1 (Nilius et al., 
2003). Finafloxacin, a pH- activated fluoroquinolone, displayed a similar activity compared to 
ciprofloxacin in an acidic environment (pH 5.8 – 6.2), with an MIC90 of 2 µg mL-1 (Stubbings 
et al., 2011). JNJ-Q2 showed comparable results to levofloxacin, but was less potent than 
ciprofloxacin (Morrow et al., 2010). Finally, ACH-702 showed comparable results to that of 
ciprofloxacin with an MIC90 of 8 µg mL-1 but was metabolized quickly. Therefore, this 
compound was excluded for systemic application, but was licensed for use in ophthalmic 
infections (Pucci & Bush, 2013) (not listed in Table 1.1).  
One new aminoglycoside, called plazomicin, has recently entered clinical trials. This 
antibiotic shows modest activity against P. aeruginosa, with an MIC90-vaue of 32 µg mL-1 
(Landman et al., 2011). In addition, also the tetracycline eravacycline shows modest activity 
(16 µg mL-1) against P. aeruginosa (Sutcliffe, 2011).  
Pleuromutilines were discovered in the early 1950s but were never further developed as a 
consequence of their weak in vivo activity. In 2007, the first pleuromutulin, retapamulin, was 
introduced on the market for topical use (Pucci & Bush, 2013). The novel pleuromutiline 
AN3365 shows anti-pseudomonal activity with 90 % of the tested isolates inhibited at a 
concentration of 4 µg mL-1 (Sutcliffe, 2011). However, phase II clinical trials were terminated 
after development of resistant bacteria during treatment with this compound.  
Several new ß-lactams are currently under clinical development. Among these is the 
monobactam named BAL30072 which is included in a clinical phase I study. This antibiotic 
is active against multiresistant strains, with a MIC90 value of 8 µg mL-1 (Page et al., 2010). 
Moreover, this antibiotic is resistant to hydrolysis by metallo-ß-lactamases (MBLs). In 
addition, two new carbapenems, named biapenem and tomopenem, are under clinical 
development. Biapenem shows good in vitro activity against P. aeruginosa with 90 % of the 
tested isolates inhibited at a concentration of 1 µg mL-1 (Cheng et al., 1999). Currently, a 
combination of biapenem with the novel ß-lactamase inhibitor RPX7009 is involved in 
clinical trials. No in vitro data on activity against P. aeruginosa are available for this 
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combination. Tomopenem showed better activity than imipenem, ceftazdime and meropenem 
with an MIC90 value of 8 µg mL-1 against P. aeruginosa strains (Koga et al., 2005). 
Ceftolozane or CXA-101, a newly developed cephalosporin, shows good activity against P. 
aeruginosa with a MIC90 of 1 µg mL-1, performing better than ceftazidime, imipenem and 
ciprofloxacin. Known resistance mechanisms against cephalosporines did not decrease 
activity of CXA-101 against P. aeruginosa (Takeda et al., 2007). Since this antibiotic is 
susceptible to additionally acquired ß-lactamases (Livermore et al., 2009), it is combined with 
the ß-lactamase inhibitor tazobactam. This combination, named CXA-201, completed several 
phase III clinical trials for intra-abdominal infections and urinary tract infections5 and is 
expected to enter a phase III clinical trial against ventilator-associated pneumonia (VAP) 
(NCT02070757).  
Several new ß-lactamase inhibitors are under clinical development, including avibactam 
(NXL104), MK-7655 and ME1071. Avibactam differs from the previous clinically approved 
inhibitors since it lacks a ß-lactam core. In addition, avibactam is a reversible inhibitor, 
representing a novel mode of action among ß-lactamase inhibitors (Ehmann et al., 2012). This 
inhibitor displays activity against classes A and C ß-lactamases. Presently, combinations of 
avibactam with ceftazidime and aztreonam are enrolled in clinical trials. The combination 
ceftazidime-avibactam showed better activity in vitro compared to ceftazidime monotreatment 
against susceptible and multi-drug resistant P. aeruginosa clinical isolates (Mushtaq et al., 
2010; Walkty et al., 2011; Levasseur et al., 2012). Currently, this combination is used in 
several phase III clinical trials including one for treatment of hospital-acquired pneumonia 
(HAP) (NCT01808092). The combination aztreonam-avibactam showed modest activity 
against P. aeruginosa (Levasseur et al., 2012), while the combination ceftaroline-avibactam 
showed very limited activity against P. aeruginosa with a MIC value > 32 µg mL-1 
(Castanheira et al., 2012). Therefore, these combinations will not be discussed. Another ß-
lactamase inhibitor named MK-7655, similar to avibactam, was developed with activity 
against class A and C carbapenemases. The combination of imipenem and MK-7655 acted 
synergistically on three different P. aeruginosa isolates each overexpressing AmpC and 
lacking OprD (Hirsch et al., 2012). Lastly, ME1071 was developed, which specifically 
inhibits MBLs (Ishii et al., 2010). This inhibitor increased the number of susceptible MBL-
producing P. aeruginosa strains in combination with biapenem and ceftazidime. In addition, 
                                               
5
 https://clinicaltrials.gov/ct2/results?term=CXA-201&Search=Search 
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the novel inhibitor RPX7009, with inhibitory activity against class A and C serine ß-
lactamases is tested in combination with biapenem. However, as mentioned above, no data on 
anti-pseudomonal activity are available for this combination therapy.   
One new polymyxin, CB-182,804, was developed showing activity against P. aeruginosa 
with an MIC90 value of 8 µg mL-1 (Quale et al., 2012). Synergy with rifampicin was observed, 
leading to a restoration of activity to polymyxin-resistant strains. In addition, two new 
promising membrane-acting agents both targeting outer membrane biogenesis are currently 
being tested in clinical trials. The first one is POL7080, a protein epitope mimetic which 
targets LptD, a protein involved in LPS transport (Srinivas et al., 2010). This antibiotic is 
highly potent, with MIC values in the nanomolar range. POL7080 was licensed by Roche 
from the pharmaceutical company Polyphor in 20136. Phase II clinical trials are currently 
ongoing. Secondly, ACHN-975 represents a new class of membrane-acting agents by 
targeting LpxC, with an MIC value below 1 µg mL-1 7.  
 
 
Table 1.1: Overview of anti-pseudomonal agents currently involved in clinical trials. Based on the recent 
review articles from Pucci & Bush (2013) and Basseti et al. (2013) Only compounds with reported activity 
against P. aeruginosa were retained. In vitro MIC values were looked up in the respective research article(s), 
the current status of the investigational drug was checked on https://clinicaltrials.gov.  
Antibiotic MIC90 
(µg mL-1) 
Phase of development* Clinical trial 
identifier or 
reference 
Quinolones    
Nemonoxacin 32 Phase II ended, CAP NCT01537250 
Delafloxacin 0.25 Phase III recruiting, skin infections NCT01984684 
Finafloxacin 2 Phase II recruiting, UTI NCT0192843 
Zabofloxacin 64 Phase III ongoing, COPD NCT01658020 
JNJ-Q2 2 Phase II ended, skin infections 
Phase II terminated, CAP 
NCT01128530 
NCT01198626 
 
                                               
6
 http://www.roche.com/media/media_releases/med-cor-2013-11-04.htm 
7
 http://www.achaogen.com/antipseudomonal-programs/ 
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Table 1.1 - continued 
Antibiotic MIC90 
(µg mL-1) 
Phase of development* Clinical trial 
identifier or 
reference 
Aminoglycosides    
Plazomicin (ACHN-490) 32 Phase III recruiting, bloodstream 
infections and nosocomial pneumonia 
NCT01970371 
 
   
Tetracyclines    
Eravacycline (TP-434) 16 Phase III recruiting, UTI 
Phase III ongoing, cIAI 
NCT01978938 
NCT01844856 
CB-182,804 8 Phase I (Bassetti et al., 
2013) 
 
   
Polymyxins    
CB-182,804 8 Phase I (Bassetti et al., 
2013) 
 
   
Pleuromutilins    
AN3365** 4 Phase II terminated, community acquired 
infection  
Phase II terminated, cIAI 
Phase II terminated, UTI 
NCT01702350 
NCT01495065 
NCT01381562 
NCT01381549 
 
   
ß-lactams    
BAL30072 8 Phase I Bassetti et al. (2013) 
Biapenem (RPX2003) 1 Phase I completed  NCT01702649 
Tomopenem (CS-023) 8 Phase II Bassetti et al. (2013) 
 
 
Combination of ß-lactams and ß-lactamase inhibitors  
Ceftazidime-avibactam < 8 Phase III recruiting, HAP NCT01808092 
Imipenem–MK-7655 ≤ 4 Phase II recruiting, UTI 
Phase II recruiting, cIAI 
NCT01505634 
NCT01506271 
Ceftolozane-tazobactam 
(CXA-201) 
1 Phase III not yet recruiting, VAP NCT02070757 
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Table 1.1 - continued 
Antibiotic MIC90 
(µg mL-1) 
Phase of development* Clinical trial 
identifier or 
reference 
Biapenem –RPX7009 NA* Phase I completed NCT01772836 
ME1071 / Phase I Bassetti et al. (2013) 
    
Membrane-acting     
POL7080 0.25 Phase II recruiting, VAP and 
bronchiectasis 
NCT02096328 
NCT02096315 
ACHN-975 < 1 Phase I completed 
Phase I terminated 
NCT01597947 
NCT01870245 
*CAP, community-acquired pneumonia; UTI, urinary tract infections; COPD, chronic obstructive 
pulmonary disease; HAP, hospital acquired pneumonia; cIAI: complicated intra-abdominal infections; 
VAP: ventilator-associated pneumonia; NA, not available 
** Phase II trials terminated because of development of resistant bacteria during treatment for UTI 
 
 
1.4.2 Immunization and immunotherapy  
An alternative strategy for treatment or prevention of P. aeruginosa infections is 
immunization of the host. This can be done passively, by using antibodies targeting specific 
features of P. aeruginosa, or actively, by administration of the antigen itself. In addition, 
stimulation of the innate immune system is another way to improve bacterial clearance. 
Below, some examples of each strategy are given.  
 
1.4.2.1 Passive immunization  
In patients already infected or colonized with P. aeruginosa, passive immunization or 
immune therapy using antibodies targeting P. aeruginosa can be used in combination with 
antibiotics. These antibodies stimulate the immune system response, improving outcome of 
infected patients. Several studies describe the effect of antibodies targeting specific cell-
associated virulence factors such as flagella, pili and LPS, which are important in the initial 
attachment stage of the bacterium to the epithelial cells of the host tissue (Kipnis et al., 2006). 
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Figure 1.1: Chemical structures of new anti-pseudomonal agents as listed in Table 1.1. The structure of 
POL7080 has not been made available.  
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For instance, administration of antibodies against the LPS polysaccharide moiety serotype 
O11, which is one of the most reported serotypes among epidemiological studies, reduced the 
bacterial load and inflammation response upon acute pulmonary infection in immune 
competent (Secher et al., 2011) and neutropenic mice (Secher et al., 2013). Furthermore, a 
phase II clinical trial on critical patients suffering from nosocomial pneumonia showed an 
improved clinical outcome upon adjunctive treatment with the anti-LPS antibody 
panobacumab (Que et al., 2014). Another example is provided by the anti-Pseudomonas 
antibody IgY, showing high affinity for flagellin (Nilsson et al., 2007). This antibody 
prevents adherence of P. aeruginosa to epithelial cells, inhibiting colonization of epithelial 
cells. Based on phase I feasibility studies (Kollberg et al., 2003), treatment of CF patients 
intermittently colonized by P. aeruginosa with IgY is permitted in Sweden (Nilsson et al., 
2008). Currently, a phase III trial is ongoing which aims to delay the onset of P. aeruginosa 
reinfections in CF patients which had been successfully treated for an infection 
(NCT01455675).  
After the initial phase of infection, P. aeruginosa secretes several virulence factors that cause 
severe damage to the host tissue and play a role in invasion and further dissemination within 
the host (Kipnis et al., 2006). Examples include proteases such as alkaline protease, 
hemolysines including exotoxin A and the type III secreted exotoxins ExoS, ExoT, ExoU and 
ExoY. Antibodies targeting these secreted virulence factors have been developed. An example 
includes the genetically engineered antibody against PcrV, a component of the type III 
secretion system of P. aeruginosa, which reduced virulence in a mouse pneumonia model 
(Baer et al., 2009). A phase II dose-finding study on VAP patients colonized by P. 
aeruginosa showed a reduction in pneumonia incidence upon treatment with anti-PcrV 
(Francois et al., 2012). Recently, this anti-PcrV antibody was evaluated in CF patients, and 
was shown to reduce inflammation compared to the control group (Milla et al., 2014). 
 
1.4.2.2 Active immunization  
In theory, infections can be delayed or even prevented by immunization of the host against P. 
aeruginosa by a process called active immunization. Active immunization is carried out by 
exposing the host to a P. aeruginosa antigen to stimulate the host immune system. This can be 
done by administration of the purified antigen itself or by the use of DNA vaccines encoding 
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the P. aeruginosa antigen (Doring & Pier, 2008). Several antigens have proved to be 
successful in a number of studies.  
Immunization of mice with semi-purified exotoxin A (Manafi et al., 2009) or the combination 
of pure exotoxin A with an adjuvant (Pavlovskis et al., 1981) significantly protected mice 
from induced P. aeruginosa burn wound infections. Another study showed that immunization 
of mice with the combination of purified exotoxin A and alkaline protease protected mice 
against gut-derived P. aeruginosa sepsis (Matsumoto et al., 1998). Another virulence factor 
successful in immunization of hosts against P. aeruginosa infections is LPS. For instance, 
immunization with LPS protects mice from burn wound infections (Cryz et al., 1984), guinea 
pigs from pneumonia (Pennington, 1979) and was reported to be successful in treatment of 
humans with burn infections (Roe & Jones, 1983). Furthermore, this treatment elicits a good 
immunogenic reaction in non-Pseudomonas colonized CF patients (Schaad et al., 1991). 
Immunization with outer membrane proteins protected immunosuppressed mice from 
intraperitoneal challenge with P. aeruginosa (von Specht et al., 1994; von Specht et al., 
1995), burn wound infections (Matthews-Greer & Gilleland, 1987), systemic infections 
(Gilleland et al., 1984) and lung infections (Hughes & Gilleland, 1995) while immunized rats 
were protected against pulmonary infections (Gilleland et al., 1988). Active immunization 
with flagellin was also reported in several studies. For example, administration of 
recombinant type A flagellin protected mice with burn injuries against lethal P. aeruginosa 
infections (Faezi et al., 2014). In addition, several vaccines have been described in which two 
or more bacterial antigens are conjugated. Examples include a fusion protein of OprF epitope 
8, OprI, and type A and B flagellins (Weimer et al., 2009) and a conjugate of alginate and 
flagellin (Campodonico et al., 2011). Active immunization can also be achieved by using 
whole, attenuated P. aeruginosa strains. It was shown that immunization with a live-
attenuated Pseudomonas vaccine protected neutropenic mice against lethal pneumonia 
infections induced by both homologous and heterologous strains (Kamei et al., 2013).  
Several clinical trials have been conducted to assess the efficacy of vaccination in CF 
patients. Vaccines were tested for their capability to prevent or reduce established P. 
aeruginosa infections in the CF airway. Three of them are reviewed in Johansen & Gotzsche 
(2013) and include two large trials, one with a vaccine composed of flagellin proteins (Doring 
et al., 2007). The other one tested the efficacy of a vaccine known as Aerugen of which the 
composition was not disclosed (unpublished data cited by Johansen & Gotzsche (2013)). A 
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third small trial was conducted with a polysaccharide vaccine containing 16 different 
serotypes (Langford & Hiller, 1984). Analysis of these data did not show effective prevention 
of P. aeruginosa infection (Johansen & Gotzsche, 2013).  
 
1.4.2.3 Supplementation of the innate immune system 
Another possibility to improve bacterial clearance by the host is stimulation of the innate 
immune response. For instance, one of the responses of the airway to bacterial infection, 
defective in CF patients, is the production of hypothiocyanite (OSCN-), which acts 
bactericidal (Moskwa et al., 2007). In addition, it has been shown that lactoferrin, a 
constituent of human external secretions, prevents biofilm formation of P. aeruginosa (Singh 
et al., 2002). Treatment of CF patients with nebulized hypothiocyanite in combination with 
lactoferrin showed good results and was recently approved as an orphan drug known as 
Meveol (Hurley et al., 2012).  
 
1.4.3 Targeting non-essential processes 
Several processes that are not essential for bacterial viability contribute to the severe outcome 
of infections caused by P. aeruginosa. One of them is expression of a wide arsenal of 
virulence factors, of which many are under the control of QS. Secondly, the formation of 
biofilms by this pathogen seriously hampers accurate eradication (described in Section 1.3.2). 
Treatments aimed at reducing virulence or preventing biofilm formation would therefore 
greatly help in improving patients’ outcome upon infection by P. aeruginosa. In theory, since 
these processes are not essential for viability of the bacterium in vitro, targeting them may 
impose a weaker selection pressure in vivo, decreasing the rate of resistance development. 
These strategies attenuate the pathogen, giving the immune system the opportunity to 
eliminate the bacterial population from the human body. Some examples are described below.   
 
1.4.3.1 Targeting virulence 
Many anti-virulence strategies targeting P. aeruginosa have been described (for an overview 
see Hurley et al. (2012)) and some examples will be discussed briefly. Virulence of P. 
aeruginosa can be altered by targeting specific cell-associated virulence factors. For instance, 
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it was shown that flagellum-deficient mutants are defective in causing acute infections 
(Feldman et al., 1998), and mutants lacking pili caused less severe infections in mice (Tang et 
al., 1995). Furthermore, the functional expression of the type III secretion system is 
associated with increased mortality in hospital patients (Roy-Burman et al., 2001). These cell-
associated virulence factors can be targeted by immunization as discussed in Section 1.4.2.  
Another strategy to reduce virulence consists of reducing the expression of virulence factors. 
The expression of some of these factors is regulated by QS, a bacterial communication system 
based on population density through the production and detection of signaling molecules. The 
concentration of signaling molecules rises upon increasing population size and, once a certain 
threshold is reached, expression of specific genes, including some involved in virulence, is 
coordinated within the bacterial community (Waters & Bassler, 2005). P. aeruginosa contains 
at least three different QS systems of which the Las and Rhl pathways use N-acylhomoserine 
lactones (AHLs) as signaling molecules (Winson et al., 1995), the alkylquinoline pathway 
uses 2-heptyl-3-hydroxy-4-quinolone (Diggle et al., 2006). The latter is also known as the 
pseudomonas quinolone signal. Several strategies have been described to interfere with QS, 
often referred to as ‘quorum quenching’ (QQ). 
One way to achieve QQ is by preventing the accumulation of signal molecules within the 
bacterial cell through interference with signal production. An example is given by the small 
molecule triclosan, which binds to FabI, an enoyl-acyl carrier protein reductase, with an 
essential role in the production pathway of AHLs (Hoang & Schweizer, 1999). Secondly, 
degradation of the signaling molecules itself represents an effective way to prevent signal 
molecule accumulation. For this purpose, enzymes that degrade the autoinducer AHL can be 
used, such as AHL lactonase or acylase (Czajkowski & Jafra, 2009). For example, a P. 
aeruginosa strain overproducing an AHL acylase was shown to be less virulent in the fast-
killing assay on Caenorhabditis elegans, while a P. aeruginosa mutant lacking this enzyme 
showed higher virulence in a slow-killing assay. In addition, exogenous addition of the 
purified acylase reduced pathogenicity of P. aeruginosa (Papaioannou et al., 2009). More 
recently, it was shown that overexpression of the AHL lactonase AiiM reduces cytotoxicity of 
P. aeruginosa in a mice model of acute pneumonia (Migiyama et al., 2013). Another 
approach lies in antagonizing the mode of action of the produced signaling molecules. This 
can be achieved by administration of synthetic AHL analogues (Smith et al., 2003) that 
interfere with binding of the signaling molecules to their receptor or that reduce the 
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concentration of available receptors within the bacterial cell. An example of QS inhibition by 
an AHL mimic is given by administration of furanone C-30, a synthetic derivate of natural 
furanone compounds, which reduced QS of P. aeruginosa in a mouse pulmonary infection 
model hereby allowing the immune system to clear the infection (Hentzer et al., 2003). Also 
non-natural AHL-mimics have been synthetized. An example is given by a structurally novel 
class of chimerics composed of the natural tail region of the native signaling molecule of the 
LasR-system and a non-natural homoserine lactone head group. Administration of these 
AHL-mimics reduced the production of virulence factors of P. aeruginosa in vitro 
(Hodgkinson et al., 2012). 
Lastly, virulence of P. aeruginosa can be decreased by interfering with iron uptake and 
metabolism. This metal is essential for growth but is present in low amounts at the site of 
infection. Therefore, P. aeruginosa produces iron chelators with pyoverdine the most 
important one under iron limiting conditions (Cornelis & Dingemans, 2013). Repressing the 
production of pyoverdine, by targeting the sigma factor PvdS which among others controls 
genes necessary for biosynthesis of this iron chelator, was shown to reduce virulence of P. 
aeruginosa in a mouse model (Imperi et al., 2013). Alternatively, the redox inactive iron 
mimetic gallium can be used to interfere with iron uptake and metabolism (as reviewed by 
Minandri et al. (2014)). Combining gallium with the pyochelin siderophore further improved 
the anti-pseudomonal activity of gallium by increasing its intracellular concentration 
(Frangipani et al., 2014).  
 
1.4.3.2 Targeting biofilms 
QS plays an important role in the formation and dispersion of biofilms (Harmsen et al., 2010). 
Consequently, by interfering with this process, formation of biofilms is prevented. Strategies 
to disrupt QS were discussed in the previous Section. Some additional approaches to prevent 
or eradicate biofilms without targeting essential processes are discussed below.   
A first strategy entails prevention of biofilm formation. An example of this strategy consists 
of blocking the sugar-specific binding sites of lectins. Lectins are outer membrane proteins 
with specific sugar-binding sites that allow bacteria to cross-link and form biofilms. By 
adding specific competitive inhibitors of the lectins LecA and LecB, biofilm formation of P. 
aeruginosa was prevented (Johansson et al., 2008; Kadam et al., 2011). Another way to 
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prevent biofilm formation is by interfering with iron uptake, which is important in the 
formation of these multicellular structures (Banin et al., 2005). For example, addition of iron 
chelators prevented biofilm formation in aerobic as well as anaerobic environments (Singh et 
al., 2002; O'May et al., 2009). The metal gallium, which is very similar to iron, interfered 
with biofilm formation by hindering the uptake of iron (Kaneko et al., 2007). Prevention of P. 
aeruginosa biofilm formation is also achieved by addition of D-amino acids, which probably 
replace D-alanine in the peptide side chain of peptidoglycan. How exactly this influences 
biofilm formation in P. aeruginosa was not reported (Kolodkin-Gal et al., 2010).  
Secondly, when biofilms are already established, they can be disrupted by adding agents that 
promote dispersion. For instance, the small fatty acid messenger cis-2-decenoic acid induces 
dispersion of established biofilms formed by many bacterial species, including P. aeruginosa 
(Davies & Marques, 2009). The addition of the NO donor sodium nitroprusside (Barraud et 
al., 2006), and high-affinity ligands of LecB (Johansson et al., 2008) also efficiently disperse 
P. aeruginosa biofilms. Ginseng extract also prevented the formation of biofilms. Treatment 
of biofilms with alginate lyase loosens the biofilm matrix, making biofilm cells more 
susceptible to antibiotic killing (Alkawash et al., 2006).  
So far, only a limited number of in vivo and clinical studies have demonstrated improved 
treatment of biofilm infections, as listed in Romling & Balsalobre (2012).  
 
1.4.4 Bacteriophages  
A promising therapeutic option is the use of bacteriophages, bacteria-specific viruses capable 
of killing their particular host pathogen. One of the first publications on bacteriophages 
originates from 1917, were D’Herelle describes the isolation of ‘an invisible microbe 
endowed with antagonistic properties towards a pathogenic bacillus’ from stools of people 
recovering from bacterial dysentery (D'Herelle, 2007). A few years later, the first report on 
the use of phages as an antibacterial therapy was published (Bruynoghe & Maisin, 1921) and 
many firms produced phage preparations to treat bacterial infections (Hausler, 2006). 
However, after world war II, research and clinical use of phage therapy was abandoned 
because of the introduction of antibiotics in combination with the mixed successes obtained 
with phages. Only in countries of the former Soviet Union, development of phage therapy 
continued, and was used as a conventional treatment of bacterial infections (Kutateladze & 
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Adamia, 2010; Viertel et al., 2014). Publications on successful use of phages in the 1980s 
(Smith & Huggins, 1982; Smith & Huggins, 1983; Smith et al., 1987) along with the 
development of antibiotic resistance in the early 1990s, rekindled the interest in phage 
therapy.  
Phage therapy possesses several advantages but also disadvantages over antibiotic therapy as 
discussed in Hausler (2006) and Lu & Koeris (2011). Phages are highly specific to the target 
organism without causing a negative effect on the commensal microbiota hereby preventing 
side effects often associated with conventional antibiotic therapies. As a consequence, no 
selection of resistances in these commensal bacteria occurs. Nevertheless, this great 
specificity of phages becomes a disadvantage when the identity of the infecting bacterial 
species is unknown or when the infection is polymicrobial. Another advantage is provided by 
the fact that phages are active against bacterial strains resistant to multiple antibiotic classes. 
However, bacteria also develop resistance against phages through several different 
mechanisms (as reviewed by Labrie et al. (2010)). Other disadvantages associated with phage 
therapy include challenges associated with phage delivery. Phages are removed by the 
immune system before they reach the site of infection, especially when administered 
systemically. In addition, antibodies against these phages are produced, limiting the number 
of systemic treatments that can be carried out with one specific phage formulation. Therefore, 
many studies focus on treatment of non-systemic infections such as wound or ear infections. 
In addition, bacteria residing inside human cells are inaccessible to phages, making them 
unsusceptible to phage therapy. Endotoxins and antigens, which may be present in phage 
formulations as a result from the manufacturing process, or which are released upon phage-
mediated lysis of bacterial cells stimulate an inflammatory response leading to significant 
morbidity. Interestingly, phages can be engineered to overcome some of the problems related 
to phage therapy (Lu & Koeris, 2011). In addition, by adding monomethoxypolyethylene 
glycol to the phage surface, the immune response of the host is delayed (Kim et al., 2008). 
Another example is the use of lysis-deficient engineered phages in order to prevent release of 
toxic substances due to bacterial lysis (Paul et al., 2011).  
Several phage therapies based on the use of whole phages were evaluated in clinical trials. For 
example, a phase I/II clinical trial demonstrated the efficacy and safety of a phage cocktail 
targeting resistant P. aeruginosa strains in chronic otitis (Wright et al., 2009). Another 
clinical trial proved the safe application of phages for treatment of venous leg ulcers (Rhoads 
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et al., 2009). Other trials are ongoing, including evaluation of phage therapy on P. aeruginosa 
burn wound infections (NCT02116010) and non-healing wounds (NCT00945087). Currently, 
no phage therapy is approved for clinical use in humans, although some applications were 
approved for use in the food (ListShieldTM and LISTEXTM P100) and agricultural 
(Omnilytics’ AgriPhageTM) industry (Lu & Koeris, 2011; Viertel et al., 2014). 
Phages can also be engineered to deliver genes or lethal substances to the site of infection. For 
instance, treatment of P. aeruginosa infected mice with a phage encoding a restriction 
endonuclease proved to be successful (Hagens et al., 2004). Alternatively, phage-derived lytic 
enzymes can be used as antibiotic substances themselves. An example is provided by the 
endolysins, target-specific enzymes that degrade the bacterial cell wall. However, in case of 
P. aeruginosa, a Gram-negative bacterium, the action of endolysins is hindered by the 
presence of the outer membrane (Walmagh et al., 2013). This problem can be overcome by 
combining an endolysin with a targeting peptide, which transports the endolysin through the 
outer membrane of Gram-negative bacteria (Briers et al., 2014c).  
 
1.5 Concluding remarks 
P. aeruginosa is a versatile human pathogen, especially known to infect persons in which the 
local and/or systemic immune system is impaired or does not function properly. As the 
number of people receiving immunosuppression and invasive treatments increases, 
nosocomial Pseudomonas infections become more prevalent. P. aeruginosa has the 
remarkable ability to acquire additional resistance mechanisms, and consequently, infections 
are increasingly caused by strains resistant to one or more antibiotic classes. In critical cases, 
infecting strains are resistant to all currently available antibiotics. In general, the need for new 
antibacterial agents is further stressed by the World Health Organization, which identified 
multi-drug resistant bacteria as a serious threat to human health8. Importantly, without 
antibacterial agents, some medical interventions become impossible as they rely on the 
protection offered by antibiotics.  
Currently, some new anti-pseudomonal agents are under clinical investigation but they mainly 
belong to existing antibiotic classes to which resistance develops within short time frames 
                                               
8WHO (2014) Antimicrobial resistance: global report on surveillance  
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after introduction of the new antibiotic on the market. Therefore, new discovery strategies 
need to be followed to increase chances of discovering mechanistically novel antibacterial 
agents. Exploration of alternative natural sources combined with improved screening 
platforms, which filter out already discovered structures, might lead to identification of new 
promising antibacterial substances. In addition, new treatment strategies, which slow down 
the rate of resistance development, and development of alternative approaches such as phage 
and immunotherapy, are necessary to win the battle against infectious diseases. 
Even in the absence of antibiotic resistance, infections caused by P. aeruginosa may be 
difficult to treat. This can be attributed to the formation of biofilms and the presence of 
persister cells, which prevent accurate treatment of bacterial infections. Combining an 
antibiotic with a compound targeting a non-essential process such as biofilm or persister 
formation may increase efficacy of treatment, hereby avoiding relapse of infection. 
Taken together, there is an urgent need for new anti-pseudomonal agents and treatment 
strategies. Special efforts should be made to improve eradication of infecting bacterial 
populations in order to prevent recurring infections. This eliminates the necessity to expose 
the organism to another round of antibiotics and, as a consequence, decreases chances of 
resistance development against the used antibacterial agent. 
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Chapter 2 
Persister cells, clinical importance and treatment 
strategies 
 
2.1 Introduction 
Exactly 70 years ago, it was noticed that upon treatment of antibiotic-sensitive 
Staphylococcus aureus cultures with penicillin, a small fraction of cells survived. When these 
cells were re-cultured, again, a small fraction of surviving cells was observed, excluding the 
involvement of resistance. Therefore, these cells were called persisters (Bigger, 1944). At the 
time, the clinical relevance was overlooked, which resulted in little attention from the 
scientific community for persister cells. In the beginning of the 21st century it was reported 
that persister cells are also present in biofilms, which are held responsible for the recalcitrant 
nature of infections (Brooun et al., 2000; Spoering & Lewis, 2001), leading to renewed 
interest in these antibiotic-tolerant cells. 
The presence of persister cells in an isogenic bacterial population typically results in a 
biphasic killing pattern upon treatment with a bactericidal antibiotic, with non-persisters 
exhibiting fast killing kinetics and persisters dying slowly. During treatment, persister cells 
are not able to grow, but upon a drop in antibiotic concentration, persisters revert to regular 
cells and regrow into a susceptible population (Cohen et al., 2013)(Figure 2.1). Formation of 
persister cells is dependent on the growth phase. Typically, persister levels are low in early 
exponential phase, increase during late-exponential phase and reach a maximum during 
stationary phase (Keren et al., 2004a). Initially, the persister population was considered 
homogeneous, but it is becoming increasingly clear that different subpopulations of persisters 
can be identified. It was suggested that the diversity in persisters results from the fluctuations 
and variability in cellular processes. This means that persisters can arise as a consequence of 
different mechanisms, giving rise to distinct persister populations, each with their particular 
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tolerance mechanisms (Allison et al., 2011b). This hypothesis is further supported by the 
observation that different levels of persisters are detected upon treatment of a population with 
antibiotic belonging to different classes (Keren et al., 2004a; Goneau et al., 2014). 
 
 
Figure 2.1: Biphasic killing pattern of a sensitive bacterial population in response to a bacteriocidal antibiotic. 
Addition of increasing concentrations of a bactericidal antibiotic initially leads to a sharp decrease of the 
number of viable cells. However, a further increase of antibiotic concentration does not lead to additional 
killing. A small fraction of cells, the persister cells (black), remain viable. If the antibiotic pressure drops, 
persister cells revert to growing cells and give rise to a susceptible population (as depicted by the arrow), which 
again contains a small fraction of persisters. Adapted from Kint et al. (2012).  
 
2.2 Characteristics of persister cells  
Traditionally, persisters are considered to be non-dividing, metabolically quiescent cells in 
which inactivity of the antibacterial targets impairs the bactericidal effect (Bigger, 1944). This 
is supported by the observation that genes involved in metabolic pathways, energy production 
and non-essential genes are downregulated, lending support to a dormant state of persisters 
(Keren et al., 2004b; Shah et al., 2006; Keren et al., 2011; Wood et al., 2013). However, it is 
becoming clear that the persistent state is far more complex than just a passive dormant state. 
A first clue was provided by the observation that an isolated dormant population, based on 
activity of the growth-dependent rrnB P1 promotor, is not entirely composed of persister cells 
(Shah et al., 2006). Moreover, it was shown that Escherichia coli persister cells still display 
some degree of translation (Gefen et al., 2008). Additional evidence supportive of this 
hypothesis was provided by the observation that a dormant state is not sufficient or required 
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for a cell to become persistent (Orman & Brynildsen, 2013). Furthermore, no correlation 
between the growth rate of an individual cell and persistence was observed in Mycobacterium 
(Wakamoto et al., 2013).  
Persister cells are already present in the population before antibiotic treatment (Balaban et al., 
2004) were they can serve as insurance for the entire population in case of a sudden antibiotic 
attack (Kussell et al., 2005). Combined with the fact that persister cells comprise a very small 
fraction of an isogenic population (Keren et al., 2004a), it was hypothesized that formation of 
persisters occurs through stochastic processes (Lewis, 2010). However, the formation of 
persisters can also be triggered by environmental cues such as signaling molecules (Moker et 
al., 2010; Vega et al., 2012), stress (Dorr et al., 2009; Wu et al., 2012; Kwan et al., 2013; 
Goneau et al., 2014) and entry into stationary phase (Keren et al., 2004a). This points to the 
involvement of a deterministic compound in persister formation. Based on these observations, 
the following model was proposed. The mean expression level of a dedicated persister protein 
in a population, set by environmental conditions, represents the deterministic compound. 
Random stochastic fluctuations around this mean will give rise to a small fraction of cells in 
which the persister protein exceeds a certain treshold, causing these cells to switch to the 
persistent state (Kint et al., 2012). This theory is supported by the observation that E. coli 
cells become persistent when the intracellular concentration of the toxin HipA reaches a 
certain threshold (Rotem et al., 2010). More recently, it was shown that individual cell fate 
under antibiotic treatment conditions was linked to stochastic expression of the isoniazid-
activating enzyme catalase peroxidase (KatG) in Mycobacterium (Wakamoto et al., 2013).  
 
2.3 Clinical importance 
Persister cells comprise a small subfraction of a genetically homogeneous population that 
remains viable during treatment with high doses of antibiotics. It is generally assumed that, 
upon successful treatment with a bactericidal antibiotic, the host immune system is able to 
cope with this small fraction of surviving cells. However, in situations where bacteria are able 
to evade the immune system, persisters may become a threat to human health (Gefen & 
Balaban, 2009). A causal link between persister cells and the recalcitrant nature of infections 
has been provided, pointing to the in vivo relevance of these antibiotic-tolerant cells. Below, 
evidence in support of the in vivo relevance of persister cells and situations in which persister 
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cells become a threat for human health are discussed. In addition, the role of persisters in 
development of resistance and the interplay between persistence and resistance mechanisms is 
described.  
 
2.3.1 In vivo selection for high persistence 
In vivo relevance has been provided for the role of Pseudomonas aeruginosa persister cells in 
chronic infections (Mulcahy et al., 2010). Comparison of early and late isolates of a 
chronically infected cystic fibrosis (CF) patient taken at the age of 8 and 96 months 
respectively, showed a 100-fold increase in persister cells. This was confirmed upon 
examination of isolates from additional CF patients. This result indicates that prolonged 
periodical administration of antibiotics selects for strains capable of producing substantial 
higher levels of persisters, pointing to the importance of persister cells in the recalcitrant 
nature of infection. Characterization of the persister fraction of uropathogenic E. coli strains 
isolated from same-strain acute and recurrent infections showed a higher survival of the latter 
when exposed to antibiotic treatment, pointing to selection for a higher persister level as the 
infection becomes more persistent (Goneau et al., 2014). The presence of persister cells is not 
restricted to prokaryotes as they were also detected in biofilms formed by the eukaryotic 
pathogen Candida albicans (LaFleur et al., 2006). Similarly, when comparing early and late 
isolates from patients chronically infected with C. albicans, a significant increase in persister 
level was observed for late-stage isolates (Lafleur et al., 2010).  
 
2.3.2 Clinical implications of persister cells 
In specific cases, persister cells become a threat to human health (Gefen & Balaban, 2009). 
The first example includes persons in which the immune system is suppressed or (partially) 
impaired. With the many advances that were made in medical technology, the number and 
expected lifetime of such patients has increased. Here, the surviving persisters are not 
removed because of a malfunctioning host immune system, and may form a reservoir of 
viable bacteria able to re-establish infection. Examples include patients receiving 
chemotherapy, immunosuppressed transplant recipients, HIV patients, CF patients and 
patients in intensive care units.  
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Secondly, the presence of persisters becomes problematic in situations where pathogens evade 
the host immune system by residing at places which are poorly accessible. Examples include 
the central nervous system (Honda & Warren, 2009), the gastro-intestinal tract (Peterson et 
al., 2000) and cells of the immune system. An example of the latter is provided by the Gram-
negative pathogen Salmonella enterica. This bacterium can enter and replicate within 
macrophages (Haraga et al., 2008), specialized white blood cells involved in the innate 
immune system of the host. It was shown that immediately after uptake into macrophages, a 
non-replicating population was formed, which could not be cleared by antibiotic treatment of 
infected mice. Experiments indicated that these remaining cells represent persisters, tolerant 
to multiple antibiotic classes (Helaine et al., 2014). Similar results were obtained by Kaiser 
and coworkers using an intragastric mouse infection model where, after antibiotic treatment, a 
small fraction of slow-growing multi-drug tolerant bacteria was recovered (2014). A second 
example includes Mycobacterium tuberculosis, a facultative intracellular pathogen which can 
replicate within macrophages (Vergne et al., 2004). According to the WHO9, it is estimated 
that 1/3rd of the human population is latently infected by M. tuberculosis, with 10 % of them 
eventually developing an acute infection due to regrowth of non-replicating bacteria, 
resembling persister cells, present in the human body.  
Lastly, persister cells can be present in specific niches within the human body that provide 
protection against components of the host immune system. An example is provided by 
persister cells residing in biofilm structures (Lewis, 2005). Biofilms are multicellular 
structures of bacterial cells embedded in a self-produced extracellular matrix adherent to an 
inert or living surface (Costerton et al., 1999). Within these biofilms, persister cells are 
protected against the action of the host immune system by the extracellular matrix which 
contains among others different polysaccharides, proteins and DNA (Mann & Wozniak, 
2012). It was shown that the polysaccharide alginate protects P. aeruginosa cells from the 
action of neutrophils and macrophages. These immune cells accumulate at the biofilm surface 
but are not able to engulf the bacterial cells. The mechanism by which alginate exerts its 
action is still unknown (Leid et al., 2005; Mulcahy et al., 2013). The extracellular DNA 
(eDNA) present in the matrix also plays an immunoprotective role. In P. aeruginosa, it was 
shown that eDNA is able to bind antimicrobial peptides (AMPs) and metal cations. The latter 
activate expression of genes including the ones responsible for modification of the lipid A 
                                               
9
 http://www.who.int/mediacentre/factsheets/fs104/en/ 
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part of lipopolysaccharide and genes responsible for spermidine synthesis. In this way, the 
negative bacterial surface charge is masked, protecting the outer membrane against AMPs 
(Lewenza, 2013). The matrix also offers protection against the humoral immune system. A 
study showed that penetration of antibodies is prevented by the biofilm matrix (de Beer et al., 
1997). Not only the matrix but also production of quorum sensing (QS)-regulated products 
contributes to tolerance of biofilms to the immune system. In P. aeruginosa, upon 
encountering polymorphonuclear neutrophils, synthesis of rhamnolipid is activated through 
QS, which eliminates phagocytes (Alhede et al., 2009). In addition, expression of the 
virulence factors alkaline protease and elastase is upregulated during the biofilm mode of 
growth. These  are capable of inactivating complement (Kharazmi, 1991).  
 
2.3.3 Persistence and its role in resistance 
Besides hindering effective clearance of bacterial populations, persister cells also contribute 
to the development of resistance. In theory, they prolong the stay of the pathogen in the 
human body, increasing exposure to antibiotic agents leading to a higher possibility of 
developing additional resistance mechanisms (Levin & Rozen, 2006). Furthermore, crosstalk 
between resistance and persistence has been reported in P. aeruginosa (De Groote et al., 
2011). In this study, the authors show that strains resistant to fosfomycin, either by fosA 
overexpression or by glpT mutation, have a decreased persister fraction upon ofloxacin 
treatment. On the other hand, it was shown that induction of an efflux pump, a classical 
resistance mechanism, increased levels of persister formation in E. coli (Wu et al., 2012). 
 
2.4 Mechanisms of persister formation in Pseudomonas aeruginosa 
The molecular mechanism underlying persister formation in P. aeruginosa is largely 
unknown and only few genetic determinants have been described to influence the level of 
persister cells in this pathogen (as reviewed in Fauvart et al. (2011)). These genes are mainly 
involved in processes related to stress responses. How exactly they regulate persister 
formation is unknown but it seems that some of the genes are somehow correlated. Some of 
the mechanisms implicated in P. aeruginosa persistence were also shown to influence 
persistence in other bacterial species. The most important mechanisms in P. aeruginosa, 
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along with their similarities and differences in other bacterial species, are briefly discussed 
below.  
 
2.4.1 The alternative sigma factors RpoS and RpoN  
Bacterial cells possess several sigma factors, constitutively active or activated under particular 
conditions, which determine the specificity of RNA polymerases. In this way, expression of 
proteins, needed in specific stress conditions, is regulated (Borukhov & Nudler, 2003; 
Kazmierczak et al., 2005) 
The alternative sigma factor RpoS is activated upon entry in the stationary phase, inducing 
expression of genes required to cope with the low-nutrient conditions encountered in the 
stationary phase. In addition, this sigma factor is also involved in regulation of virulence and 
specific stress responses (Suh et al., 1999). An rpoS mutant showed an increased 
susceptibility towards antibiotics (Murakami et al., 2005) indicating that RpoS positively 
influences antibiotic tolerance.  
The sigma factor RpoN, which regulates several processes needed for bacteria to adapt to 
unfavorable environmental conditions, is involved in the regulation of virulence factors and 
negatively regulates QS (Totten et al., 1990; Cases & de Lorenzo, 2001; Heurlier et al., 
2003). A rpoN mutant showed a higher survival rate upon antibiotic treatment compared to 
the wild-type strain (Viducic et al., 2007), pointing to a negative effect of RpoN on antibiotic 
tolerance. 
 
2.4.2 Quorum sensing 
The persister fraction of E. coli, P. aeruginosa and S. aureus species sharply increases at mid 
to late-exponential phase. Therefore, it was postulated that QS may play a role in the 
formation of persisters (Keren et al., 2004a). Addition of spent growth medium to growing 
cells did not increase the persister fraction of E. coli or P. aeruginosa, suggesting that QS is 
not involved (unpublished result cited by Lewis (2007)). However, a few years later, several 
reports indicate the involvement of QS in P. aeruginosa antibiotic tolerance (Kayama et al., 
2009; Moker et al., 2010; Que et al., 2013). 
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P. aeruginosa possesses three different QS systems, named the Las, Rhl and alkylquinoline 
pathways. The first two use AHLs as signaling molecules, which are synthetized by LasI and 
RhlI respectively, and sensed by LasR and RhlR (Waters & Bassler, 2005). The third system 
uses the Pseudomonas quinolone signal as signaling molecule (Diggle et al., 2006) The 
antibiotic tolerance of lasR and lasI mutants was significantly reduced compared to the 
parental strain, while overexpression of rpoS restored the persister fraction of the lasR mutant 
to wild-type level (Kayama et al., 2009). Addition of the quorum-sensing-related signaling 
molecules pyocyanin or the AHL 3-oxododecanoyl-homoserine lactone increased the 
persister fraction (Moker et al., 2010), further supporting the positive influence of quorum 
sensing on antibiotic tolerance. A first insight into the role of QS in antibiotic tolerance was 
provided by Que and colleagues (2013). They showed that the small volatile molecule 2-AA, 
of which the production is controlled by the QS regulator MfvR, increases the number of 
antibiotic tolerant cells by decreasing the transcription of genes involved in the translational 
capacity of the cell. Importantly, 2-AA also increased persister formation of Burkholderia 
thailandensis and Acinetobacter baumannii, pathogens frequently isolated together with P. 
aeruginosa (Harrison, 2007; Rezaei et al., 2011).  
So far, no reports show the involvement of QS in other bacterial species. However, intra-
species QS was indicated to play a role in persistence in different bacterial species. For 
instance, mutant cells of the Gram-positive Streptococcus mutans, unable to respond to the 
stress-inducible pheromone named competence-stimulating peptide, produced less persisters 
(Leung & Levesque, 2012). Another example is 2-AA, produced by P. aeruginosa, which 
increases the persister fraction of Burkholderia thailandensis and Acinetobacter baumannii 
(Que et al., 2013) as described above. Recently, an additional example was reported in which 
pyocyanin, produced by P. aeruginosa, plays in role in the formation of antibiotic-tolerant 
cells in Acinetobacter baumannii. Pyocyanin induces protection against oxidative stress 
through elevation of the levels of detoxifying enzymes (Bhargava et al., 2014).  
In E. coli, another form of chemical signaling is likely involved in the formation of persister 
cells. Upon sensing nutrient limitation, E. coli cells produce the signaling molecule indole 
(Han et al., 2011). It was shown that upon addition of this molecule to the growth medium, 
the fraction of multidrug-tolerant persisters increased. Accordingly, a mutant defective in 
indole synthesis showed a decreased persister fraction. The authors showed that indole 
activates the OxyR and phage shock pathways in a fraction of cells, leading to the formation 
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of a subpopulation of persisters (Vega et al., 2012). Recently, contrasting results were 
published, showing that the level of persisters and the concentration of indole are inversely 
proportional. Overexpression of the toxin YafQ increased persistence through reduction of 
TnaA, leading to lower levels of indole (Hu et al., 2014). Importantly, these results connect 
toxin-antitoxin (TA) modules with chemical signaling.  
 
2.4.3 Stringent response 
When nutrients are limiting, the alarmone (p)ppGpp, a mixture of guanosine 5'-triphosphate 
3'-diphosphate (pppGpp) and guanosine 5'-diphosphate 3'-diphosphate (ppGpp), accumulates 
within the cell, inducing changes in gene expression to ensure survival of the cells. Synthesis 
and degradation of (p)ppGpp is regulated by the synthetase RelA and the bifunctional enzyme 
SpoT, acting as a synthetase or hydrolase depending on the conditions (Potrykus & Cashel, 
2008). Genes involved in or linked to the stringent response have been implicated to play a 
role in P. aeruginosa persistence (Viducic et al., 2006). A spoT mutant showed higher 
survival rates compared to the wild type, in contrast to a relA mutant, displaying reduced 
survival upon antibiotic treatment. The survival rate was correlated with the intracellular level 
of (p)ppGpp, with high concentrations leading to better survival upon antibiotic exposure 
(Viducic et al., 2006). This is supported by the observation that a dksA mutant, showing 
increased tolerance against antibiotics, possesses high intracellular (p)ppGpp levels. DksA 
interacts with RNA polymerases in the presence of (p)ppGpp, hereby increasing binding to 
rRNA promoters, which negatively affects rRNA transcription. More recently, the role of the 
stringent response in P. aeruginosa persister formation was further elucidated (Nguyen et al., 
2011). The authors showed that activation of the stringent response upon starvation leads to 
suppression of oxidative stress by inducing antioxidant defenses and restricting the production 
of pro-oxidants. The role of oxidative stress in persistence is discussed below (see Section 
2.4.4). 
In E. coli, the stringent response was also shown to mediate antibiotic tolerance. Inactivation 
of the stringent response caused a decrease in the number of persister cells and was 
accompanied by reduced catalase and increased intracellular OH• levels, indicating that the 
stringent response also controls oxidative stress in this bacterium (Nguyen et al., 2011). In 
addition, the stringent response has also been linked to toxin-antitoxin (TA) modules in E. 
coli. TA modules consist of a stable toxin, targeting essential processes in the bacterial cell, 
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and an unstable antitoxin, which counteracts the effects of its cognate toxin (Yamaguchi et 
al., 2011). In the presented model, high levels of (p)ppGpp induce degradation of antitoxins 
through the action of the Lon-PolyP complex, rendering the toxins active. These activated 
toxins inhibit cell growth, causing insensitivity of the cells towards the bactericidal action of 
antibacterial agents (Maisonneuve et al., 2013). Very recently, evidence was provided for a 
role of the stringent response through activation of TA modules in the intracellular pathogen 
S. enterica. A relAspoT double mutant, defective in (p)ppGpp synthesis, and a lon mutant, 
which is not able to degrade class II antitoxins, formed less persisters upon uptake into 
macrophages. Additionally, it was shown that 14 TA modules were upregulated in a 
relAspoT-dependent manner (Helaine et al., 2014). According to the TA database (Shao et al., 
2011), the P. aeruginosa genome contains 7-12 type II TA loci, depending on the strain. A 
triple knock-out mutant lacking three TA modules did not show any difference in antibiotic 
tolerance (unpublished results cited by Mulcahy et al. (2013) although it is possible that more 
TA modules need to be removed to observe an effect on the persister fraction (Maisonneuve 
et al., 2011). In P. putida, the toxin GraT slows down growth, permeabilizes the membrane 
and causes increased tolerance to antibiotic treatment (Tamman et al., 2014). To date, no 
peer-reviewed journal articles were published regarding the role of TA-modules in P. 
aeruginosa persistence but it is clearly a topic that warrants further investigation.  
 
2.4.4 Oxidative stress 
As described above, the stringent response is involved in the formation of persisters by 
inducing antioxidant defenses and restricting the production of pro-oxidants (Nguyen et al., 
2011). In support of a role of oxidative stress in the formation of persisters, it was shown that 
H2S induces antibiotic tolerance by mitigating oxidative stress via sequestration of ferrous 
iron and by stimulating activity of antioxidant enzymes (Shatalin et al., 2011). Based on these 
results, it seems that active processes, like suppression of oxidative stress, are involved in 
persister formation, indicating that dormancy per se is not sufficient to explain the persistent 
phenotype. This is in accordance with other reports, where it was shown that the persistent 
state is far more complex than just a passive dormant state (see Section 2.2).  
Oxidative stress and persistence are also correlated in species such as E. coli and M. 
tuberculosis. In general, lowered cellular levels of hydroxyl radicals counteract the 
bactericidal action of antibiotics in persister cells. These lowered levels can be reached by 
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increased levels of detoxifying enzymes. In E. coli and S. aureus it was shown that, as in P. 
aeruginosa, the production of H2S alleviates oxidative stress by stimulating the activity of 
detoxifying enzymes. As a result, antibiotic tolerance increases (Shatalin et al., 2011). In 
addition, another report showed that M. tuberculosis persister cells have a different 
susceptibility to OH• radicals produced during antibiotic treatment (Grant et al., 2012). 
Furthermore, in E. coli, a mechanism was described in which cells increase their tolerance to 
quinolones in response to oxidative stress. Upon incubation of cells with a superoxide-
generating agent, cells regulate expression of genes through SoxRS, including upregulation of 
an efflux pump which extrudes quinolones. The lower intracellular concentration of this 
antibiotic allowed a greater fraction of the population to become a persister cell (Wu et al., 
2012).   
 
2.4.5 SOS-response 
The SOS-response, which is activated upon DNA damage, has also been shown to play a role 
in P. aeruginosa persistence. A transposon mutant of dinG, encoding a putative DNA 
helicase, showed a decreased persister fraction upon antibiotic treatment (De Groote et al., 
2009). How exactly the SOS-response is involved in P. aeruginosa antibiotic tolerance is 
currently unknown. The SOS-response has been implicated in persistence of E. coli. It was 
shown that induction of the SOS-response activates the TisB toxin, part of the tisAB TA 
module (for information on TA modules see Section 2.4.3), which binds to the membrane and 
disrupts proton motive force, causing a drop in ATP levels. As a consequence, cellular targets 
of bactericidal agents are shut down, making the cell tolerant to antibiotic treatment (Dorr et 
al., 2009; Dörr et al., 2010).  
 
2.5 Anti-persister strategies 
As described in Section 2.3.2, persisters are a major cause of treatment failure in 
immunosuppressed or immunocompromised persons. The incomplete eradication of the 
infecting bacterial population gives rise to lingering infections, which negatively affects the 
patients’ outcome. Therefore, it is important to find strategies to eliminate these antibiotic-
tolerant cells. The first hypothetical solution to deal with persisters was already reported in 
1944, along with the first description of these antibiotic-tolerant isolates in literature (1944). It 
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was suggested that treatment with a bactericidal agent which kills all susceptible cells, 
followed by withdrawal of the antibiotic, would allow persisters to resuscitate and regain 
susceptibility. By adding a second dose of antibiotics shortly after the persisters restarted 
growth, complete eradication of the bacterial population may be achieved. Many years later, 
this simple approach is supported by a mathematical model (De Leenheer & Cogan, 2009). 
Despite the successful in vitro result of such an approach (Lewis, 2007), the optimal in vivo 
protocol remains patient-specific and relies on bacterial kinetics, limiting the practical utility. 
Therefore, alternative approaches are needed to eliminate these antibiotic-insensitive cells.  
In theory, different approaches can be pursued to eliminate persisters. The first one entails 
killing of persister cells either by designing an antibiotic capable of killing both the antibiotic-
tolerant and -intolerant cells or by interfering with pathways essential for the persisters’ 
dormant state. A second approach is represented by supplementation of conventional 
antibiotics with molecules that sensitize persisters to the action of these bactericidal agents. 
Alternatively, antibiotics can be combined with molecules that prevent or decrease the 
formation of persisters by interfering with processes implicated in persistence. Below, these 
options, together with some examples, are discussed in more detail.  
 
2.5.1 Killing persisters  
It is generally accepted that the antibiotic tolerant state of persisters results from their non-
dividing, metabolically quiescent state, rendering the antibiotic targets inactive (Bigger, 1944; 
Balaban et al., 2004; Keren et al., 2004b; Shah et al., 2006; Lewis, 2007; Wood et al., 2013). 
However, integrity of the cell envelope remains crucial for viability, making these structures 
potential targets for anti-persister strategies. For instance, E. coli cells, including persisters, 
are prone to killing by membrane-acting peptides (Chen et al., 2011). In addition, the 
artylysin Art-175, a bacteriophage-encoded endolysin coupled to a targeting peptide for 
guidance through the bacterial outer membrane, kills P. aeruginosa cells including persisters 
by puncturing the peptidoglycan layer (Briers et al., 2014b).  
More recent observations provide evidence that persister cells may use active processes to 
maintain their persistent state. For instance, it was shown that active suppression of the 
oxidative stress is involved in the formation of persisters (Nguyen et al., 2011). As energy is 
needed to support these processes, an anti-persister approach may consist of inhibiting or 
Chapter 2                                                     Persister cells, clinical importance and treatment strategies  
49 
 
disturbing activity of respiratory membrane-associated enzymes (Hurdle et al., 2011). An 
example of the latter is the diarylquinoline bedaquiline, acting on the membrane-associated 
ATP synthase in M. tuberculosis (Andries et al., 2005). This compound is currently involved 
in Phase II clinical trials (NCT01691534 and NCT02193776). Another approach lies in 
targeting processes specifically needed to counteract stresses encountered in the host 
environment. For example, inhibitors of the M. tuberculosis dihydrolipoamide 
acyltransferase, an enzyme required to cope with nitric oxide-derived reactive nitrogen 
derivatives, proved to be almost exclusively bactericidal for non-multiplying M. tuberculosis 
cells (Bryk et al., 2008). Identifying such processes in P. aeruginosa could provide a starting 
point for the rational design of an anti-persister therapy.  
Another elegant strategy to kill persisters was published in which the specificity of a protease 
is removed by the acyldepsipeptide antibiotic ADEP4, resulting in self-digesting S. aureus 
cells (Conlon et al., 2013). Upon addition of ADEP4, the protease ClpP no longer needs ATP 
to exert its action, explaining its activity in energy-deprived persister cells. Since resistance 
was rapidly acquired, ADEP4 is combined with a conventional antibiotic, leading to reduced 
accumulation of resistance. This combination led to complete eradication of S. aureus in a 
neutropenic mouse thigh infection model, simulating a chronic infection in 
immunocompromised persons, within 24 hours.  
Since the physiological nature and mechanisms involved in persister formation and 
maintenance are not yet fully understood, it remains difficult to design a rational anti-persister 
strategy. Therefore, an alternative approach is to screen small-molecule collections to identify 
compounds that specifically kill dormant, non-replicating bacterial cells. A screening 
approach was described in which a nutrient-depleted stationary phase cell suspension of S. 
aureus was used to screen for novel drugs. This screen resulted in the identification of a 
quinolone-derived compound showing good activity against these non-replicating S. aureus 
cells both in vitro and in a mouse infection model. However, the drug was less potent on 
multiplying cells. The bactericidal activity of this compound results from destabilization of 
the cell membrane and destruction of the cell wall (Hu et al., 2010). Additionally, a method 
was published to identify targets for the development of drugs that prevent bacterial 
persistence. This method is based on combined transcriptional and proteolytic silencing of a 
target gene and its resulting gene product, allowing identification of proteins essential during 
growth or non-growth (Kim et al.
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2.5.2 Sensitizing persister cells 
Although persister cells perform translation at low levels (Shah et al., 2006; Gefen et al., 
2008), they remain insensitive towards the bactericidal action of protein synthesis-inhibiting 
aminoglycoside antibiotics. This results from the low metabolic state of persisters, which, 
since the uptake of aminoglycosides is an energy-dependent process (Taber et al., 1987), 
hampers entrance of these antibiotics into the bacterial cell. By adding certain metabolites to 
S. aureus or E. coli cultures, the generation of a proton-motive force increased the uptake of 
aminoglycosides and induced killing of bacterial cells (Allison et al., 2011a). More recently, 
it was shown that this was also true for P. aeruginosa (Barraud et al., 2013). In addition, it 
was shown that combining fluoroquinolones with phages expressing the major outer 
membrane protein OmpF, which forms porins that quinolones use to enter the bacterial cell 
(Nikaido, 2003), increased killing compared to monotreatment in E. coli (Lu & Collins, 
2009).  
Another example is provided by the synthetic QS inhibitor (Z)-4-bromo-5-(bromomethylene)-
3-methylfuran-2(5H)-one (BF8), which has been described to revert multidrug tolerance in 
wild type (Pan et al., 2012) and mucoid (Pan et al., 2013a) P. aeruginosa strains. 
Examination of structural analogs of BF8 revealed that not all QS inhibitors were able to 
revert persistence, pointing to the existence of other targets in addition to the ones involved in 
QS (Pan & Ren, 2013). The exact mechanism by which this molecule sensitizes persister cells 
is currently unknown.  
Lastly, screening of a small-molecule library identified a molecule that, in combination with 
ampicillin, significantly reduced the number of viable exponential phase cells compared to 
monotreatment with ampicillin (Kim et al., 2011). This molecule, 3-[4-(4-methoxyphenyl) 
piperazin-1-yl] piperidin-4-yl biphenyl-4-carboxylate (C10), reverts E. coli persisters cells to 
growing, antibiotic-sensitive cells, although the exact mechanism is currently unknown. In 
addition, it was shown that C10, in combination with a fluoroquinolone antibiotic, reduced the 
level of persister cells of a P. aeruginosa culture (Kim et al., 2011). 
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2.5.3 Interfering with processes implicated in Pseudomonas aeruginosa 
persistence 
Processes shown to play a role in persistence provide excellent targets for anti-persister 
therapies. By modulating these processes, the formation or level of persisters can be 
decreased. Some examples are given below. However, since mechanisms of persister 
formation display a high degree of redundancy (see Section 2.4), additional actions may be 
needed to completely eradicate the persister population.  
 
2.5.3.1 Interfering with stringent response 
The stringent response plays an important role in P. aeruginosa persistence by influencing 
oxidative stress protection mechanisms as described in Section 2.4.4. Since mutant P. 
aeruginosa cells defective in the stringent response showed worse survival in a murine 
infection model (Nguyen et al., 2011), components interfering with this stress response 
provide a good anti-persister strategy. Towards this end, inhibitors that prevent accumulation 
of the stringent response alarmone (p)ppGpp have been described. These molecules target 
RelA, which is absent in mammals, by interfering with binding of GDP/GTP to the active site 
(Wexselblatt et al., 2010). More recently, a more potent inhibitor of RelA, named relacin, was 
reported to reduce the (p)ppGpp level in Gram-positives in vivo (Wexselblatt et al., 2012) but 
failed to penetrate Gram-negatives efficiently.  
 
2.5.3.2 Interfering with oxidative stress 
Another possibility consists of interfering with oxidative stress responses. It was shown that 
killing of E. coli persister cells is enhanced when conventional antibiotics are combined with 
bacteriophages delivering SoxR, which is involved in the coordination of the cellular response 
to superoxide. By delivering SoxR to the bacterial cell, the response to superoxide stress is 
disturbed, enhancing the action of quinolones (Lu & Collins, 2009). Another way to enhance 
killing of persister cells is by stimulating production of intracellular reactive oxygen species 
induced by the action of antibiotics (Grant et al., 2012; Brynildsen et al., 2013).  
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2.5.3.3 Interfering with SOS-response 
An additional stress response pathway that could be targeted is the SOS-response. Phages 
overexpressing the SOS-response repressor LexA3 significantly reduced persister levels in 
combination with different classes of antibiotics (Lu & Collins, 2009). Furthermore, infected 
mice showed a significantly increased survival rate upon combination treatment, pointing to 
the feasibility of such a combination strategy for clinical use. Interestingly, several RecA 
inhibitors have been identified which attenuate the SOS-response in E. coli, providing 
possible candidates to be used in combination with conventional antibiotics for complete 
eradication of bacterial infections (Wigle et al., 2009).  
 
2.5.3.4 Interfering with quorum sensing 
Lastly, in theory, inhibitors of QS pathways should reduce the level of P. aeruginosa persister 
cells (see Section 2.4.2). Inhibitors of QS are described in Section 1.4.3).   
 
2.6 Concluding remarks 
With the many advances made in medical technology, the number and expected lifetime of 
patients with a suppressed or (partially) impaired immune system has increased. Here, 
persister cells may become a threat as they prevent total eradication of an infecting population 
upon antibiotic treatment. This small fraction of antibiotic-tolerant cells forms a reservoir of 
viable cells, capable of re-initiating an infection once the antibiotic pressure drops. In this 
way, the infection can become chronic.  
Several anti-persister strategies have been proposed which rely on designing molecules that 
interfere with processes important in formation and/or maintenance of persister cells. 
However, the persistent state, as well as the mechanisms involved in formation of these 
antibiotic-tolerant cells are not yet clear. It also becomes clear that some processes implicated 
in persistence are bacterium-specific. To better understand the mechanistic basis of 
persistence in P. aeruginosa, further research is needed. In addition, it seems that multiple 
pathways play a role in the formation of persisters. This is illustrated by the fact that, to date, 
no mutant which completely lacks the formation of persister cells was reported. Therefore, 
rational design of an anti-persister therapy remains difficult. Furthermore, future experiments 
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need to reveal whether inhibiting one of these processes is sufficient to improve clearance of 
infection in vivo.  
In the meantime, since no targets are available for rational design of an anti-persister therapy, 
a top-down approach can be used to identify molecules that, alone or in combination with a 
conventional antibiotic, kill the entire bacterial population including persister cells. The latter 
already proved to be successful (Kim et al., 2011), however, this screening was carried out on 
growing cells, which most likely does not reflect the growth state in vivo were nutrients are 
limiting. Screening of compound libraries under test conditions which better reflect the in vivo 
environment may lead to potential anti-persister molecules. 
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Chapter 3 
Scope of the thesis 
 
This thesis focuses on the nosocomial pathogen Pseudomonas aeruginosa. As treatment 
options are limited, identification of new anti-pseudomonal agents as well as development of 
new treatment strategies, which eliminate infections more effectively, are necessary. A major 
factor responsible for treatment failure is the presence of persister cells. As they survive the 
bactericidal action of antibiotics, they form a reservoir of viable cells capable of causing 
relapse of infection. Therefore, targeting these persisters will greatly improve treatment. 
However, mechanisms underlying formation of P. aeruginosa persister cells remain largely 
unknown, making it hard to develop a rational anti-persister strategy. In order to obtain more 
insight into the mechanistic basis of persistence in P. aeruginosa, a screening was previously 
conducted to identify genes involved in fluoroquinolone tolerance in this pathogen (De 
Groote et al., 2009). In this thesis, we follow up on this research. Additionally, a new research 
line was initiated, focusing on the development of an anti-persister therapy using small 
molecules.  
In a first part of the thesis, we further characterize a newly identified gene, named dnpA (de-
N-acetylase involved in persistence; gene locus PA14_66140/PA5002), which is a possible 
target for an anti-persister strategy. In Chapter 4, we demonstrate that this gene is a genuine 
persistence gene in P. aeruginosa and discuss how DnpA may contribute to fluoroquinolone 
tolerance. In Chapter 5, as a follow-up to this study, we determine the subcellular 
localization of DnpA in detail and examine its relation to persistence.  
As it becomes clear that multiple mechanisms underlie the formation of persister cells, 
rational design of an anti-persister strategy is difficult. Therefore, in a second part of this 
thesis, we conducted a medium-throughput screening to identify small molecules that, in 
combination with conventional antibiotics, reduce the persister fraction of P. aeruginosa. 
Chapter 6 describes the identification and initial characterization of such anti-persister 
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molecules. In Chapter 7, a more detailed characterization of one promising anti-persister 
molecule is carried out as well as first experiments to unravel its mode of action. These 
identified anti-persister molecules may serve as a starting point for the development of novel 
anti-persister therapies. Moreover, unraveling the mode of action of such molecules may 
reveal additional targets for the rational design of an anti-persister strategy.  
Finally, Chapter 8 contains the general conclusions of this thesis and some future 
perspectives.  
As new anti-pseudomonal compounds are limiting, a screen for growth inhibitory compounds 
against P. aeruginosa was carried out in parallel with the one described in Chapter 6. Since 
this thesis focuses on persistence, the identification and initial characterization of a promising 
anti-pseudomonal compound is described in Addendum I. 
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Chapter 4 
DnpA, a putative de-N-acetylase of the PIG-L 
superfamily affects fluoroquinolone tolerance in 
Pseudomonas aeruginosa10 
 
 4.1 Introduction  
A major cause of antibiotic treatment failure is the presence of persister cells, phenotypic 
variants of the wild type that are transiently capable of surviving prolonged periods of 
antibiotic treatment. Upon a drop in antibiotic concentration, persisters can revert to normal 
cells and regrow into a susceptible population. A few years ago, a causal link between 
persister cells and recalcitrance of chronic infections was provided (Lafleur et al., 2010; 
Mulcahy et al., 2010) underlining the importance of this cell subpopulation in treatment 
failure. 
Traditionally, persisters are considered to be non-dividing, metabolically quiescent cells in 
which inactivity of the antibacterial targets impairs the bactericidal effect (Bigger, 1944; 
Balaban et al., 2004; Keren et al., 2004b; Shah et al., 2006; Lewis, 2007). Recently, evidence 
was provided that the persistent state is far more complex than just a passive dormant state. 
Escherichia coli persister cells display some degree of translation (Gefen et al., 2008) and it 
was shown that a dormant state is not sufficient or required for a cell to become persistent 
(Orman & Brynildsen, 2013). In addition, no correlation between the growth rate of an 
individual cell and persistence was observed in Mycobacterium (Wakamoto et al., 2013). The 
                                               
10
 This Chapter was published as Liebens, V., Defraine, V., Van der Leyden, A., De Groote, V., Fierro Gutiérrez, 
A., Beullens, S., Verstraeten, N., Kint, C., Jans, A., Frangipani, E., Visca, P., Marchal, K., Versées, W., Fauvart, 
M., Michiels, J. (2014). A putative de-N-acetylase of the PIG-L superfamily affects fluoroquinolone tolerance in 
Pseudomonas aeruginosa. Pathogens and Disease, 71 (1), 39-54. 
Analysis of transcriptome data described in this Chapter was performed by Dr. Carolina Fierro (KU Leuven) 
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molecular mechanism underlying persister formation in Pseudomonas aeruginosa is largely 
unknown and only few genetic determinants have been described to influence persister 
formation in this pathogen (Fauvart et al., 2011). These include the quorum sensing 
determinants lasI and lasR (Kayama et al., 2009), the alternative sigma factor RpoN (Viducic 
et al., 2007) and the stationary phase regulators RpoS, DskA, RelA and SpoT (Murakami et 
al., 2005; Viducic et al., 2006). More recently, it was shown that persistence in P. aeruginosa 
is mediated by the stringent response. Activation upon starvation leads to suppression of 
oxidative stress by inducing antioxidant defenses and restricting the production of pro-
oxidants (Nguyen et al., 2011). This result further supports the theory that, as in E. coli, target 
inactivity per se is not sufficient to explain the persistent phenotype. In order to improve 
treatment of chronic P. aeruginosa infections, a better understanding of the persistent state 
and formation of these antibiotic-tolerant cells is necessary.  
Previously, we performed a high-throughput screening of a P. aeruginosa PA14 mutant 
library to identify new persistence genes (De Groote et al., 2009). In this Chapter, we 
demonstrate that dnpA (de-N-acetylase involved in persistence; gene locus 
PA14_66140/PA5002) is a genuine persistence gene in P. aeruginosa and discuss how DnpA 
may contribute to fluoroquinolone tolerance.  
 
4.2 Experimental procedures 
Bacteria and culture conditions. P. aeruginosa strains were cultured in Trypticase Soy 
Broth (TSB) or in Mueller Hinton Broth (MHB) at 37 °C. For solidified medium, 1.5 % agar 
was added. Following antibiotics were used: ofloxacin, ciprofloxacin, piperacillin, 
cefotaxime, ceftazdime, tobramycin, amikacin, polymyxin B, gentamicin (45 µg mL-1), 
tetracycline (10 or 100 µg mL-1) and ampicillin (100 µg mL-1). Strains used in this study are 
listed in Table 4.1.  
Persistence assay. The persistence assay was performed as described previously with minor 
modifications (De Groote et al., 2009). Briefly, stationary phase cultures grown in MHB were 
treated with ofloxacin at a final concentration of 5 µg mL-1 for 5 hours at 37 °C while shaking 
at 200 rpm. A control treatment with sterile water was performed in parallel. The number of 
colony forming units (CFU) was determined by plate counts. The persister fraction is defined 
as the number of surviving cells after treatment with ofloxacin divided by the number of cells 
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after control treatment. These conditions were previously optimized as higher ofloxacin 
concentrations or increased incubation times do not lead to a further reduction of the number 
of surviving cells. Each experiment was independently repeated at least three times.  
 
Table 4.1: Bacterial strains and plasmids used in this study 
Strain Description* Source 
Escherichia coli 
TOP10 F- mcrA ∆(mrr-hsdRMS-mcrBC) 
φ80lacZ∆M15 ∆lacX 74 recA1 
araD139 ∆(ara leu) 7697 galU galK 
Invitrogen 
   
Pseudomonas aeruginosa  
PA14 Wild type Liberati et al. (2006) 
dnpA mutant PA14 with an insertion in PA14_66140 
(dnpA) (mutant ID 27910); GmR 
Liberati et al. (2006) 
PA14_66120 PA14 with an insertion in PA14_66120 
(mutant ID 33516); GmR 
Liberati et al. (2006) 
   
Plasmids 
pME6032 pVS1 derived shuttle vector; TcR Heeb et al. (2000) 
pME6032-dnpAHis dnpA containing C-terminal His-tag 
cloned into pME6032 
This chapter 
pME6032-dnpAD190NHis dnpA-D190N containing C-terminal 
His-tag cloned into pME6032 
This chapter 
pME6032-dnpAD340NHis dnpA-D340N containing C-terminal 
His-tag cloned into pME6032 
This chapter 
pUC18 Broad host range shuttle vector; ApR Yanisch-Perron et al. (1985) 
pUC18-dnpA EcoRI - PstI digestion of pME6032-
dnpAHis cloned into pUC18 
This chapter 
*GmR, gentamicin resistant; TcR, tetracycline resistant; ApR ampicillin resistant 
 
MIC determination. The minimal inhibitory concentration (MIC)
 
was determined with a 
broth microdilution procedure using MHB growth medium. A start inoculum of 5.105 cells 
per mL-1 was prepared and incubated in the presence of a 2-fold dilution series of each 
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antibiotic. After 24 hours of growth at 37 °C, the OD595 was measured and the lowest 
antibiotic concentration that completely inhibited bacterial growth was considered the MIC. 
The following concentration ranges were tested: ofloxacin (10 - 0.02 µg mL-1), ciprofloxacin 
(2.5 - 0.005 µg mL-1), piperacillin (60 - 0.10 µg mL-1), cefotaxime (250 - 0.49 µg mL-1), 
ceftazdime (100 - 0.2 µg mL-1), tobramycin (8 - 0.016 µg mL-1), amikacin (80 - 0.16 µg mL-1) 
and polymyxin B (10 - 0.02 µg mL-1). Each antibiotic was tested independently three times.  
Biofilm assay. The assay was performed essentially as described previously (Merritt et al., 
2005; Maisonneuve et al., 2013) with the following adjustments: P. aeruginosa stationary 
phase cultures were washed in phosphate buffered saline (PBS; composition for 1 L: 8 g 
NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g KH2PO4, pH 7.4), diluted to an OD595 of 0.05 and 
spotted on sterile membranes (Durapore® Membrane Filter 0.22 µm GV, Millipore) placed 
on solid TSB. The plates were incubated at 37 °C for 24 hours. To assess the persister 
fraction, membranes were placed in parallel on solid medium with or without 20 µg mL-1 
ofloxacin for 24 hours. Subsequently, the number of surviving cells was determined by 
resuspending the biofilm mass in sterile PBS by vigorous vortexing and plating serial 
dilutions on solid TSB medium. The number of persister cells was determined as described 
above.  
Plasmid construction. For complementation experiments, dnpA was amplified by using 
primer couple SPI6628-6634. SPI6634 encodes a His-tag. The resulting PCR fragment was 
EcoRI - BglII cloned into pME6032 (Heeb et al., 2000) and confirmed by sequencing. The 
plasmid was introduced into a P. aeruginosa dnpA insertion mutant by electroporation 
(Farinha & Kropinski, 1990). To obtain pUC18-dnpA, pME6032-dnpAHis was digested with 
EcoRI - PstI and dnpA was subcloned into pUC18. For sequences of the primers see Table 
4.2. 
Lipopolysaccharide (LPS) analysis. LPS isolation was performed essentially as described 
previously (Hitchcock & Brown, 1983). Briefly, stationary phase cells were washed in PBS 
after which they were resuspended in 250 µL of Hitchcock and Brown lysis buffer. Samples 
were heated for 30 minutes at 100 °C, cooled to room temperature and incubated overnight at 
55 °C with 1.5 µL proteinase K solution (20 µg mL-1). For sodium dodecyl sulphate 
polyacrylamide gel electrophoresis analysis (SDS-PAGE), samples were heated at 100 °C for 
5 minutes prior to loading on gel (NuPAGE® Novex, 12 % BisTris, Invitrogen). LPS profiles 
were visualised by the ultra-fast silver staining method described by Fomsgaard et al. (1990).  
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Table 4.2: Primers used in this Chapter 
Primer name Sequence 
SPI6628 CACCGAATTCAGCATGAGCGCACGCAAG 
SPI6634 ACTCAGATCTTCAATGATGATGATGATGATGCTCGAGCGCCTCCCCATCCAG 
SPI5463 CATTTCGATCCGCACCCGAACCATGTCCGCGCCCAGG 
SPI5464 CCTGGGCGCGGACATGGTTCGGGTGCGGATCGAAAT 
SPI8820 TCGGCGTCGTTGGCATGCGGA 
SPI8821 TCCGCATGCCAACGACGCCGA 
 
Isolation of membrane fractions. Outer and inner membrane fractions were isolated by a 
modification of the Hancock and Nikaido method (Hancock & Nikaido, 1978). An overnight 
culture was diluted 100-fold into fresh medium. At an OD595 of 0.5, the cells were induced 
with 1 mM isopropyl ß-D -1-thiogalactopyranoside (IPTG) for one hour after which the cells 
were harvested by centrifugation. The resulting cell pellet was washed in a 30 mM Tris/HCl 
150 mM NaCl buffer (pH = 7) and resuspended in a 30 mM Tris/HCl buffer (pH = 8) 
containing 20 % sucrose, 1 mM phenylmethylsulfonyl fluoride, 0.5 mg mL-1 lysozyme, 0.05 
mg mL-1 DNase and 0.05 mg mL-1 RNase. After 30 minutes of incubation at 37 °C, the cells 
were further disrupted by sonication. The cell debris was removed by low speed 
centrifugation and the supernatant was layered onto a sucrose step gradient containing one mL 
of 70 % (wt/vol) sucrose and 6 mL of 30 % (wt/vol) sucrose in 30 mM Tris/HCl buffer (pH = 
8). These samples were centrifuged at 183,000 g in a Beckman SW41Ti rotor for one hour. 
After centrifugation, the interface between the 30 % and 70 % layers was collected and used 
for another round of ultracentrifugation with a sucrose density gradient containing steps of 
one mL of 70 % (wt/vol) sucrose, 3 mL of 60 % (wt/vol) sucrose, 3 mL of 52 % (wt/ vol) 
sucrose, and 3 mL of 30 % (wt/vol) sucrose in Tris buffer. After overnight centrifugation (14 
hours at 183,000 g), the inner and outer membrane fractions were removed by suction from 
above. These fractions were washed in 20 % (wt/vol) sucrose (1 hour at 183,000 g) and the 
resulting cell pellet was resuspended in a small volume of double distilled water. The outer 
membrane fraction was subjected to a treatment with 2 % N-lauryl-sarcosine (Sarcosyl) in 
order to ensure the purity of this fraction.  
Site-directed mutagenesis. Site-specific mutations were introduced using the QuikChange 
Site-Directed Mutagenesis Kit (Stratagene) with pUC18-dnpA as template DNA. Briefly, a 
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PCR reaction was carried out using SPI5463-5464 and SPI8820-8821 for introduction of the 
D340N and D190N mutations, respectively, using a nonstrand-displacing DNA polymerase. 
The resulting PCR product was treated with DpnI to destroy the methylated parental non-
mutated DNA after which it was transformed into chemocompetent E. coli TOP10 cells. 
Subsequently, dnpA was EcoRI-PstI subcloned into pME6032-dnpAHis and the resulting 
plasmid was introduced into P. aeruginosa wild type by electroporation (Farinha & 
Kropinski, 1990). The presence of the correct mutation was verified by sequencing. 
Expression of mutant proteins was checked by western blotting. Sequences of the primers are 
listed in Table 4.2.  
Western blotting. Overnight cultures were diluted 100-fold in TSB containing appropriate 
antibiotics and incubated at 37 °C while shaking at 200 rpm. After three hours of growth, 
cultures were induced with 1 mM IPTG for 4 hours after which the cells were collected by 
centrifugation and stored at -80 °C. The resulting cell pellet was resuspended in lysis buffer (8 
M Urea, 100 mM NaH2PO4, 10 mM TrisCl, pH 8) containing 1 mg mL-1 lysozyme and 
incubated at 37 °C for 30 minutes. Subsequently, the cells were further disrupted by 
sonication after which the total protein fraction was separated from the cell debris by 
centrifugation. Next, proteins were separated by SDS-PAGE on a NuPAGE® Novex 12 % 
BisTris protein gel (Invitrogen). Following western blotting, hybridization was performed 
using a monoclonal anti-His6 antibody solution (Roche) and Anti-Mouse IgG Alkaline 
Phosphatase Conjugated Antibody (Sigma-Aldrich) as primary and secondary antibody, 
respectively. 
Sample preparation and microarray hybridization. Overnight cultures were diluted 100-
fold into fresh medium and grown until late-exponential phase (OD595 = 1). The RNA content 
of 20 mL bacterial culture was stabilized by adding 1:5 volume of ice-cold phenol:ethanol 
(5:95) after which cells were harvested by centrifugation. The cell pellet was frozen in liquid 
nitrogen and stored at -80 °C. Total RNA was isolated as described by Vercruysse et al. 
(2010) and Meysman et al. (2014) using the Pure Link RNA mini Kit (Ambion). RNA 
integrity was evaluated using Experion RNA StdSens Chips (Bio-Rad). RNA quantity and 
purity was assessed by measuring the A260/A280 and A260/A230 ratio of each sample. The 
ratio of all samples was ≥ 1.8. For each strain RNA isolation was done in triplicate. cDNA 
generation, fragmentation, biotinylation and hybridization on GeneChip P. aeruginosa 
Chapter 4                                     dnpA controls fluoroquinolone tolerance in Pseudomonas aeruginosa  
63 
 
Genome Arrays (Affymetrix) was performed according to the Affymetrix protocol by The 
Centre for Applied Genomics, The Hospital for Sick Children, Toronto, Canada.  
Microarray data analysis. Microarray data were normalized using RMA implemented in the 
Bioconductor ”affy” package. Pearson correlation across samples and spectral map analysis 
(Wouters et al., 2003) were used to check consistency between samples and to identify an 
outlier that was removed from subsequent analysis. Differential expression was calculated 
using an empirical Bayesian method implemented in the LIMMA R package (Smyth, 2004). 
P-values were adjusted for multiple testing using the Benjamini & Hochberg method 
(Benjamini & Hochberg, 1995). A final list of differentially expressed genes was obtained at a 
False Discovery Rate (FDR) of 15 %. Lower FDR thresholds drastically reduced the gene 
selection and resulted in very limited functional annotation. P. aeruginosa gene annotation 
was obtained from www.pseudomonas.com (Winsor et al., 2011) and KEGG (Kanehisa & 
Goto, 2000). PseudoCAP functional classes were used to calculate functional enrichment on 
the lists of differentially expressed genes. Enriched terms were obtained with Fisher’s exact 
test at a FDR of 5 %.  
Network analysis. P. aeruginosa functional interactions were obtained from the STRING 
database (Jensen et al., 2009). Only gene-gene interactions with a minimum reliability score 
of 0.8 were retained. A deregulated network was extracted by selecting interactions in which 
both genes are differentially expressed in the dnpA mutant and/or under dnpA overexpression. 
Network visualization was done with Cytoscape (Smoot et al., 2011). The deregulated 
network was used to identify groups of genes which are consistently up/down (or down/up) 
regulated in the dnpA mutant and in the strain overexpressing dnpA, respectively. Two 
community detection methods were used to subdivide the largest network component into 
smaller sub-networks: walktrap (Pons & Matthieu, 2005) and edge betweenness (Newman & 
Girvan, 2004) algorithms. The 58 smallest network components were used as independent 
sub-networks without any modification. We used Fisher’s exact test to select sub-networks 
with significant and consistent differential expression (P < 0.05). Only the genes present in 
the deregulated network were considered for Fisher’s exact test. Each significant and 
consistent sub-network was annotated with the PseudoCAP functional classes (see above). 
Statistical analysis. For each comparative analysis, significant difference in variance of the 
log persister fractions was checked using a Fisher F-test. In case of statistically different 
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variances a Welch test for the means was applied, otherwise a student’s t-test was performed. 
Normality of the log persister fractions was verified.  
 
4.3 Results 
4.3.1 DnpA is involved in fluoroquinolone tolerance 
Previously, a P. aeruginosa PA14 random insertion mutant library was screened to identify 
new persistence genes. Nine mutants with an altered persister fraction after treatment with the 
fluoroquinolone antibiotic ofloxacin were selected (De Groote et al., 2009). One of these 
mutants, CMPG13401, displays a 10-fold decreased persister fraction compared to the wild 
type and was selected for further characterization. The mutant contains an insertion in gene 
locus PA14_66140 (PA5002 in P. aeruginosa PAO1, Figure 4.1) which we propose to 
rename dnpA (de-N-acetylase involved in persistence). The mutant displays the same MIC 
value for ofloxacin as the isogenic wild-type strain (De Groote et al., 2009), excluding the 
involvement of fluoroquinolone resistance mechanisms. Growth characteristics of the mutant 
were indistinguishable from wild-type growth (De Groote et al., 2009).  
 
 
Figure 4.1: Overview of LPS core oligosaccharide gene cluster. Arrows indicate ORFs, gene names and both 
PAO1 and PA14 gene numbers are indicated.  
 
Next, we analyzed a mutant in the same gene obtained from an independent mutant library 
(Liberati et al., 2006). Similarly, the strain shows a 6-fold (P < 0.01) decrease in persister 
cells (Figure 4.2A), while no differences could be detected in MIC (Table 4.3) and growth 
characteristics (data not shown). All subsequent experiments were carried out with this strain. 
Controlled overexpression of dnpA in the dnpA mutant resulted in a 2.6-fold increase of the 
persister fraction compared to the empty vector control (Figure 4.2B). It should be noted that 
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the persister fraction of wild type and dnpA mutant strain containing the empty vector is 
similar. Finally, overexpression of the dnpA allele in the wild-type background increased the 
persister fraction 4-fold (P < 0.05; Figure 4.2C). Taken together, these results strongly support 
a role for dnpA in fluoroquinolone tolerance in P. aeruginosa. 
 
 
Figure 4.2: Relative persister fractions. Stationary phase cells of A. wild type (WT) and dnpA mutant (dnpA
-
) B. 
wild type and dnpA mutant containing plasmid pME6032 (WT\pME6032 and dnpA
-
\pME6032 respectively) and 
dnpA mutant overexpressing dnpA from the plasmid pME6032 (dnpA
-
\pME6032-dnpAHis) C. wild type carrying 
pME6032 and wild type strain overexpressing dnpA from the plasmid pME6032 (WT\pME6032 and 
WT\pME6032-dnpAHis respectively) were treated in parallel with ofloxacin and sterile water for 5 hours. 
Subsequently, the cell suspension was diluted and plated out after which the number of surviving cells was 
determined. Data points correspond to the mean relative persister fraction. Each experiment was repeated 
independently at least three times. Error bars represent the standard error of the mean (SEM). A persister 
fraction of 100 % corresponds to 1.04 × 10
-4 
(panel A) and 3.43 × 10
-5
 (panel B and C). *P < 0.01, **P < 0.05. 
 
Polar effects on expression of genes located downstream of the transposon insertion site in 
dnpA could contribute to a change in fluoroquinolone tolerance of the dnpA mutant. However, 
recent RNA-Seq data suggest that dnpA (PA14_66140) is the distal gene of a transcriptional 
unit starting from PA14_66170 (Wurtzel et al., 2012) or PA14_66150 (Filiatrault et al., 2010; 
Dotsch et al., 2012), rendering this possibility unlikely. To formally exclude polar effects, a 
mutant with an insertion in the downstream gene PA14_66120 (Liberati et al., 2006) was 
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analyzed. The mutant displays wild-type levels of fluoroquinolone tolerance (with an absolute 
persister fraction of 1.04 × 10-4 ± 3.81 × 10-6 and 2.86 × 10-4 ± 1.99 ×10-5; P-value = 0.12 for 
wild type and PA14_66120 mutant, respectively) suggesting that PA14_66120 is not required 
for persistence. More importantly, this result shows that the decrease in persistence observed 
for the dnpA insertion mutant is solely caused by inactivation of dnpA. 
 
4.3.2 DnpA is involved in biofilm persistence 
Persisters are believed to contribute significantly to the recalcitrance of biofilm-associated 
infections (Lewis, 2005; Percival et al., 2011). To analyse whether dnpA is required for 
persistence in biofilms, we performed a recently described colony biofilm susceptibility assay 
(Maisonneuve et al., 2013). Static biofilms were grown on a membrane during 24 hours after 
which they were exposed to ofloxacin for 24 hours. As shown in Figure 4.3A, the dnpA 
mutant exhibits a 10-fold reduction in persister fraction (P < 0.1). Biofilm formation of the 
mutant strain was not different from the wild type as determined by viable cell counts of 
untreated biofilms (Figure 4.3B). These results show that dnpA plays a role in persistence 
both in free-living conditions and in a biofilm mode of growth. 
 
4.3.3 The antibiotic resistance profile of the dnpA mutant is unchanged  
The two gene loci adjacent to dnpA were previously implicated in antibiotic resistance. The 
PA14 derivatives mutated in PA14_66120 and PA14_6150, respectively downstream and 
upstream of dnpA, were identified in several independent large-scale, systematic screenings 
for resistance genes. Both genes are involved in susceptibility to the penicillin antibiotic 
piperacillin, the cephalosporines ceftazidime and cefotaxime, and the carbapenem meropenem 
(Wiegand et al., 2008; Dotsch et al., 2009; Alvarez-Ortega et al., 2010). In addition, it was 
shown that PA14_66120 is also involved in susceptibility to the aminoglycoside tobramycin 
(Schurek et al., 2008). However, neither mutant was implicated in resistance to 
fluoroquinolone antibiotics (Breidenstein et al., 2008; Dotsch et al., 2009). We therefore 
decided to test the sensitivity of the dnpA mutant to antibiotics belonging to different classes: 
piperacillin (penicillins), cefotaxime and ceftazidime (cephalosporins), ciprofloxacin and 
ofloxacin (fluoruoquinolones), tobramycin and amikacin (aminoglycosides) and polymyxin B. 
The MIC values for PA14 wild type and dnpA mutant are listed in Table 4.3. The mutant 
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displays unaltered susceptibility towards all antibiotics listed. Modest changes in MIC value 
(2-fold) were observed for the β-lactams piperacillin and cefotaxime but such changes are 
generally considered within the acceptable range of error.  
 
 
Figure 4.3: DnpA is involved in biofilm persistence. A. Biofilms formed by wild type (WT) and dnpA mutant 
(dnpA
-
) strains were subjected to a 24 hour treatment. Subsequently, the cells were diluted and plated out 
after which the number of surviving cells was determined. Data points correspond to the mean relative 
persister fraction. A persister fraction of 100 % corresponds to 3.22 × 10
-3
. *P < 0.1. B. The number of viable 
cells within untreated biofilms of WT and dnpA
-
. Data points correspond to the mean. Each experiment was 
repeated independently at least three times. Error bars represent SEM.  
 
Table 4.3: Antibiotic resistance profile of wild type and dnpA mutant. MIC (µg mL
-1
) for each antibiotic is 
shown.  
Antibiotic Wild type dnpA mutant 
Ofloxacin 1.25 1.25 
Ciprofloxacin 0.15 0.15 
Piperacillin 15 30 
Cefotaxime 31.25 62.50 
Ceftazidime 6.25 6.25 
Polymyxin B 0.32 0.32 
Tobramycin 0.50 0.50 
Amikacin 1.25 1.25 
 
4.3.4 Genomic conservation of DnpA  
dnpA is part of the LPS biosynthesis gene cluster that comprises P. aeruginosa PA14 genes 
PA14_66250 to PA14_66060. Conservation analysis revealed that the cluster is present in 
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each of the 45 sequenced Pseudomonas genomes (totaling 13 species)(Winsor et al., 2011), as 
well as in Azotobacter vinelandii, a close relative of Pseudomonas (Rediers et al., 
2004)(Figure 4.4). Surprisingly, an dnpA orthologue was also identified in the genome 
sequence of the unclassified β-proteobacterium “Candidatus Accumulibacter phosphatis”. 
The first seven genes of this cluster (PA14_66250-PA14_66190) are well conserved in all 
sequenced Pseudomonas species with regard to their presence and location within the cluster 
and are involved in the inner core biosynthesis of the LPS oligosaccharide (King et al., 2009). 
Even though most of the other cluster genes are present throughout all of the sequenced 
Pseudomonas species (except for wapH, wapR, PA14_66120, waaL and PA14_66060), our 
analysis revealed that they exhibit a low level of synteny. PA14_66150-dnpA is conserved as 
one unit in all the analyzed genomes; however, its genomic location relative to the cluster is 
not conserved. This is most pronounced in Pseudomonas putida where they are clustered in a 
different genomic location. This might implicate that these genes are not necessarily involved 
in the LPS core oligosaccharide synthesis. PA14_66150 is related to the Salmonella enterica 
sv. Typhimurium regulatory mig-14 gene (Pfam PF07395). Recently, it was shown that this 
locus is involved in lipid A modification upon recognition of cationic antimicrobial peptides 
(AMPs) in P. aeruginosa PAO1 (Jochumsen et al., 2011). The glycosyltransferase WapR is 
the least conserved locus in the cluster. 
 
4.3.5 DnpA does not cause major LPS modifications 
To assess whether DnpA is involved in LPS biosynthesis or modification, LPS profiles of 
wild type, dnpA mutant and dnpA overexpressing strains were compared (Figure 4.5A). No 
differences in LPS profile were visible between these strains and their respective wild-type 
parent. This result indicates that DnpA, if involved in LPS synthesis, likely induces minor 
changes. These minor changes do not disrupt LPS core stability and therefore do not result in 
altered LPS profiles. In addition, we compared outer and inner membrane protein profiles of 
wild type and dnpA mutant but no significant differences could be detected (Figure 4.5B). 
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Figure 4.4: Conservation and synteny of the LPS core oligosaccharide gene cluster. A representative set of genomes of sequenced Pseudomonas species and the 
closely related Azotobacter  vinelandii are shown. Arrows indicate Open Reading Frames (ORFs), coloured arrows indicate genes that correspond to the PA14 cluster 
genes. Orthologous ORFs are shaded in identical colors and are connected by grey areas, pink areas connect orthologues of the PA14_66150-dnpA unit. // indicates 
discontinuity in gene order. Gene names and PA14 gene numbers are indicated.  
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Figure 4.5: LPS profiles and membrane fractions. A. LPS profiles of wild type, dnpA mutant and dnpA 
overexpressing strains. LPS was isolated and analyzed as described in material and methods. LPS profiles of WT 
and dnpA mutant (dnpA
-
) (left panel) and of WT containing plasmid pME6032 (WT\pME6032) and WT 
overexpressing dnpA from the plasmid pME6032 (WT\pME6032-dnpAHis) (right panel). B. SDS-PAGE analysis of 
outer (OM) and inner membrane (IM) fractions of wild type and dnpA mutant (dnpA
-
) respectively. Membrane 
fractions were isolated as described in material and methods. M: Wide range SigmaMarker (Sigma-Aldrich).  
 
4.3.6 DnpA is a putative de-N-acetylase 
Based on its deduced amino acid sequence DnpA is a member of the PIG-L or LmbE-like 
superfamily (Pfam PF02585) grouping over 4150 protein sequences (as of January 2014) 
from eukaryotes, archaea and bacteria. Over a dozen of these have been biochemically 
characterized and were shown to deacetylate the N-acetyl group of N-acetylglucosamine in 
various substrates (Watanabe et al., 1999; Newton et al., 2000; Chang et al., 2002; Smith et 
al., 2002; Steffek et al., 2003; Tanaka et al., 2004; Urbaniak et al., 2005; Vats et al., 2005; Ho 
et al., 2006; Truman et al., 2007; Yokoyama et al., 2008; Wehmeier & Piepersberg, 2009; 
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Deli et al., 2010; Gaballa et al., 2010; Ashraf et al., 2013). The proteins typically display low 
overall sequence identity (~25 %) but share a catalytic site containing a number of conserved 
residues that are essential for enzymatic activity. Multiple sequence alignment of DnpA with 
all PF02585 members with reported activity suggests that crucial amino acid residues of the 
DnpA active site are intact (Figure 4.6). We therefore predict that DnpA is also a de-N-
acetylase, probably acting on N-acetylglucosamine residues, though the exact nature of its 
substrate remains to be determined.  
 
 
Figure 4.6: Partial sequence alignment of the active site of DnpA and related N-deacetylases. All proteins 
except for DnpA were previously demonstrated to exhibit enzymatic activity (see indicated references below). 
Fully conserved residues are shown in white text on a black background. Metal binding residues are indicated 
by diamonds, the catalytic base by a star and the substrate binding residue by a circle. The alignment was 
constructed using Cobalt (Papadopoulos & Agarwala, 2007). Full species names and Genbank protein accession 
numbers: Homo sapiens, BAA74775 (Watanabe et al., 1999); Rattus norvegicus, BAA74776 (Watanabe et al., 
1999; Urbaniak et al., 2005); Trypanosoma brucei, AAN60997 (Chang et al., 2002); Leishmania major, 
AAN60998 (Chang et al., 2002); Plasmodium falciparum, CAG25059.2 (Smith et al., 2002); Entamoeba 
histolytica, XP_654497.1 (Vats et al., 2005; Ashraf et al., 2013); Thermococcus kodakaraensis, Q6F4N1 (Tanaka 
et al., 2004); Nonomuraea sp. ATCC39727, CAD91216 (Ho et al., 2006); Actinoplanes teichomyceticus, 
CAG15014 (Ho et al., 2006); Streptomyces fradiae, BAD95829 (Yokoyama et al., 2008); Streptomyces 
kanamyceticus, CAF31592 (Wehmeier & Piepersberg, 2009); Mycobacterium tuberculosis, NP_215686 (Newton 
et al., 2000) and NP_215598 (Steffek et al., 2003); Bacillus anthracis, AAP25493 (Gaballa et al., 2010); Bacillus 
circulans, BAE07068 (Truman et al., 2007); Bacillus cereus, NP_831313 (Deli et al., 2010); P. aeruginosa, 
NP_253689. 
 
Overexpression of dnpA in a wild-type background increases the persister fraction 
significantly. To test if this putative de-N-acetylase activity is important for persistence, two 
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specific point mutations were independently introduced into the putative catalytic site of 
DnpA. Expression of the mutant alleles was verified by western blotting (Figure 4.7A). Next, 
the effect of overexpression of the mutant alleles on persistence was examined. The first 
mutation converts Asp-340 into Asn (D340N). This specific mutation has been reported to 
inactivate the in vitro de-N-acetylase activity of the Bacillus cereus PIG-L protein BC1534 on 
many but not all substrates (Deli et al., 2010). Secondly, a D190N mutation was introduced, 
changing the predicted catalytic base Asp-190 into Asn. The corresponding mutation in 
mammalian PIG-L completely abolishes de-N-acetylase activity (Urbaniak et al., 2005). The 
persister fraction in a wild-type background increased significantly upon overexpression of 
DnpA-D190N (P < 0.05), whereas overexpression of the DnpA-D340N allele had no effect 
(Figure 4.7B).  
 
 
Figure 4.7: A. Western blot analysis of cells expressing wild-type and mutant dnpA alleles from pME60332. 
Precision Plus Protein Kaleidoscope Standards (Bio-Rad) was used as molecular marker. The molecular weight 
of DnpA-His is approximately 54,64 kDa. B. Relative persister fraction upon overexpression of wild-type and 
mutant dnpA alleles. The persister fraction was determined by treating stationary phase cells for 5 h with 
ofloxacin and sterile water respectively. Prior to treatment, cells were induced with IPTG to ensure expression 
of dnpA from the Ptac promoter on pME6032. Data points correspond to the mean relative persister fraction. 
Each experiment was repeated independently at least three times. Error bars represent SEM. A relative 
persister fraction of 100 % corresponds to 4.59 × 10
-5
. P < 0.05. 
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4.3.7 Trancriptome analysis 
In order to shed more light on the cellular function of DnpA and its role in fluoroquinolone 
tolerance in P. aeruginosa, a transcriptome analysis was carried out. Sampling was carried out 
at late-exponential phase, when the persister fraction started to increase (Figure 4.8). RNA 
from PA14 wild type, dnpA mutant and PA14 wild type overexpressing dnpA was isolated in 
triplicate and analyzed on GeneChip® P. aeruginosa Genome Arrays (Affymetrix). 
Differentially expressed genes were identified as described in Experimental procedures.  
 
 
Figure 4.8: Evolution of the persister fraction after dilution into fresh medium. Stationary phase cells were 
diluted 100-fold into fresh medium. Every hour, an aliquot was taken of which A. the optical density (595 m) 
and B. the persister fraction was monitored. The persister fraction was determined following a 5 h treatment 
with ofloxacin. Untreated cells were used as a control. Data points correspond to the mean relative persister 
fraction. Each experiment was repeated independently at least three times. Error bars represent SEM. A 
relative persister fraction of 100 % corresponds 2.15 × 10
-5
. Samples for RNA isolation were taken at an OD595 of 
1 when the persister fraction started to increase (indicated by an arrow).   
 
In total, 601 and 393 genes were differentially expressed in mutant and overexpression strain, 
respectively. In the mutant, 54.1 % (327/601) of the genes were downregulated whereas in the 
overexpression strain this percentage increased up to 63.9 % (251/393) (Figure 4.9).  
The differentially expressed genes were classified into functional categories according to the 
PseudoCAP categories for both dnpA mutant and overexpression strain. Enriched functional 
categories were obtained according to Fisher’s exact test (P < 0.05). This resulted in five 
enriched functional categories for both dnpA mutant and overexpression strain (Figure 4.10), 
of which categories “Amino acid biosynthesis and metabolism” and “Energy metabolism” 
Chapter 4                                     dnpA controls fluoroquinolone tolerance in Pseudomonas aeruginosa  
74 
 
were shared among both conditions. For all categories, the majority of the genes was 
downregulated. 
 
 
Figure 4.9: Gene expression overview. Venn diagram representing the number of differentially expressed 
genes in the dnpA mutant (dnpA
-
) and the dnpA overexpression strain (dnpA
+
) and the overlap between the 
two strains. Upward- and downward-oriented arrows indicate gene induction and repression, respectively. 
 
 
Figure 4.10: Differentially expressed genes grouped by functional categories. The number of up-and 
downregulated genes are shown for each functional category. The differential gene expression of A. the dnpA 
mutant and B. the dnpA overexpression strain using wild type as a reference condition.  
 
4.3.8 Functional network analysis of differentially expressed genes  
To identify processes that are consistently affected in both the dnpA mutant and 
overexpression strain, a functional interaction network was constructed. This network was 
constructed based on interactions in which both genes were differentially expressed in the 
dnpA mutant and/or dnpA overexpression strain. This deregulated network contains 429 genes 
and 1030 interactions and resulted in a large network component of 253 genes and 850 
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interactions and 58 smaller components with 2 to 16 genes. Based on this network we selected 
5 sub-networks that were consistently up/down or down/up in both conditions (Fisher’s exact 
test P < 0.05). These sub-networks were annotated with the PseudoCAP functional classes 
and are shown in Figure 4.11. Genes belonging to each sub-network are shown in Table 4.4.  
Sub-network 1 contains genes with a role in amino acid biosynthesis and metabolism. Genes 
of this category that are differentially expressed in the dnpA overexpressing strain are 
downregulated. Likewise, genes of sub-network 4 belonging to the amino acid biosynthesis 
and metabolism functional category are downregulated in the dnpA overexpressing strain. In 
addition, genes with a role in energy metabolism (sub-network 5) are downregulated upon 
overexpression of dnpA. Taken together, these results suggest that overexpression of dnpA 
may lead to a lower metabolic activity.  
Sub-network 2 consists of genes all classified into the “Cell wall/LPS/Capsule” functional 
category. Overall, these genes are downregulated in the dnpA mutant. However, as mentioned 
earlier, no difference could be detected between LPS profiles of wild type and mutant. Genes 
belonging to the third sub-network are all involved in motility and attachment. More 
specifically, genes involved in synthesis of type IV pili are downregulated in the mutant while 
a regulator of twitching motility fimS/algZ (Whitchurch et al., 1996) is upregulated in the 
overexpressing strain.  
 
4.4 Discussion  
We report the characterization of a new P. aeruginosa persistence gene named dnpA (PA14 
locus PA14_66140/PAO1 locus PA5002). A dnpA insertion mutant shows a reduced persister 
fraction both in broth and in a colony biofilm model while overexpression of the dnpA allele 
in the wild-type background increases the persister fraction. Furthermore, the corresponding 
PAO1 mutant displays a similar decrease in persister fraction (De Groote et al., 2009) lending 
support for a non-strain-specific role of dnpA in fluoroquinolone tolerance.  
dnpA is part of a gene cluster responsible for synthesis of the LPS core that contains 17 ORFs 
(P. aeruginosa PA14 PA14_66250 - PA14_66060). Excepted dnpA, PA14_66150 and 
PA14_66190, these genes have a predicted or verified role in the assembly and regulation of 
the biosynthesis of LPS core molecules in P. aeruginosa (King et al., 2009; Lam et al., 2011). 
C
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Figure 4.11: Differentially expressed genes mapped on the functional interaction network STRING. Dark blue and red coloured circles represent genes downregulated 
in dnpA mutant or dnpA overexpression strain, respectively. Upregulated genes in mutant and overexpression strain are represented by purple and green coloured 
circles. Light blue and orange circles define genes down or upregulated in both conditions respectively. The five selected sub-networks are indicated (P < 0.05) and 
gene names or PA14 gene numbers are shown. 
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Table 4.4: Genes differentially expressed in dnpA mutant (dnpA
-
) or overexpressing strain (dnpA
+
) for each 
selected sub-network 
Gene number Gene  
name 
Product name and/or function Fold change (log2) 
dnpA- 
/WT 
dnpA+ 
/WT 
Sub-network 1: Amino acid biosynthesis and metabolism   
   
PA14_05220/PA0399  Cystathionine beta-synthase  -0.78 
PA14_14470/PA3831 pepA Leucine aminopeptidase  -0.39 
PA14_32985/PA2446 gcvH2 Glycine cleavage system protein H2  -0.57 
PA14_33010/PA2444 glyA2 Serine hydroxymethyltransferase  -0.54 
PA14_33030/PA2443 sdaA L-serine dehydratase  -0.44 
PA14_53260/PA0851  Hypothetical protein 0.29  
PA14_68860/PA5214 gcvH1 Glycine cleavage system protein H1  -0.29 
     
Sub-network 2: Cell wall/LPS/Capsule   
   
PA14_66090/PA4998  Conserved hypothetical protein -0.34  
PA14_66110/PA5000 wapR alpha-1,3-rhamnosyltransferase WapR -1.10  
PA14_66120/PA5001  Conserved hypothetical protein -2.23  
PA14_66140/PA5002  Conserved hypothetical protein  4.21 
PA14_66160/PA5004 wapH Probable glycosyl transferase -0.60  
PA14_66060/PA4996 rfaE LPS biosynthesis protein RfaE -0.41  
     
Sub-network 3: Motility and attachment; Two-component regulatory systems  
   
PA14_05190/PA0396 pilU Twitching motility protein PilU -0.55  
PA14_23830/PA3115 fimV Motility protein FimV -0.31  
PA14_66610/PA5039 aroK Shikimate kinase  -0.37  
PA14_66620/PA5040 pilQ Type 4 fimbrial biogenesis outer 
membrane protein 
PilQ precursor 
-0.36  
PA14_66640/PA5042 pilO Type 4 fimbrial biogenesis protein PilO -0.34  
PA14_66650/PA5043 pilN Type 4 fimbrial biogenesis protein PilN -0.39  
PA14_66660/PA5044 pilM Type 4 fimbrial biogenesis protein PilM -0.54  
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Table 4.4 - continued 
Gene number Gene  
name 
Product name and/or function Fold change (log2) 
dnpA- 
/WT 
dnpA+ 
/WT 
PA14_69480/PA5262 fimS/algZ FimS, phosphorelay signal transduction 
system 
 0.33 
     
Sub-network 4: Biosynthesis of cofactors; Amino acid biosynthesis; Adaptation and protection 
     
PA14_04110/PA0316 serA D-3-phosphoglycerate dehydrogenase  -0.37 
PA14_07740/PA0593 pdxA Pyridoxal phosphate biosynthetic protein 
PdxA 
 -0.32 
     
PA14_07760/PA0594 surA Peptidyl-prolyl cis-trans isomerase SurA  -0.31 
PA14_35330/PA2262  Probable 2-ketogluconate transporter 0.21  
PA14_35320/PA2263  Probable 2-hydroxyacid dehydrogenase 0.34  
PA14_23270/PA3167 serC 3-phosphoserine aminotransferase  -0.27 
PA14_07770/PA0595 ostA Organic solvent tolerance protein OstA 
precursor 
 
 -0.35 
Sub-network 5: Energy metabolism   
     
PA14_45280/PA1483 ccmI Cytochrome c-type biogenesis protein 
CcmI 
 -0.46 
PA14_45290/PA1482 ccmH Cytochrome c-type biogenesis protein 
CcmH 
 -0.55 
PA14_49270/PA1172 napC Cytochrome c-type protein NapC 0.46  
 
LPS is an important surface-associated molecule involved in a variety of bacterial processes 
of great clinical importance, such as virulence, immune response modulation, motility and 
biofilm formation (King et al., 2009). P. aeruginosa has extensively been used as a model 
system to study this complex molecule and many of the biosynthesis and regulatory genes 
have been characterized. In addition, most of the transferase genes that are involved in the 
assembly of the core oligosaccharide are located in this gene cluster. The cluster is generally 
well conserved among P. aeruginosa strains, as is the structure of the LPS core 
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oligosaccharide (Kocincova & Lam, 2011). Surprisingly, no difference could be detected 
when comparing LPS profiles of dnpA mutant, dnpA overexpression strain and wild type. 
Interestingly, the deduced gene product of E. coli CFT073 c2486 is also a member of the PIG-
L superfamily. c2486 is part of a gene cluster (c2485-c2490) that is required for 
hypercolonization in mice. It was postulated to encode an LPS modification system, but, as 
was the case in our study, no changes in LPS structure were observed for a mutant lacking 
c2485-c2490 (Haugen et al., 2007). It is possible that DnpA is responsible for minor 
modifications of the LPS core which do not affect the LPS profile. For instance, it has been 
described that a change in acetylation state does not affect LPS synthesis when evaluated  by 
a LPS profile (Slauch et al., 1995). On the other hand, dnpA could be involved in a process 
other than LPS core biosynthesis. PA66150-dnpA is conserved as one unit in all of the 
genomes analyzed but its genomic location relative to the cluster is not conserved. This is 
most obvious in P. putida W619 where parts of the P. aeruginosa cluster can be found in 
three discrete genomic locations separated by several hundreds of unrelated genes (Figure 
4.4). This “uncoupling” of PA14_66150-dnpA from the validated core LPS genes lends 
indirect support for a role in a process other than LPS core biosynthesis. In fact, the 
PA14_66150 orthologue in P. fluorescens was attributed a role in the regulation of 
exopolysaccharide synthesis (Nian et al., 2007). More recently, it was reported that 
PA14_66150 is involved in sensing cationic AMPs which leads to the induction of the LPS 
modification operon arnBCADTEF-PA3559 (Jochumsen et al., 2011). This gene cluster is 
responsible for adding 4-amino-4-deoxy-L-arabinose to the phosphate group of lipid A, 
thereby increasing tolerance to cationic AMPs (Moskowitz et al., 2004). It is possible that 
dnpA, together with PA14_66150, is involved in monitoring LPS biosynthesis/assembly or 
outer membrane physiology (Jochumsen et al., 2011). Future research may reveal whether 
dnpA serves the same function in all Pseudomonas spp.  
Sequence analysis revealed that DnpA belongs to the PIG-L or LmbE-like superfamily (Pfam 
PF02585). Based on a comparison between all biochemically characterized members of this 
family, we predict that DnpA acts as a de-N-acetylase on the N-acetylglucosamine part of a 
unknown substrate. All eukaryotic members studied so far play a role in the synthesis of 
glycosylphosphatidylinositol, a glycolipid that anchors proteins at the cell surface (Nakamura 
et al., 1997; Sharma et al., 1997; Smith et al., 1997; Watanabe et al., 1999). In bacteria, 
characterized PIG-L members are involved in different unrelated pathways such as chitine 
degradation (Tanaka et al., 2004; Hou et al., 2013), biosynthesis of low-molecular-weight 
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thiols (Newton et al., 2000; Gaballa et al., 2010) and synthesis of antibiotics (Ho et al., 2006; 
Truman et al., 2006; Truman et al., 2007; Fan et al., 2008). Based on mutational and crystal 
structure analysis of PIG-L members, a few models for the catalytic activity were proposed 
(Urbaniak et al., 2005; Fadouloglou et al., 2007; Zou et al., 2008). They are all consistent 
with the mechanism of other zinc-dependent deacetylases (Hernick & Fierke, 2005). Briefly, 
zinc is pentacoordinated by two histidines (DnpA His-188 and His-341 in Figure 4.6), one 
aspartic acid (DnpA Asp-191 in Figure 4.6) and two water molecules. Upon substrate binding 
one water molecule is displaced. The second water molecule is activated by the catalytic base 
(DnpA Asp-190 in Figure 4.6) and a nucleophilic attack takes place after which a tetrahydral 
oxyanion intermediate is formed. Subsequent protonation of the leaving amino group 
completes the catalytic cycle, releasing the deacetylated substrate from the catalytic site. It has 
been suggested that the residue corresponding to His-338 interacts with the substrate and 
stabilizes the negative charge in the oxyanion intermediate. The Asp-340 residue is thought to 
be involved in this process by stabilising the positive charge on the His-338 residue (Zou et 
al., 2008). 
Overexpression of dnpA in wild-type background increases the persister fraction significantly. 
We investigated whether two mutant dnpA alleles are still capable of increasing the persister 
fraction upon overexpression. The corresponding mutations have been described to cause a 
significantly decreased enzymatic activity in vitro in other species (Urbaniak et al., 2005; Deli 
et al., 2010). Overexpression of the dnpA-D340N allele no longer increased the persister 
fraction in a wild-type background. This result indicates that the predicted de-N-acetylase 
activity is important in fluoroquinolone tolerance. Surprisingly, the D190N allele did not alter 
the persister fraction upon dnpA overexpression. This is not expected since D190 is postulated 
to function as the catalytic base. Mutation of this residue is supposed to completely abolish 
de-N-acetylase activity of the protein (Urbaniak et al., 2005). However, it has been reported 
that mutation of this general catalytic base does not change the enzymatic activity of the  
Entamoeba histolytica PIG-L protein in vitro (Ashraf, 2013). This points to the possibility 
that the catalytic mechanism is not conserved among PIG-L members. To fully answer the 
question whether the predicted de-N-acetylase activity of DnpA is important in 
fluoroquinolone tolerance, data on in vitro biochemical activity are needed. However, we 
were not able to purify sufficient amount of DnpA to carry out such tests (as described in 
Appendix A).  
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A transcriptome analysis was carried out in order to gain more insight into the overall cellular 
function of DnpA and its role in fluoroquinolone tolerance. Differentially expressed genes 
were classified into functional categories. Enriched categories were identified and two of 
them, “Amino acid biosynthesis and metabolism” and “Energy metabolism”, were shared 
between mutant and overexpression strain. Most of the genes belonging to the enriched 
classes were downregulated. In order to identify groups of genes which are consistently 
up/down (or down/up) regulated in the dnpA mutant and in the strain overexpressing dnpA 
respectively, a deregulated functional interaction network was constructed. The selected gene 
groups suggest processes that are consistently affected by both perturbations.  
In general, genes involved in “Amino acid biosynthesis and metabolism” and “Energy 
metabolism” are downregulated in the dnpA overexpression strain suggesting a lower 
metabolic activity. This is consistent with earlier microarray analyses in which non-essential 
genes and genes involved in metabolism were downregulated in persisters (Keren et al., 
2004b; Shah et al., 2006). 
In the dnpA mutant, genes belonging to “Cell wall/LPS/Capsule” and “Motility and 
attachment” are downregulated. As is the case for dnpA, genes belonging to the first category 
are all situated in the LPS core oligosaccharide cluster. As mentioned earlier, no difference in 
LPS profile could, however, be detected. The second category contains genes involved in 
pilin biosynthesis. Previously, pilH and algR were identified as genes with a role in P. 
aeruginosa persistence. Insertion mutants of both genes displayed a higher persister fraction 
(De Groote et al., 2009). PilH is a response regulator involved in regulation of pilus retraction 
(Bertrand et al., 2010), while AlgR is part of a two-component transmitter-receiver regulatory 
system involved in regulation of alginate synthesis and twitching motility (Whitchurch et al., 
1996). Type IV pili are thin, flexible filaments with a broad range of functions including a 
role in motility, adherence and aggregation, protein secretion and biofilm formation and 
remodelling (Giltner et al., 2012). Exactly how biosynthesis of type IV pili is related to 
fluoroquinolone tolerance remains an open question.  
In summary, we have shown that dnpA is a bona fide persistence gene. Contrary to 
expectations, no obvious role in LPS biosynthesis could be demonstrated. DnpA is a putative 
de-N-acetylase, and this enzymatic activity is likely essential for its role in persistence. Other 
members of the PIG-L superfamily have previously been shown to be amenable to specific 
inhibition by small molecule compounds (de Macedo et al., 2003; Metaferia et al., 2007; 
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Gammon et al., 2010). Together, our results offer the prospect of targeting DnpA in future 
anti-persister therapies to more efficiently combat recalcitrant P. aeruginosa infection. 
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Chapter 5 
Membrane localization and topology of DnpA and its 
importance in fluoroquinolone tolerance in 
Pseudomonas aeruginosa11 
 
5.1 Introduction  
In the previous Chapter, we showed that dnpA is a bona fide persistence gene. However, 
currently, the exact function of this gene is still unknown. Genome-wide transcriptome 
analysis of strains lacking or overexpressing dnpA (see Chapter 4) points to a role in 
processes associated with the cell envelope (e.g. cell wall synthesis, motility and attachment). 
In a genome-wide computational screening for N-terminal signal peptides in Pseudomonas 
aeruginosa, DnpA was identified as one of the proteins predicted to use a transmembrane 
helix for membrane targeting (Lewenza et al., 2005). The presence of DnpA within the 
membrane would provide further support for its role in a surface-associated process. 
Therefore, an important step in the functional study of DnpA is determining its subcellular 
localization as well as its topology.  
In this Chapter, the predicted membrane localization and topology are investigated in detail. 
In addition, we evaluated whether correct membrane localization of DnpA is important for its 
role in fluoroquinolone tolerance. These results will help in understanding the role of dnpA in 
the complex persistence phenomenon in P. aeruginosa.  
 
                                               
11
 Subcellular localization experiments with DnpA∆60-PhoA, DnpA∆125-PhoA and DnpA∆178-PhoA described 
in this Chapter were performed by Dr. Emanuela Frangipani (University Roma Tre, Rome); The majority of the 
experiments described in this Chapter were carried out at the Molecular Microbiology Laboratory headed by 
Prof. Paolo Visca (University Roma Tre, Rome) in the framework of a research visit supported by a FEMS 
Research Fellowhip.  
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5.2 Experimental procedures 
Strains and growth conditions. P. aeruginosa PA14 WT (Liberati et al., 2006) was cultured 
in Luria-Bertani (LB) broth, for solidified medium 1.5 % agar was added. The following 
antibiotics were used: carbenicillin (300 µg mL-1) and tetracycline (10 or 100 µg mL-1). 
Plasmids used in this Chapter are listed in Table 5.1.  
 
Table 5.1: Plasmids and encoded proteins used in this Chapter 
Plasmid or construct Description or encoded protein* Reference 
Plasmids   
pME6032 pVS1 derived shuttle vector; TcR Heeb et al. (2000) 
pPHO7 pTZ18R plasmid containing phoA lacking  
its N-terminal signal peptide; ApR  
Gutierrez and Devedjian 
(1989) 
pUCP18 E. coli-Pseudomonas shuttle vector derived 
from pUC18/19; ApR CbR 
Schweizer (1991) 
   
Constructs   
pME6032-dnpA-phoA DnpA-PhoA This chapter 
pME6032-dnpAN178-phoA DnpAN178-PhoA This chapter 
pME6032-dnpAN60-phoA DnpAN60-PhoA This chapter 
pME6032-dnpAN17-phoA DnpAN17-PhoA This chapter 
pME6032-dnpAN90-phoA DnpAN90-PhoA This chapter 
pME6032-dnpAN125-phoA DnpAN125-PhoA This chapter 
pME6032-dnpAN10-phoA DnpAN10-PhoA This chapter 
pME6032-dnpAN12-phoA DnpAN12-PhoA This chapter 
pME6032-dnpAN15-phoA DnpAN15-PhoA This chapter 
pME6032-dnpA∆178-phoA DnpA∆178-PhoA This chapter 
pME6032-dnpA∆125-phoA DnpA∆125-PhoA This chapter 
pME6032-dnpA∆60-phoA DnpA∆60-PhoA This chapter 
* TcR, tetracycline resistant; ApR, ampicillin resistant; CbR, carbenicillin resistant 
 
In silico analysis. The hydrophobic character of DnpA was analysed using the Kyte-Doolittle 
method (Kyte & Doolittle, 1982). A window size of 19 amino acids was applied in order to 
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identify putative hydrophobic membrane-spanning domains (http://web.expasy.org/protscale). 
Transmembrane regions were predicted using TmPred (Hofmann & Stoffel, 1993), TMHMM 
(Krogh et al., 2001) and DAS (Cserzo et al., 1997) (available on 
http://web.expasy.org/tools/). The presence of signal peptide cleavage sites was examined by 
using Signal4P (Petersen et al., 2011), default settings were used for D-cutoff values and 
minimal predicted signal peptide length.  
Construction of DnpA-PhoA translational fusions. Several N- and C-terminal fragments of 
DnpA were fused in frame with PhoA. For each fusion, the desired dnpA fragment was 
amplified using primers as listed in Table 5.2 with P. aeruginosa PA14 genomic DNA as a 
template. In each primer an appropriate restriction site was included which allowed 
directional incorporation of the resulting PCR product into the compatible restriction site of 
pME6032 using EcoRI and BglII. DnpAN10, DnpAN12 and DnpAN15 fragments were 
constructed using the oligonucleotide adaptor technique (Invitrogen). Subsequently, the phoA 
reporter sequence from pPHO7 was cloned downstream of the N- or C-terminal fragment 
between the XhoI site of pME6032 and the HindIII sites incorporated in the sense primer used 
to construct each dnpA fragment. The resulting fusions were confirmed by sequencing. 
Plasmids were introduced into P. aeruginosa PA14 WT by transformation. In addition, all 
resulting strains were transformed with the plasmid pUCP18 in order to obtain constitutive ß-
lactamase production. 
 
Table 5.2: Primers used in this Chapter 
Primer name Sequence * Description Restriction site 
SPI6628 CACCGAATTCAGCATGAG
CGCACGCAAG 
 
Antisense primer for 
amplification of N-terminal 
fragments 
EcoRI 
SPI10088 ACTCAGATCTAAGCTTA
GCGCCTCCCCATCCAG 
Sense primer for 
amplification of full length 
dnpA 
BglII and HindIII 
SPI10089 ACTCAGATCTAAGCTTA
GACGGTAATCGGGATGGC 
Sense primer for 
amplification of dnpAN178 
BglII and HindIII 
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Table 5.2 - continued 
Primer name Sequence * Description Restriction site 
SPI10090 ACTCAGATCTAAGCTTA
GATAGAACAGGTGATCGG
CG 
Sense primer for 
amplification of dnpAN60 
BglII and HindIII 
SPI10092 ACTCAGATCTAAGCTTA
GCCGCTTGTTGC 
Sense primer for 
amplification of dnpAN17 
BglII and HindIII 
SPI10152 ACTCAGATCTAAGCTTA
GGCCGTCGACTCGC 
Sense primer for 
amplification of dnpAN90 
BglII and HindIII 
SPI10153 ACTCAGATCTAAGCTTA
GGGCCTCCGCGC 
Sense primer for 
amplification of dnpAN125 
BglII and HindIII 
SPI10365 AATTCAGCATGAGCGCAC
GCAAGCAGCAGTTGCTCA
AGCTAAGCTTA 
Antisense oligonucleotide 
dnpAN10 
EcoRI, HindIII 
and BglIII 
SPI10366 GATCTAAGCTTAGCTTGA
GCAACTGCTGCTTGCGTG
CGCTCATGCTG 
Sense oligonucleotide 
dnpAN10 
BglII, HindIII and 
EcoRI 
SPI10367 AATTCAGCATGAGCGCAC
GCAAGCAGCAGTTGCTCA
AGCGTCATCTAAGCTTA 
Antisense oligonucleotide 
dnpAN12 
EcoRI, HindIII 
and BglIII 
SPI10368 GATCTAAGCTTAGATGA
CGCTTGAGCAACTGCTGC
TTGCGTGCGCTCATGCTG 
Sense oligonucleotide 
dnpAN12 
BglII, HindIII and 
EcoRI 
SPI10369 AATTCAGCATGAGCGCAC
GCAAGCAGCAGTTGCTCA
AGCGTCATCGACGCAAC 
CTAAGCTTA 
Antisense oligonucleotide 
dnpAN15 
EcoRI, HindIII 
and BglIII 
SPI10370 GATCTAAGCTTAGGTTGC
GTCGATGACGCTTGAGCA
ACTGCTGCTTGCGTGCGC
TCATGCTG 
Sense oligonucleotide 
dnpAN15 
BglII, HindIII and 
EcoRI 
SPI10174 CACCGAATTCATGTCGCC
GGGCGAGGACTACCGCTA
CCGTTTC 
Antisense primer for 
amplification of dnpA∆60 
EcoRI 
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Table 5.2 - continued 
Primer name Sequence * Description Restriction site 
SPI10175 CACCGAATTCATGGATGC
CCAGGCTTTCGAACGTGG 
Antisense primer for 
amplification of dnpA∆125 
EcoRI 
SPI10176 CACCGAATTCATGGAGCG
GCGGGTGATGGTCATCG 
Antisense primer for 
amplification of dnpA∆178 
EcoRI 
*(Partial) restriction sites are indicated in bold 
 
Isolation of membrane fractions. This procedure was carried out as described in Chapter 4. 
The presence of DnpA-PhoA and the inner membrane marker XcpY (Filloux et al., 1990) in 
each fraction was analyzed by western hybridization using respectively anti-PhoA (Sigma) 
and anti-XcpY (kind gift from Dr. Romé Voulhoux, Aix-Marseille Université) as primary 
antibodies.  
Subcellular fractionation. Overnight cultures were diluted 100-fold into LB medium and 
incubated at 37 °C while shaking at 200 rpm. At an OD595 of 0.5, cultures were induced with 
1 mM isopropyl ß-D -1-thiogalactopyranoside (IPTG) for one hour at 37 °C after which the 
cells were harvested by centrifugation (20 minutes at 5000 rpm). Subcellular fractions were 
isolated as described by Imperi et al. (2008) with minor adaptations. Briefly, cells were 
spheroplasted by the lysozyme/sucrose method (Robles-Price et al., 2004) to release 
periplasmic proteins. Next, spheroplasts were disrupted by sonication and cell debris were 
removed by low-speed centrifugation (10 min at 3000 g). Separation of the cytosolic and 
membrane fractions was carried out by ultracentrifugation at 100,000 g for one hour at 4 °C. 
The purity of subcellular fractions was verified by measuring relative isocitrate 
dehydrogenase, lactate dehydrogenase and ß-lactamase activities. Equal volumes of each 
fraction were separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) analysis after which the presence of DnpA-PhoA in each fraction was verified by 
immunoblot analysis with anti-PhoA (Sigma) as a primary antibody. 
Enzymatic assays. Isocitrate dehydrogenase activity was measured as described previously 
(Goldberg & Ellis, 1983) with minor modifications. Essentially, the enzymatic activity was 
measured by monitoring the reduction of NADP+ to NADPH during conversion of isocitrate 
to 2-oxoglutarate. The increase in NADPH production was monitored by measuring the 
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absorbance at 339 nm over time. Reactions were carried out at room temperature in a 0.065 M 
triethanolamine buffer (pH = 7.3) containing 1.66 mM MnCl2. ß-lactamase activity was 
determined essentially as described by O’Callaghan et al. (1972) with minor adjustments. 
Briefly, enzymatic activity was measured by monitoring cleavage of nitrocefin, a 
chromogenic cephalosporin substrate, by evaluating the increase in absorbance at 486 nm 
over time. The enzymatic assay was carried out at room temperature in a 50 mM Na-
phosphate buffer (pH = 7). Lactate dehydrogenase activity was assessed using a modification 
of the Vassault (1983) protocol. This enzyme converts pyruvate into lactate resulting in the 
oxidation of NADH to NAD+. This decrease of NADH was determined by measuring the 
absorbance at 339 nm over time at room temperature. The enzymatic reaction was carried out 
in a 80 mM Tris/200 mM NaCl (pH = 7.2) solution. 
Membrane association assay. The biochemical nature of the DnpA membrane association 
was evaluated by treating total membrane fractions of cells overexpressing the DnpA-PhoA 
fusion protein with different chemical agents as described by Imperi et al. (2008) with minor 
modifications. Briefly, membrane fractions were treated for 30 minutes at 4 °C with 1 % SDS, 
2 % Sarcosyl, 1 M NaCl, 1.5 M and 5 M urea and 0.01 M NaOH. Next, treated samples were 
centrifuged at 55,000 g for two hours at 4 °C. Equal volumes of pellet and supernatant were 
separated by SDS-PAGE and analyzed for the presence of DnpA-PhoA by immunoblot 
analysis using a primary antibody targeting PhoA (Sigma).  
PhoA activity. Overnight cultures were diluted 100-fold into LB medium and incubated at 37 
°C while shaking at 200 rpm. At an OD595 of 0.2, IPTG was added to the bacterial cultures to 
a final concentration of 1 mM. After two hours of induction, 5 µl of each culture was spotted 
onto LB agar plates containing 40 µg mL-1 5-bromo-4-chloro-3-indolyl phosphate (BCIP), 1 
mM IPTG and the appropriate antibiotics. Additionally, KH2PO4 was added to a final 
concentration of 10 mM to inhibit the endogenous phosphatase activity. Expression of the 
respective fusion proteins was verified by western hybridization using a primary antibody 
targeting PhoA (Sigma).  
Persistence assay. Determination of the persister fraction was carried out as described in 
Chapter 4.  
Statistical analysis was performed as described in Chapter 4. 
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5.3 Results 
5.3.1 In silico analysis of DnpA 
Analysis of a hydrophobicity plot of the DnpA amino acid sequence, calculated by the Kyte-
Doolittle algorithm, revealed a highly hydrophobic peak encompassing amino acids 10-50 
(Figure 5.1A). This hydrophobic region corresponds to a putative transmembrane domain 
predicted by TmPred, TMHMM (Figure 5.1B and C) and DAS. These algorithms predict one 
putative transmembrane helix and, additionally, TMHMM and TmPred strongly suggest an 
Nin/Cout orientation of DnpA meaning that the majority of the protein is predicted to reside in 
the periplasmic space. When analyzing the DnpA amino acid sequence by Signal4P, no 
putative signal peptide cleavage site was detected.  
 
5.3.2  Membrane localization of DnpA 
To verify the localization of DnpA in the cytoplasmic membrane, the full-length dnpA gene 
was coupled in-frame with phoA, which encodes a reporter enzyme. Inner and outer 
membrane fractions of P. aeruginosa cells overexpressing this fusion protein were isolated. 
The resulting fractions were separated on SDS-PAGE after which the presence of the fusion 
protein was evaluated by western hybridization using anti-PhoA antibodies as a primary 
antibody (Figure 5.2A). DnpA-PhoA was present in the whole cell lysate and inner membrane 
fraction, confirming the predicted localization in the cytoplasmic membrane. As expected, the 
same result was obtained when the presence of the known inner membrane protein XcpY 
(Filloux et al., 1990) was evaluated in these fractions.  
 
5.3.3 Orientation of DnpA in the cytoplasmic membrane 
In order to determine the orientation of DnpA in the cytoplasmic membrane, the enzymatic 
activity of the C-terminally coupled fusion protein DnpA-PhoA was examined. PhoA is an 
enzyme that only displays activity when located in the periplasm. The PhoA fragment used 
here lacks its signal sequence. It therefore folds and thus becomes enzymatically active only 
when the fusion protein DnpA-PhoA is exposed at the periplasmic side of the membrane 
(Manoil et al., 1990). P. aeruginosa cells overexpressing the fusion protein were plated on  
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Figure 5.1: Hydrophobicity plot and transmembrane domain predictions for DnpA of Pseudomonas 
aeruginosa. A Hydrophobicity plot generated by the Kyte and Doolittle algorithm which gives a score for the 
hydrophobic character of each amino acid of DnpA. B. Prediction of transmembrane domains by TmPred with a 
TmPred score assigned for each DnpA residue. Only scores > 500 are considered significant and indicate that 
the residue likely belongs to a transmembrane helix. C. Predictions of transmembrane domains by the TMHMM 
algorithm in which a probability score is given for the transmembrane (red), inside (blue) and outside (pink) 
location for each amino acid residue of DnpA. At the top of the plot the best prediction is shown. GenBank 
protein accession number NP_253689. 
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solid growth medium containing the PhoA substrate BCIP, which is converted into a blue 
precipitate upon phosphatase activity. The DnpA-PhoA fusion protein does not display 
enzymatic activity, indicating that the C-terminal part of DnpA is located at the cytoplasmic 
side of the inner membrane (Figure 5.2B). 
 
5.3.4 Membrane association of DnpA 
To further characterize the biochemical association of DnpA with the cytoplasmic membrane, 
total membrane fractions of P. aeruginosa cells overexpressing DnpA-PhoA were treated 
with different chemical agents (Figure 5.3). DnpA-PhoA was released from the membrane 
fraction upon treatment with the detergents SDS (1 %) and Sarcosyl (2 %). The latter 
specifically disrupts the inner membrane, hereby independently confirming the inner 
membrane localization of DnpA. Treatment of membrane fractions with NaCl (1 M), which 
specifically disrupts protein–protein and protein–phospholipid interactions, did not cause 
solubilization of DnpA-PhoA. In addition, neither did treatment with denaturant (1.5 M and 5 
M urea) or alkali (0.01 M NaOH), which specifically cause solubilization of peripheral 
membrane proteins. Taken together, these results indicate that DnpA is an integral membrane 
protein.  
 
 
Figure 5.2: Membrane localization and orientation of DnpA. A. Western hybridization analysis of whole cell 
lysates (WC) and inner (IM) and outer (OM) membrane fractions of P. aeruginosa cells overexpressing the 
DnpA-PhoA fusion protein (theoretical molecular weight of 102.55 kDa). Equal volumes of each fraction were 
analyzed. Analysis was carried out with an anti-PhoA or anti-XcpY primary antibody as indicated. B. 
Phosphatase activity of IPTG-induced cells containing the plasmid pME6032 or pME6032-dnpA-phoA. The 
absence of phosphatase activity is indicated by (–).  
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Figure 5.3: Membrane association of DnpA. Total membrane fraction of cells overexpressing DnpA-PhoA from 
the plasmid pME6032 were treated with the different detergents indicated. The resulting pellet was 
resuspended in an equal volume of buffer. Pellet and supernatant were subjected to western hybridization 
analysis using an anti-PhoA antibody. Theoretical molecular weight of DnpA-PhoA is 102.55 kDa.  
 
5.3.5 Topology of DnpA 
5.3.5.1 Confirmation of the predicted model  
To confirm the presence of the predicted transmembrane domain, different N-terminal 
fragments of DnpA were fused in-frame with the reporter enzyme PhoA, which lacks its 
native signal peptide. To prevent disruption of helical structures which might be involved in 
transmembrane segments, the secondary structure of DnpA as predicted by JPred (Cole et al., 
2008), was consulted. Fusion points were chosen before and after the predicted 
transmembrane domain and just before the start of the predicted PIG-L domain (Figure 5.4). 
Expression after induction from pME6032 was verified by western hybridization analysis 
using an anti-PhoA antibody. DnpAN15-PhoA was not expressed at detectable levels and 
therefore excluded from further testing. 
The subcellular localization of each fusion protein was experimentally determined (Figure 
5.5A). DnpAN60-PhoA, containing the first 60 N-terminal amino acid residues of DnpA 
fused to PhoA, is predominantly located in the membrane fraction, which confirms the 
presence of the predicted transmembrane helix. As expected, DnpAN178-PhoA, as well as 
DnpA-PhoA, is also dominantly present in the membrane fraction. To verify the cytoplasmic 
localization of the DnpA N-terminus, the following additional translational fusions were 
constructed: dnpAN10-phoA, dnpAN12-phoA and dnpAN17-phoA. When assessing 
expression of these fusion proteins, none of them could be detected (data not shown). To 
independently provide support for the presence of the predicted transmembrane helix, inner 
and outer membrane fractions of cells overexpressing DnpAN60-PhoA were isolated. The 
fusion protein was exclusively detected in the inner membrane fraction of the cell (Figure 
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5.5B) as was the inner membrane marker XcpY. This indicates the presence of a 
transmembrane domain in the 60 N-terminal amino acid residues of the protein.  
 
 
Figure 5.4: Secondary structure prediction of DnpA. Light grey horizontal arrows represent predicted strands, 
helices are visualized by dark grey bars. Vertical arrows indicate fusion points used for the reporter enzyme 
encoded by phoA. Residues belonging to the predicted PIG-L domain are enclosed in the dark grey rectangle, a 
stretch of positively charged amino acid residues preceding the first predicted transmembrane helix is boxed in 
the light grey rectangle. The prediction was visualized using Jalview (Waterhouse et al., 2009). 
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Figure 5.5: Subcellular localization of DnpA-PhoA fusion proteins. A. Immunoblot analysis of the different 
subcellular fractions of cells overexpressing the indicated DnpA-PhoA fusions proteins. Equal volumes of whole 
cell lysate (WC), cytoplasmic fraction (C), membrane fraction (M) and periplasmic fraction (P) were loaded onto 
protein gels. Immunoblot analysis was carried out with an anti-PhoA antibody. B. Western hybridization 
analysis of whole cell lysates (WC) and inner (IM) and outer (OM) membrane fractions of P. aeruginosa cells 
overexpressing the DnpAN60-PhoA fusion protein. Equal volumes of each fraction were analyzed. Immunoblot 
analysis was carried out with an anti-PhoA and anti-XcpY primary antibody. Theoretical molecular weight of 
55.92 kDa, 68.97 kDa and 102.55 kDa for DnpAN60, DnpAN178 and DnpA-PhoA respectively.  
 
Next, the phosphatase activity of each fusion protein was determined by plating the cells on 
BCIP-containing plates (Figure 5.6). P. aeruginosa cells overexpressing DnpAN60-PhoA are 
clearly able to convert BCIP into a blue precipitate, meaning that the C-terminal part of the 
DnpAN60 is located at the periplasmic side of the membrane. DnpAN178-PhoA 
overexpressing cells did not show enzymatic activity, indicative of a cytoplasmic localization 
of the DnpAN178 C-terminal part. This observation suggests the presence of an additional 
transmembrane segment between amino acid residues 60 and 178. 
 
 
Figure 5.6: Enzymatic activity of DnpA-PhoA fusion proteins. Enzymatic activity of cells overexpressing the 
indicated fusion proteins after plating on BCIP containing agar plates. The presence or absence of phosphatase 
activity is indicated by (+) or (–) respectively.  
 
5.3.5.2 Confirmation of second transmembrane domain  
When studying the predictions made by TmPred and DAS, an additional transmembrane helix 
encompassing amino acids 98-119, although indicated as statistically insignificant, was 
detected. This amino acid region contains hydrophobic residues, further lending support for 
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an additional transmembrane domain. However, analysis of the predicted secondary structure 
does not reveal the presence of a helix. To examine the presence of a transmembrane domain, 
two additional translational fusions, dnpAN90-phoA and dnpAN125-phoA, were constructed. 
As expected, both fusion proteins were predominantly situated in the membrane fraction of P. 
aeruginosa cells. However, phosphatase activity tests were negative (Figure 5.7A), meaning 
that the C-terminus of DnpAN90 and DnpAN125 resides at the cytoplasmic side of the 
membrane. As cells overexpressing DnpAN60-PhoA showed phosphatase activity, our results 
indicate the presence of a transmembrane segment located between amino acid 60 and 90. To 
independently confirm the presence of this second membrane-crossing domain, the 
subcellular localization of DnpA lacking amino acids 1 to 60, was determined (Figure 5.7B). 
The result shows that this protein, DnpA∆60-PhoA, predominantly resides in the membrane 
fraction, consistent with the presence of a second transmembrane segment downstream of 
amino acid residue 60. However, we also observed the presence of part of the fusion protein 
in the periplasmic fraction. Possibly, this second transmembrane domain requires the first one 
for correct insertion into the membrane.  
 
 
Figure 5.7: Evaluation of DnpAN90-PhoA, DnpAN125-PhoA and DnpA∆60-PhoA. A. Subcellular localization 
and phosphatase activity of DnpAN90-PhoA and DnpAN125-PhoA (theoretical molecular weight of 60.46 kDa 
and 64.13 kDa respectively). Equal volumes of whole cell lysate (WC), cytoplasmic fraction (C), membrane 
fraction (M) and periplasmic fraction (P) were loaded onto protein gels. Immunoblot analysis was carried out 
with an anti-PhoA antibody. Enzymatic activity of cells overexpressing the indicated fusion proteins after 
plating on BCIP containing agar plates. The absence of phosphatase activity is indicated by (–). B. Subcellular 
localization of cells overexpressing DnpA∆60-PhoA (theoretical molecular weight of 96.95 kDa). Membrane 
fraction is 1:2 diluted compared to the other samples. Immunoblot analysis was carried out with an anti-PhoA 
antibody. 
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5.3.6 Importance of membrane localization of DnpA in fluoroquinolone tolerance 
Overexpression of dnpA in a wild-type background increases the persister fraction 
significantly (see Section 4.3.1). To evaluate if membrane localization of DnpA is important 
for its role in fluoroquinolone tolerance, we evaluated the persister fraction upon 
overexpression of dnpA alleles lacking the first (dnpA∆60-phoA) or both transmembrane 
domains (dnpA∆125-phoA and dnpA∆178-phoA). Only overexpression of DnpA-PhoA 
increased the persister fraction significantly compared to the wild type (P < 0.05) (Figure 
5.8A). Next, the subcellular localization of DnpA∆125-PhoA and DnpA∆178-PhoA was 
examined. Unexpectedly, both were dominantly present in the membrane fraction (Figure 
5.8B).  
 
 
Figure 5.8: Relative persister fractions of cells overexpressing DnpA-PhoA fusion proteins lacking one or both 
transmembrane domains and subcellular localization of DnpA∆125-PhoA and DnpA∆178-PhoA. A. Stationary 
phase cells of wild type (WT) containing plasmid pME6032 (WT pME6032) and WT overexpressing dnpA∆125-
phoA, dnpA∆178-phoA and dnpA-phoA respectively from the plasmid pME6032 (WT pME6032-dnpA∆x-phoA) 
were treated in parallel with ofloxacin and sterile water for 5 hours. Subsequently, the cells were diluted and 
plated out after which the number of surviving cells was determined. Data points correspond to the mean 
relative persister fraction. Each experiment was repeated independently at least three times. Error bars 
represent standard error of the mean. A persister fraction of 100 % corresponds to 6.81 × 10
-5
.
 
*P < 0.05. B. 
Subcellular localization of DnpA∆125-PhoA and DnpA∆178-PhoA (theoretical molecular weight of 89.92 kDa 
and 83.90 kDa respectively). An aliquot of whole cell lysate (WC), cytoplasmic fraction (C), membrane fraction 
(M) and periplasmic fraction (P) were loaded onto protein gels. The membrane fraction was diluted two times 
compared to the other samples. Immunoblot analysis was carried out with an anti-PhoA antibody.  
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5.4 Discussion  
dnpA is involved in fluoroquinolone tolerance in P. aeruginosa, hereby contributing to the 
recalcitrant nature of infections caused by this pathogen. The role and cellular function of 
dnpA are currently unknown. Transcriptome analysis points to a possible role for DnpA in 
cell surface-associated processes. This is supported by its conserved genomic localization in 
the lipopolysaccharide (LPS) core oligosaccharide cluster, which is involved in synthesis of 
the extracellular factor LPS. In a genome-wide computational screening for N-terminal signal 
peptides in P. aeruginosa, DnpA was picked up as one of the proteins predicted to use a 
transmembrane helix for membrane targeting (Lewenza et al., 2005). Presence of DnpA 
within the membrane would further lend support for a role of dnpA in cell-surface associated 
processes. However, to date, no experimental evidence is available in support of this 
prediction. In this Chapter, the subcellular localization of DnpA was investigated in detail as 
well as its relation to persistence.  
All algorithms used predict the presence of a single transmembrane helix which anchors 
DnpA to the inner membrane, leaving the major part of DnpA at the periplasmic side of the 
lipid bilayer. Our test results confirm the presence of DnpA in the inner membrane but 
indicate an opposite orientation in which the C-terminal part of DnpA, which contains the 
PIG-L domain, is located in the cytoplasmic compartment. Errors regarding the orientation of 
the protein are amongst the most commonly ones made by the TMHMM algorithm (Krogh et 
al., 2001), the best rated program for prediction of transmembrane helices (Moller et al., 
2001). 
To confirm the presence and orientation of the predicted transmembrane helix, the reporter 
tag phoA was translationally fused to different N-terminal truncated variants of dnpA. P. 
aeruginosa cells overexpressing DnpAN60-PhoA clearly showed phosphatase activity on the 
substrate BCIP, confirming the periplasmic localization of the DnpAN60 C-terminal part. The 
cytoplasmic localization of the N-terminal part could not be confirmed since the fusion 
proteins DnpAN10-PhoA, DnpAN12-PhoA, DnpAN15-PhoA or DnpAN17-PhoA were not 
expressed. However, a stretch of positively charged amino acids residues (between residue 9 
and 18)(Figure 5.4) precedes the transmembrane helix, which, according to the positive-inside 
rule (von Heijne, 1992), provides evidence for the cytoplasmic localization of the DnpA N-
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terminal part. In addition, our results point to the presence of a second transmembrane domain 
downstream of amino acid residue 60, which we mapped between residues 60 and 90. This 
protein region neither contains a high number of hydrophobic amino acid residues, nor is it 
predicted to form a helix. However, increasing evidence is provided that marginally 
hydrophobic or helical segments can become incorporated in the membrane as well (von 
Heijne, 2011; Bogdanov et al., 2014). Incorporation of these segments depends on the 
flanking sequences or, in some cases, on interaction with other transmembrane segments of 
the protein. As DnpA∆60-PhoA lacks the first transmembrane domain and consequently its 
N-terminal flanking sequence, this may influence correct transfer or insertion of the second 
transmembrane segment into the membrane. This may account for the observed presence of 
the truncated form in the periplasm. The hydrophobic amino acid stretch between residues 90 
and 125 possibly represents a region buried within the protein or associates with the 
cytoplasmic membrane without crossing it.  
Based on in silico predictions and our experimental results, we suggest that DnpA possesses 
two transmembrane domains situated between amino acid residues 18-50 and 60-90 with an 
Nin/Cout and Nout/Cin orientation respectively. The majority of DnpA, including the PIG-L 
domain, is situated at the cytoplasmic side of the inner membrane (Figure 5.9).  
Overexpression of the full length dnpA allele increases the persister fraction in a wild-type 
background, while overexpression of dnpA alleles lacking both transmembrane domains does 
not increase the persister fraction. This result suggests that correct membrane localization of 
DnpA is necessary for its effect on persistence. Surprisingly, unlike predicted, subcellular 
localization analysis of fusion proteins lacking both transmembrane domains revealed that 
these fragments were still located in the membrane fraction. Possibly, additional hydrophobic 
domains anchor DnpA peripherally to the cytoplasmic membrane. Based on Figure 5.1A, 
several candidate hydrophobic domains are present in DnpA which may fulfill this role. 
Additional experiments are needed to confirm this interaction of DnpA∆125-PhoA and 
DnpA∆178-PhoA with the membrane. For instance, treatment with alkali and denaturant 
should solubilize peripheral membrane proteins (Rosenberg, 2005; Imperi et al., 2008). The 
presence of such additional hydrophobic domains would provide an explanation for the 
problematic purification of DnpA isoforms lacking the two transmembrane segments after 
overexpression in Escherichia coli (as described in Appendix A). Alternatively, DnpA may be 
Chapter 5                                                                           Membrane localization and topology of DnpA  
99 
 
 
bound by another membrane protein, hereby anchoring it to the membrane even in the 
absence of its two transmembrane segments. Taken together, correct transmembrane insertion 
of DnpA, but not membrane association per se, is needed to exert its effect on quinolone-
tolerance in P. aeruginosa.  
 
 
Figure 5.9: Topological map of P. aeruginosa DnpA based on in silico analysis, subcellular localization 
experiments and phoA fusion analysis. Purple regions represent transmembrane domains, green amino acids 
indicate fusion points for phoA and red amino acids belong to the PIG-L domain. The cytoplasmic membrane is 
shown in orange. This topological map was generated using Protter (Omasits et al., 2013). Transmembrane 
domains were manually entered based on predictions made by TmPred and DAS and our experimental results.  
GenBank protein accession number NP_253689. To reflect the possible peripheral association of the DnpA C-
terminus with the inner membrane, one of the candidate hydrophobic domains (amino acid residues 255-270), 
is shown to interact with the membrane.  
 
5.5 Concluding remarks 
We showed that DnpA resides in the inner membrane of P. aeruginosa by means of two 
transmembrane domains with the majority of DnpA including the catalytic domain located in 
the cytoplasmic compartment. Future experiments, in which the membrane association of 
dnpA alleles lacking the two transmembrane domains is investigated, will shed more light on 
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additional DnpA-membrane or DnpA-protein interactions. Furthermore, the observation that 
the catalytic domain of DnpA is located at the cytoplasmic face of the membrane may in the 
future be helpful to understand the cellular function of DnpA.  
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Chapter 6 
Identification and characterization of anti-persister 
molecules 
 
6.1 Introduction  
Screening of knockout libraries, both in Pseudomonas aeruginosa (De Groote et al., 2009) 
and Escherichia coli (Hu & Coates, 2005; Hansen et al., 2008), did not result in the 
identification of mutants completely lacking persister cells, indicating the involvement of 
multiple mechanisms in persister formation. Furthermore, different bacteria use different 
mechanisms to form persister cells (See Chapter 2). For example, a major mechanism of 
persister formation in E. coli, a model system for persistence, involves toxin-antitoxin (TA) 
modules (Maisonneuve et al., 2011; Maisonneuve et al., 2013). However, the involvement of 
TA modules in P. aeruginosa has not been reported. Until now, the mechanism of persister 
formation in P. aeruginosa is largely unknown (as reviewed by Fauvart et al. (2011) and 
Mulcahy et al. (2013)) impeding the development of a target-based strategy against these 
antibiotic-insensitive cells. Additionally, persister cells are generally considered to be non-
dividing, metabolically quiescent cells in which inactivity of the antibacterial targets impairs 
the bactericidal effect of currently known antibiotics (Bigger, 1944; Balaban et al., 2004; 
Keren et al., 2004b; Shah et al., 2006; Lewis, 2007; Wood et al., 2013). Consequently, no 
targets are available for developing a rational anti-persister strategy.  
In this Chapter, using an untargeted approach, the identification and further characterization 
of small molecules with promising anti-persister properties is described. To identify anti-
persister molecules, we conducted a medium-throughput screening in search of small 
molecules that, in combination with a clinically used antibiotic, specifically kill P. aeruginosa 
persister cells. These compounds can act as a starting point for the development of an anti-
persister therapy. Additionally, by unraveling their mode of action, more insight is generated 
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into the mechanisms underlying persistence in P. aeruginosa. This may reveal molecular 
targets that will allow the future development of target-based anti-persister strategies. Since 
new anti-pseudomonal compounds are limited (Section 1.4.1.4), a parallel screening was 
carried out for growth inhibitory compounds. Identification and initial characterization of a 
promising compound is described in Addendum I.  
 
6.2 Experimental procedures 
Bacterial strains, media and growth conditions. Bacterial strains were cultured in 1:20 
diluted Trypticase Soy Broth (1:20 TSB) at 37 °C shaking at 200 rpm. For solidified medium, 
TSB was supplemented with 1.5 % agar. The following antibiotics were used: ofloxacin, 
amikacin and ceftazidime. Concentrations are indicated throughout the text. Strains used in 
this Chapter are listed in Table 6.1.  
 
Table 6.1: Strains used in this Chapter 
Strain Descriptiona Source or reference  
P. aeruginosa PA14 Wild type, KmR Lee et al. (2006) 
P. aeruginosa PAO1 Wild type  Morita et al. (2001) 
P. aeruginosa YM64 mexAB-oprM::FRT, mexXY::FRT,  
mexCD-oprJ::FRT, mexEF-oprN::FRT 
Morita et al. (2001) 
E. coli TOP10 F- mcrA ∆(mrr-hsdRMS-mcrBC) 
φ80lacZ∆M15 ∆lacX 74 recA1 araD139 
∆(ara leu) 7697 galU galK 
Invitrogen 
S. aureus SH1000 Functional rsbU derivative of 8325-4  
rsbU+ (wild type strain cured of prophages) 
O’Neill et al.(2010);  
Horsburgh et al. (2002)  
S. enterica serovar 
Typhimurium SL1344 
Wild type  Hoiseth & Stocker (1981) 
KmR: kanamycin resistant; TcR: tetracycline resistant 
 
Small-molecule library. The small-molecule library (< 500 g mol -1) was provided in a dry 
powder 96-well format by the Centre for Drug Design and Discovery (CD3) of the KU 
Leuven. These small molecules were selected and purchased from multiple commercial 
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suppliers. Initial selection of compounds was based on different parameters (Lipinski’s rule of 
five, solubility, toxicophores, frequent hitters, unstable fraction) (Walters et al., 1999; Segers 
et al., 2011).  
Compound storage. Just before first use, plates containing the small molecules were 
centrifuged (4000 rpm, 5 minutes) after which the compounds were dissolved in 100 % 
dimethyl sulfoxide (DMSO) to a final concentration of 2-5 mM. Next, plates were sealed and 
stirred for 10 minutes after which a centrifugation step was carried out (4000 rpm, 5 minutes). 
After usage, dissolved compounds were stored at - 20 °C in closed bags under N2-atmosphere 
in a dark environment.  
Screening method. In the optimized protocol, stationary phase cells of P. aeruginosa 
cultured in 1:20 TSB were treated for 5 hours in the wells of a 96-well plate with a 
combination of ofloxacin and compound. Next, the treated cells were diluted 100-fold into 
fresh TSB growth medium and incubated in an automated OD plate reader (Bioscreen C, Oy 
Growth Curves Ab Ltd.). Based on a linear relationship between the number of cells 
incubated in the automated plate reader and the duration of the lag phase of the resulting 
growth curve, a first selection of promising small molecules was made. Each 96-well plate 
was evaluated separately and compounds that gave rise to a value that had less than 5 % 
probability to occur under the given normal distribution, were selected. The effect of the 
compound in combination with ofloxacin was re-evaluated independently three times and 
compared to the effect of treatment with only ofloxacin.  
Persistence assay. This assay was carried out as described before (Chapter 4) with minor 
adaptations. Briefly, P. aeruginosa PA14 wild-type cells were grown overnight until 
stationary phase. Next, cells were treated in a 96-well plate with a combination of antibiotic 
and compound for 5 hours (unless indicated otherwise). Plates were sealed with a breathable 
sealing membrane (Greiner Bio-One) and incubated at 37 °C while shaking at 200 rpm. After 
treatment, cells were washed in 10 mM MgSO4 (6000 rpm, 10 minutes, 4 °C) after which a 
dilution series was plated out on solid growth medium to determine the number of viable 
cells.  
Statistical analysis. Statistical analysis was carried out as described in Chapter 4 on the log 
CFU values. 
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6.3 Results 
6.3.1 Optimization of screening method  
Previously, a screening method was designed and successfully used to select mutants that 
display a significant difference in persister fraction after treatment with the antibiotic 
ofloxacin (De Groote et al., 2009). Based on a linear relationship between the number of 
surviving persisters and the duration of the lag phase of the surviving population upon 
reinoculation, mutants that produced an altered number of persister cells were selected. Here, 
this screening method was optimized for detection of small molecules that, in combination 
with ofloxacin, significantly reduce the number of persister cells compared to a control 
treatment.  
 
6.3.1.1 Choice of growth medium, starting culture and antibiotic  
Since nutrients are not always abundantly present at the site of infection, in vivo situations are 
likely better represented by poor medium. Additionally, it was reported that small molecules 
can interact with peptides present in rich growth media (personal communication, CD3), 
which lowers the active concentration of the compound. Therefore, it was decided to optimize 
the screening conditions using 1:20 diluted TSB medium.  
Fast-growing exponential phase cultures typically contain few or even no persister cells. 
However, when bacterial cultures enter stationary phase, the persister fraction rises 
significantly. This growth phase-dependence of the persister fraction has been observed for 
many bacterial species after treatment with different classes of antibiotics (Spoering & Lewis, 
2001; Keren et al., 2004a). The number of persister cells is even higher in stationary phase 
cultures than in biofilms (Spoering & Lewis, 2001). Since planktonic and biofilm cultures 
display similar killing kinetics when exposed to a bactericidal agent, it is believed that 
persister cells present in both populations are similar (Spoering & Lewis, 2001). Therefore, as 
planktonic populations are easier to manipulate than biofilm cultures, the screening was 
carried out on free-living stationary phase cells.  
In literature, several mechanistically different antibiotics such as ß-lactams, aminoglycosides 
and fluoroquinolones have been used to study persistence (Spoering & Lewis, 2001). 
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According to the guide for antibiotic usage published by the University Hospital of Leuven12, 
ß-lactam antibiotics are widely recommended for treatment of P. aeruginosa infections. 
However, this class of antibiotics cannot be used in our setup as they only act bactericidal on 
fast-growing cells (Tuomanen et al., 1986). Furthermore, it was observed that the 
aminoglycoside tobramycin was ineffective in killing stationary phase cultures (Spoering & 
Lewis, 2001). Therefore, it was decided to use the fluoroquinolone ofloxacin in our screening. 
Ofloxacin is a second-generation quinolone, displaying improved activity against DNA 
gyrase, the main target of quinolones in Gram-negative bacteria. Because of the presence of a 
fluorine, these second-generation quinolones are often named fluoroquinolones (Aldred et al., 
2014).  
 
6.3.1.2 Choice of antibiotic and compound concentration  
To find compounds that specifically act on persister cells, conditions were optimized at which 
only persister cells survive after treatment with ofloxacin. Killing curves were determined 
using varying antibiotic concentrations. Based on these results (Figure 6.1A) an ofloxacin 
concentration of 10 µg mL-1 was chosen since higher concentrations did not lead to a further 
reduction of the number of surviving cells. Previously, it was shown in our group that 
incubation times beyond 5 hours of treatment did not improve bactericidal activity of 
ofloxacin. Consequently, treatment duration was set at 5 hours. 
Typically, whole-cell based screens for new antibacterials or potentiators are carried out using 
compound concentrations in the micromolar range (Payne et al., 2007; Ejim et al., 2011). 
Therefore, we decided to screen the library at a final concentration of 20-50 µM. 
Since the compounds are dissolved in DMSO, the susceptibility of P. aeruginosa cells 
towards this solvent was tested. A concentration of 2 % (v/v) did not affect cell growth, 
whereas a concentration of 4 % or higher acts growth inhibitory. Complete growth inhibition 
was achieved at a concentration of 16 % (Figure 6.1B). Based on the stock solution 
concentration and the choice of compound concentration used in the screening, a DMSO 
background concentration of 1 % will be reached, which does not affect growth. 
                                               
12
 http://www.uzleuven.be/antibioticagids/ 
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Figure 6.1: Optimization of screening conditions. A. Stationary phase cells were treated for 5 hours with 
different concentrations of ofloxacin prior to viable cell counts by plating. B. Susceptibility of growing cells to 
DMSO was determined by exposing growing cells to a range of DMSO concentrations (v:v). Effect on growth 
was evaluated by determination of OD595. Each experiment was repeated independently at least three times, 
data points correspond to the mean. Error bars represent standard error of the mean (SEM).  
 
6.3.1.3 Correlation between number of cells and lag phase 
To define the linear correlation between the number of cells incubated in the automated plate 
reader and the lag phase of the resulting growth curve, the following experiment was carried 
out: P. aeruginosa was grown in 1:20 TSB until stationary phase after which the cells were 
treated with water or ofloxacin (10 µg mL-1) for 5 hours. After treatment, a 10-fold dilution 
series was prepared in 10 mM MgSO4. Next, these samples were diluted 100-fold into fresh 
TSB growth medium and incubated in the automated plate reader to generate growth curves. 
In parallel, an aliquot of each diluted sample was plated on solid growth medium in order to 
determine the number of viable cells present in each sample. This experiment was repeated 
independently three times. The results along with an example are shown in Figure 6.2.  
 
6.3.2 Screening of a small-molecule library for anti-persister compounds 
A small-molecule collection comprising 23909 commercially available diverse molecules was 
screened to identify compounds that, in combination with the fluoroquinolone antibiotic 
ofloxacin, reduce the persister fraction compared to treatment with only ofloxacin. The 
screening is based on a correlation between the number of surviving persisters and the 
duration of the lag phase of the surviving population (De Groote et al., 2009). 
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Figure 6.2: Selection method of promising anti-persister compounds. A. Linear relationship between the 
logarithmic value of the number of cells incubated in the automated plate reader and the duration of the lag 
phase of the resulting growth curves, represented by the time needed to reach an optical density (595 nm) of 
0.6. Values represent the mean of 3 independent repeats, error bars indicate standard deviation. B. 
Representative growth curves of cells diluted after treatment with a combination of ofloxacin (Of) and 
compound A (dashed curve), compound B (dotted curve) or DMSO (solid curve). Compound A increases and 
compound B reduces the number of cells in combination with ofloxacin as compared to monotreatment, 
respectively.  
 
Based on this screening, 105 compounds were selected and re-evaluated as described in 
Experimental procedures. The majority of them (85.7 %) caused no or only a minor effect on 
the persister fraction in combination with ofloxacin as compared to monotreatment with the 
antibiotic. The remaining compounds, in total 15 out of 105, decreased the number of 
surviving persister cells over four times compared to treatment with only ofloxacin (Figure 
6.3A) and were selected for independent confirmation experiments. The effect of the 15 
selected compounds was independently evaluated using plate counts. Here, cells were plated 
out after treatment in order to determine the number of viable cells.  
Based on these results, five compounds belonging to three structurally distinct families named 
CIM007228, CIM006251 and CIM010682, were selected (Figure 6.3B). Although the 
decrease in persister fraction was not always statistically significant, we decided to test a 
resupply for three of these compounds, each of them belonging to a different compound 
family. Again, the persister fraction was not significantly reduced but a preliminary test 
showed that doubling the tested concentration further decreased the persister fraction (data not 
shown). Therefore, it was decided to evaluate commercially available analogues of these three 
compound families in a dose-response study.  
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Figure 6.3: Overview of compounds selected during screening. A. Selection of 15 compounds after re-
evaluation of the initially selected compounds. Treated cells were diluted 100-fold after which growth was 
monitored. Based on the correlation between the number of surviving cells and duration of the lag phase of 
the resulting growth curve, the relative decrease in persistence was calculated. 15 compounds, enclosed in the 
grey box, were selected for confirmation experiments. B. Relative decrease in persistence compared to 
treatment with only ofloxacin. Stationary phase cells were treated for 5 hours with a combination of ofloxacin 
and compound after which the number of remaining viable cells was determined. Data points correspond to 
the mean of three independent experiments, error bars represent SEM. Statistical analysis was carried out on 
the number of surviving cells. * P < 0.0001.  
 
6.3.3 Evaluation of commercially available analogues 
6.3.3.1 Dose-response analysis 
Evaluation of chemical analogues by monitoring regrowth after treatment 
44 commercially available analogues of the three identified structural families were obtained 
and a first dose-response experiment was conducted. Stationary phase cells were treated for 5 
hours at 37 °C with a combination of ofloxacin (10 µg mL-1) and compound. For each 
analogue, a concentration gradient was tested, with the highest concentration being 200 µM 
and the lowest 0.78 µM. The background concentration of DMSO was kept constant at 1 % 
(v/v). After treatment, samples were diluted and incubated in the automated plate reader. 
Based on the duration of the lag phase of the surviving population, the difference in number 
of surviving cells was calculated. 10 out of 44 chemical compounds tested showed a dose-
response effect (Table 6.2).  
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Table 6.2: Overview of chemical analogues of the three compound families. The compounds are classified as 
those possessing and those lacking an anti-persistence dose-response effect as determined by monitoring 
regrowth of diluted cells after treatment. 
Family 1 (CIM007228)  Family 2 (CIM006251)  Family 3 (CIM010682) 
Dose 
response 
No  
dose response 
 Dose  
response 
No  
dose response 
 No  
dose response 
CIM007228 CIM008379  CIM006251 CIM056264  CIM009198 CIM056287 
CIM013729 CIM008494  CIM056262 CIM056265  CIM009279 CIM056288 
CIM056268 CIM056263   CIM056277  CIM009682 CIM056289 
CIM056271 CIM056269   CIM056278  CIM010582 CIM056290 
CIM056282 CIM056270     CIM011277 CIM056291 
CIM056283* CIM056272     CIM011495 CIM056292 
CIM056305 CIM056273     CIM056284 CIM056293 
CIM056307 CIM056274     CIM056285 CIM056294 
 CIM056275     CIM056286  
 CIM056276       
 CIM056306       
 CIM056308      
 
 CIM056309       
*Preliminary tests showed a bactericidal effect 
 
The objective of this study was to identify compounds that specifically target persister cells. 
In this way it is possible, by unraveling the compounds’ mode of action, to gain more insight 
in the fundamentals underlying these dormant antibiotic-insensitive cells. Therefore, a 
preliminary test was carried out in which the bactericidal effect of all analogues was 
evaluated. Here, stationary phase cells were treated for 5 hours with compound (concentration 
range of 0-200 µM) after which the treated cells were diluted in fresh growth medium to 
monitor regrowth. Based on the duration of the lag phase, the number of viable cells was 
determined. One of the 10 selected compounds, CIM056283, showed bactericidal activity and 
therefore was discarded for further dose-response analysis. For the remaining 9 compounds, 
the effect on persistence is shown in Figure 6.4. Preliminary data on bactericidal activity for 
all analogues can be found in Appendix B (Figure B.1), as well as data on the anti-persistence 
effect of the 35 non-selected compounds (Figure B.2).  
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Figure 6.4: Dose-response analysis of selected commercially available analogues based on the duration of the 
lag phase. Stationary phase cells were treated for 5 hours with a combination of ofloxacin (10 µg mL
-1
) and 
compound (0.78 – 200 µM). Next, samples were 100-fold diluted into fresh TSB growth medium and growth 
was monitored. Based on the duration of the lag phase of each individual growth curve, the number of 
surviving cells was estimated. Data points represent the average relative reduction in number of cells 
(indicated above selected data points) compared to treatment with only ofloxacin. The experiment was 
independently repeated three times, error bars represent SEM. ND, not detectable.  
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7 of these 9 selected compounds belong to compound family 1. In general, an effect is visible 
when ofloxacin is combined with 25, 50 or 100 µM of anti-persister molecule, depending on 
the tested compound, but a particular better effect is observed when ofloxacin is combined 
with 200 µM compound. For some molecules, like CIM007228, CIM056268 and 
CIM056305, quite some variation is seen between the repetitions of the independent 
experiments. The best performing compound of family 1 is CIM013729. Combination of 100 
µM of CIM013729 with ofloxacin resulted in a 146-fold decrease of the persister fraction 
compared to treatment with only ofloxacin. When 200 µM of this compound is used, regrowth 
of the surviving population was not detected within 24 hours. Compound CIM056282 
displays the lowest effect on the persister fraction, resulting in a 38-fold reduction in persister 
cells when 200 µM is combined with the antibiotic ofloxacin. The two remaining compounds 
both belong to compound family 2, with CIM006251 displaying the biggest effect. 
Combination of 200 µM CIM006251 with ofloxacin decreased the persister fraction 69-fold. 
No compounds of family 3 showed a dose-response effect on persistence. 
 
Further analysis of selected analogues by viable cell counting 
The effect of the nine selected compounds in combination with ofloxacin was independently 
tested with plate count experiments (Figure 6.5). In general, compounds that displayed the 
largest effect when evaluated by monitoring the duration of the lag phase were confirmed by 
plate counting experiments. For compound family 1, CIM007228, CIM056271, CIM056305 
and CIM056307 caused a significant decrease of the persister fraction in combination with 
ofloxacin when administered at a concentration of 200 µM. CIM056282, the compound 
displaying the weakest effect in the initial dose-response experiment, was not confirmed by 
plate counting experiments. Remarkably, the effect of CIM013729 and CIM056268 in 
combination with ofloxacin was not confirmed. For compound family 2, CIM006251, 
although not statistically significant, caused a 35-fold reduction of the persister fraction upon 
combination with ofloxacin. As was the case in the previous experiment, combination of 
ofloxacin and 200 µM of compound drastically reduces the number of cells, while no or a 
remarkably lower effect is detected upon use of lower compound concentrations. Based on 
these data, it seems that a certain threshold level (> 100 µM) of compound is needed to 
establish the desired effect. In addition, preliminary plate counting tests were carried out to 
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assess the bactericidal effect (see Appendix B, Figure B.3). Based on these data, it seems that 
CIM007228, CIM056271 and CIM056305 possibly exert a minor bactericidal effect when 
applied at 200 µM. However, additional tests have to be carried out to confirm these results.  
 
 
Figure 6.5: Dose-response analysis of selected commercially available analogues using plate counts. 
Stationary phase cells were treated for 5 hours with a combination of ofloxacin (10 µg mL
-1
) and compound (0 
– 200 µM). Next, samples were diluted and plated on solid growth medium in order to determine the number 
of viable cells. Data points represent the average of three independent experiments, error bars represent 
SEM. The relative decrease in viable cells is indicated above selected data points. *P < 0.05, **P < 0.005. 
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Evaluation of the anti-persistence effect by viable cell counting revealed that assessment by 
monitoring regrowth of treated cells underestimated the reduction in persister fraction. For 
example, according to the correlation between the number of surviving cells and the lag 
phase, CIM056271 reduced the persister fraction 164 times as compared to treatment with 
only ofloxacin. However, when the effect was determined by plate counting experiments, a 
~5700 fold reduction was observed. Similar differences were observed for CIM007228 and 
CIM056305. On the other hand, CIM056307 displayed a smaller effect upon evaluation by 
viable cell counting. For some compounds such as CIM056268, no correlation was visible 
between the two independent experimental setups. Despite the fact that a clear reduction in 
persistence was detectable upon monitoring regrowth of treated cells, this effect was not 
confirmed by plate counting experiments. This suggests that CIM056268 specifically affects 
regrowth of the surviving cells instead of reducing the number of viable cells during 
treatment. Based on these observations, we decided to analyze the structure activity 
relationship (SAR) by using plate counting experiments. As the effect on the persister fraction 
determined by viable cell counting is most clear when using 200 µM of compound, SAR 
analysis will be carried out using only this compound concentration. 
 
6.3.3.2 Structure-activity relationship analysis 
The anti-persistence effect was evaluated by determining the number of viable cells after a 5 h 
treatment with ofloxacin combined with each analogue (200 µM). The bactericidal effect of 
each chemical analogue was evaluated by treating stationary phase cells for 5 hours with only 
the compound. Four additional analogues (CIM057662, CIM057663, CIM057668 and 
CIM057669), belonging to compound family 1, were provided by CD3 and were taken along 
in the SAR analysis.   
SAR analysis of compound family 1 (Figure 6.6) revealed seven compounds that significantly 
reduced the persister fraction compared to ofloxacin treatment. Three of them, CIM056272, 
CIM056283 and CIM007228, also exhibited a significant bactericidal effect on stationary 
phase cells. For the reason stated above, these compounds were excluded from further 
analysis. Of the four remaining compounds, CIM056271, further referred to as SPI001, was 
selected for further characterization. This compound reduces the persister fraction ~7200-fold 
(P < 0.0001) compared to treatment with only ofloxacin.  
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Figure 6.6: Structure activity analysis of compound family 1. A. Evaluation of the anti-persistence effect of the 
chemical analogues. Stationary phase cells were treated for 5 hours with a combination of ofloxacin (10 µg mL
-
1
) and compound (200 µM). As a control, cells were treated with ofloxacin combined with DMSO (1 % v/v) 
represented by the light grey bar. B. Evaluation of the bactericidal effect of each chemical analogue. Stationary 
phase cells were treated for 5 hours with the chemical analogue (200 µM), as a control cells were treated with 
the solvent DMSO (1 % v/v). After treatment, cells were washed and plated on solid growth medium to 
determine the number of viable cells. Data points represent the average of three independent repeats, error 
bars correspond to SEM. *P < 0.05, **P < 0.005 and *** P < 0.0001. 
 
 
Figure 6.7: Structure activity analysis of compound family 2. A. Evaluation of the anti-persistence effect of the 
chemical analogues. Stationary phase cells were treated for 5 hours with a combination of ofloxacin (10 µg mL
-
1
) and compound (200 µM). As a control, cells were treated with ofloxacin combined with DMSO (1 % v/v) 
represented by the light grey bar. B. Evaluation of the bactericidal effect of each chemical analogue. Stationary 
phase cells were treated for 5 hours with the chemical analogue (200 µM), as a control cells were treated with 
the solvent DMSO (1 % v/v). After treatment, cells were washed and plated on solid medium to determine the 
number of viable cells. Data points represent the average of three independent repeats, error bars correspond 
to SEM. *P < 0.05.  
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Based on SAR analysis of compound family 2 (Figure 6.7), three compounds were selected 
that significantly decreased the persister fraction compared to ofloxacin treatment. Since two 
of them also acted bactericidal, the remaining compound CIM006251 was selected for further 
analysis. This compound decreased the persister fraction up to ~45 fold (P < 0.05). For 
convenience, this compound was named SPI002.  
Analysis of all available chemical analogues of compound family 3 (Figure 6.8) resulted in 
the identification of two compounds, CIM010582 and CIM011495, that significantly reduced 
the persister fraction compared to ofloxacin treatment (~6 and ~8 fold respectively). 
Unfortunately, these two compounds also acted slightly bactericidal (P < 0.05) as compared to 
ofloxacin and were therefore excluded from further analysis.  
 
 
Figure 6.8: Structure activity analysis of compound family 3. A. Evaluation of the anti-persistence effect of the 
chemical analogues. Stationary phase cells were treated for 5 hours with a combination of ofloxacin (10 µg mL
-
1
) and compound (200 µM). As a control, cells were treated with ofloxacin combined with DMSO (1 % v/v) 
represented by the light grey bar. B. Evaluation of the bactericidal effect of each chemical analogue. Stationary 
phase cells were treated for 5 hours with the chemical analogue (200 µM). As a control cells were treated with 
the solvent DMSO (1 % v/v). After treatment, cells were washed and plated on solid medium to determine the 
number of viable cells. Data points represent the average of three independent repeats, error bars correspond 
to SEM. *P < 0.05 and ** P < 0.005. 
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6.3.4 Further characterization of SPI001 and SPI002 
6.3.4.1 Combination with other antibiotics 
During the screening, small molecules were combined with ofloxacin. This antibiotic belongs 
to the fluoroquinolones, which target DNA replication (Aldred et al., 2014). Other widely 
used antibiotics in clinical settings against P. aeruginosa infections include the 
aminoglycoside amikacin and the cephalosporin ceftazidime13. Therefore the effect of SPI001 
and SPI002 was evaluated in combination with these antibiotics. 
 
Optimization of a persistence assay with amikacin and ceftazidime  
To assess the effect on persister cells, the concentration of antibiotic at which only persister 
cells survive was determined. P. aeruginosa stationary phase cells were subjected to a range 
of amikacin concentrations (0 - 200 µg mL-1, minimal inhibitory concentration (MIC) value = 
0.2 µg mL-1) during 5 hours. After treatment, cells were washed, diluted and plated on solid 
growth medium. This experiment was independently repeated three times. Based on these 
results, no significant additional killing occurs when cells are treated with 50 µg mL-1 or 
higher concentrations of amikacin (Figure 6.9A). This indicates the presence of an amikacin-
tolerant persister fraction. Subsequent persistence assays were carried out using 100 µg mL-1 
amikacin.  
Ceftazidime belongs to the ß-lactam antibiotics and therefore has no bactericidal effect on 
stationary phase cells. In order to find the most suitable conditions to obtain a stable persister 
fraction, the following experiment was carried out. P. aeruginosa stationary phase cells were 
diluted 100-fold into fresh 1:20 TSB. When the culture reached an optical density of 
approximately 0.005, 0.02, 0.050 and 0.125, the cells were challenged with different 
concentrations of ceftazidime (0 - 60 µg mL-1, MIC value = 6.25 µg mL-1). After 5 hours of 
treatment at 37 °C, cells were washed, diluted and plated on solid growth medium in order to 
determine the number of surviving cells. This experiment was repeated independently three 
times. A stable persister fraction was observed, regardless at which optical density the 
treatment was initiated (Figure 6.9B). Remarkably, the persister fraction already started 
                                               
13
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increasing when cells entered exponential phase (OD595 = 0.05). This is not in accordance 
with earlier reports in literature, where the persister fraction only starts rising when cells enter 
mid-late exponential phase (Keren et al., 2004a). For subsequent persistence experiments, 
growing cells that reached an optical density of 0.02 were treated with 30 µg mL-1 
ceftazidime.  
 
 
Figure 6.9: Optimization of persistence assays for amikacin and ceftazidime. A. Stationary phase cells were 
treated for 5 hours with different concentrations of amikacin prior to viable cell counts by plating. B. Stationary 
phase cells were diluted into fresh medium and after 1, 2, 3 and 4 hours respectively, growing cells were 
treated with increasing concentrations of ceftazidime. Viable cell counts were determined by plating. Data 
points correspond to the mean. Each experiment was repeated independently at least three times. Error bars 
represent SEM.  
 
Effect of SPI001 and SPI002 in combination with amikacin or ceftazidime 
Stationary phase cells were treated for 5 hours with amikacin (100 µg mL-1) combined with 
either SPI001 or SPI002 (200 µM). Growing cells were treated with ceftazidime (30 µg mL-1) 
and one of the two compounds. Since exponential phase cells are typically more sensitive 
towards antibiotic treatment, different concentrations of SPI001 and SPI002 were tested (0-
200 µM). The results are shown in Figure 6.10. SPI002 significantly reduces the persister 
fraction in combination with ceftazidime and amikacin. SPI001, on the other hand, 
completely eliminates the bacterial population in combination with both antibiotics when a 
concentration of 200 µM is used. Combining lower concentrations of compound with 
ceftazidime did not result in a significant reduction of the persister fraction (Figure 6.10B).  
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Figure 6.10: Effect of molecules in combination with amikacin and ceftazidime on P. aeruginosa. A. Stationary 
phase cells and B. exponential phase cells of P. aeruginosa were treated for 5 hours with amikacin (Am, 100 µg 
mL
-1
) or ceftazdime (Cf, 30 µg mL
-1
), respectively, in combination with 1 % DMSO, 200 µM SPI001 or 200 µM 
SPI002. Data points correspond to the mean relative persister fraction. Each experiment was repeated 
independently at least three times. Error bars represent SEM. * P < 0.05, ** P < 0.0005. ND, not detectable. 
 
Above, we demonstrated that addition of only SPI001 or SPI002 to P. aeruginosa stationary 
phase cells did not cause a significant bactericidal effect (see Figure 6.6B and Figure 6.7B). 
However, treating growing cells with SPI001 or SPI002 significantly affects viability as 
shown in Figure 6.11. Both SPI001 and SPI002 exert a significant bactericidal effect when 
administered at a concentration of 100 µM or higher, while SPI002 already kills P. 
aeruginosa cells at 50 µM. These results indicate that SPI001 and SPI002 act bactericidal on 
growing cells but not on stationary phase cells of P. aeruginosa. Moreover, compounds 
SPI001 and SPI002 are more potent than ceftazidime, reducing the number of viable cells to 
5.4 x 102 and 1.4 x 103 cells respectively when administered at 200 µM. However, the 
combination of ceftazidime with SPI001 or SPI002 shows a better effect than each of the 
treatments separately. 
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Figure 6.11: Effect of SPI001 and SPI002 on growing cells. The anti-persistence (combination of ofloxacin and 
compound) and bactericidal effect of SPI001 and SPI002 was determined by treating growing cells for 5 hours. 
After treatment, cells were washed, diluted and the number of viable cells was determined by means of plate 
counting. Data points represent the average of three independent repeats, errors bars indicate SEM. *P < 0.1, 
**P < 0.05. 
 
6.3.4.2 Effect on other pathogens 
Persister cells have been suggested to play an important role in the recalcitrant nature of 
infections caused by P. aeruginosa but also by several other pathogens (Cohen et al., 2013). 
We therefore examined whether SPI001 or SPI002 are able to reduce the persister fraction of 
the Gram-negative pathogens E. coli and Salmonella Typhimurium and the Gram-positive 
bacterium Staphylococcus aureus. For each bacterium, the anti-persistence and bactericidal 
effect of SPI001 and SPI002 was evaluated. The anti-persistence effect is determined by 
treating stationary phase cells for 5 hours with a combination of antibiotic and compound. 
The bactericidal effect is examined by treating stationary phase cultures for 5 hours with the 
anti-persister compound only. After treatment, cells were washed, diluted and plated on solid 
growth medium to determine the number of surviving cells. 
 
Effect on Escherichia coli 
The anti-persistence and bactericidal effect of SPI001 and SPI002 was tested on E. coli, a 
model organism for studying persistence. Previous optimization experiments carried out in 
our research group indicate that the use of 5 µg mL-1 ofloxacin for 5 hours allows survival of 
persister cells only (Verstraeten, 2011). Therefore, to assess the anti-persistence effect, 
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stationary phase cells were treated with the combination of ofloxacin and compound. As is 
shown in Figure 6.12A, SPI001 and SPI002 are both capable of reducing the persister fraction 
in combination with ofloxacin. SPI001 shows the best effect: combining ofloxacin with 50 
µM reduces the persister fraction 37-fold while addition of 100 µM completely eliminated the 
bacterial population. Treatment of stationary phase cells with the combination ofloxacin – 
SPI002 (100 µM) reduced the persister fraction almost 4000 times. In addition, SPI001 and 
SPI002 both act bactericidal on stationary phase E. coli cells (Figure 6.12B). Upon 
administration of 100 µM of SPI002, the number of viable cells decreased almost 8000-fold, 
whereas treatment with 100 µM of SPI001 completely eliminated the entire bacterial 
population.  
 
Effect on Salmonella enterica serovar Typhimurium  
Salmonella is an enteric pathogen, responsible for the outbreak of severe food-borne 
infections worldwide (Krtinic et al., 2010). This bacterium can enter and replicate within 
macrophages (Haraga et al., 2008), hereby evading the host immune system. Recently it was 
published that, immediately after uptake into these macrophages, Salmonella forms a non-
replicating population representing antibiotic-insensitive persister cells (Helaine et al., 2014). 
In this way, persisters form a reservoir of bacteria that can cause relapse of infection. 
Therefore, we tested the susceptibility of this pathogen to the anti-persistence and bactericidal 
effect of SPI001 and SPI002. 
Previous optimization experiments carried out in our group indicate that treatment of 5 hours 
using 5 µg mL-1 ofloxacin results in a stable persister fraction (Valerie Defraine, personal 
communication). Therefore, compounds were combined with ofloxacin to assess the anti-
persistence effect. Assessment of the bactericidal effect was carried out by Valerie Defraine. 
As is shown in Figure 6.13A, both anti-persister molecules have an effect on the persister 
fraction when applied at a concentration of 100 µM or higher. However, in this case, the best 
effect was obtained with the combination ofloxacin and SPI002. The combination of 
ofloxacin with 100 µM SPI002 reduced the persister fraction 450-fold compared to ofloxacin 
treatment, while using a concentration of 200 µM reduced the number of persisters more than 
4 log units. Furthermore, as was the case in E. coli, SPI001 and SPI002 both act bactericidal 
on stationary phase cultures of Salmonella (Figure 6.13B). Addition of 100 µM drastically 
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reduced the number of surviving cells (> 5 log units), treating cells with 200 µM SPI001 even 
completely eliminated all detectable viable cells.  
 
 
Figure 6.12: Effect of SPI001 and SPI002 on E. coli. A. Anti-persistence and B. bactericidal effect was evaluated 
by treating stationary phase cultures for 5 hours with a combination of ofloxacin (Of) and compound or the 
compound alone, respectively. After treatment, cells were washed, diluted and plated on solid medium to 
determine the number of surviving cells. Data points represent the average of three independent repeats, error 
bars indicate SEM. *P < 0.05 and **P < 0.0001. ND, not detectable.  
 
 
Figure 6.13: Effect of SPI001 and SPI002 on S. Typhimurium. A. Anti-persistence and B. bactericidal effect was 
evaluated by treating stationary phase cultures for 5 hours with a combination of ofloxacin (Of) and compound 
or the compound alone, respectively. After treatment, cells were washed, diluted and plated on solid medium 
to determine the number of surviving cells. Data points represent the average of three independent repeats, 
error bars indicate SEM. Assessment of the bactericidal effect of SPI001 was carried out by Valerie Defraine. *P 
< 0.05, **P < 0.005 and ***P < 0.0005. ND, not detectable. 
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Effect on Staphylococcus aureus 
The Gram-positive bacterium S. aureus is the second most frequently isolated pathogen 
among all hospital-associated infections, and moreover, is the leading cause of surgical site 
infections in Europe and throughout the US (ECDC, 2013; Magill et al., 2014). Infections 
caused by this pathogen are often difficult to eradicate. Exactly 70 years ago, Joseph Bigger 
discovered the presence of a small antibiotic-insensitive subpopulation of staphylococcal cells 
that survived antibiotic treatment which he named ‘persisters’ (Bigger, 1944). Today, these 
persister cells are believed to play a major role in the recalcitrant nature of Staphylococcus 
infections. 
To evaluate the anti-persistence effect, experimental conditions were optimized in our 
research group. The use of 10 µg mL-1 rifampicin for 5 hours killed all antibiotic-sensitive 
cells, leaving only the persister cells (Valerie Defraine, personal communication). Therefore, 
the anti-persistence effect of the compounds was examined in combination with rifampicin. 
The bactericidal effect on stationary phase cultures was assessed by Valerie Defraine. The 
results are given in Figure 6.14A. A combination of rifampicin with 100 µM anti-persister 
compound or higher significantly decreases the persister fraction. As was the case for E. coli 
and P. aeruginosa, SPI001 causes the biggest decrease of the persister fraction. Combination 
of rifampicin with 200 µM SPI001 resulted in a 2468-fold reduction. Both anti-persister 
molecules also act bactericidal on S. aureus stationary phase cells (Figure 6.14B). Treatment 
with 100 µM or higher significantly reduced the number of viable cells. Remarkably, 
monotreatment with only the persister compound performs better than the combination 
therapy.  
 
6.3.4.3 Effect on a P. aeruginosa efflux mutant 
A higher concentration of SPI001 or SPI002 is needed to significantly decrease the persister 
fraction in P. aeruginosa as compared to E. coli. It is known that P. aeruginosa has a highly 
impermeable membrane, 100 times less permeable than E. coli (Yoshimura & Nikaido, 1982) 
(see Section 1.3.1.1). The presence of efflux pumps further prevents the accumulation of 
molecules in the bacterial cell. To test if SPI001 and SPI002 work more efficiently if more 
compound is retained within the bacterium, a P. aeruginosa efflux mutant was used. This 
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PAO1-derived mutant strain YM64 lacks four major mex operons (mexAB-oprM, mexCD-
oprJ, mexEF-oprN and mexXY) for multidrug efflux pumps (Morita et al., 2001).  
 
Optimization of a persistence assay with ofloxacin  
To determine the concentration of ofloxacin at which only persister cells survive, P. 
aeruginosa wild type and mutant strain YM64 stationary phase cells were treated with 
increasing concentrations of ofloxacin (0-50 µg mL-1, MIC value = 0.08 µg mL-1) for 5 hours. 
Based on viable cell counting, no additional killing was observed when using 10 or 5 µg mL-1 
or higher (Figure 6.15) on wild type and mutant strain respectively. This indicates the 
presence of an ofloxacin-tolerant persister fraction. To compare the persister fractions of both 
strains, assessment of the persister fraction will be carried out using 15 µg mL-1 ofloxacin.  
 
Effect of SPI001 and SPI002 on the efflux mutant YM64  
Both the anti-persistence and bactericidal effect of SPI001 and SPI002 was tested on YM64 
and its parental PAO1 wild-type strain. The results show that the efflux mutant was far more 
sensitive towards the persistence effect of both SPI001 and SPI002, with SPI001 causing the 
best effect (Figure 6.16). While the persister fraction of the wild-type strain was not affected, 
combination of ofloxacin with 50 µM SPI001 or higher significantly reduced the persister 
fraction of the efflux mutant YM64. The combination of SPI002 (100 µM) with ofloxacin 
reduced the persister fraction of the efflux mutant 385-fold, while no effect was detected upon 
treatment of the wild type strain. This is in agreement with previous described data where a 
reduction in persister fraction of PA14 wild type strain was only achieved when using 200 
µM of the anti-persister molecules (see Section 6.3.3).  
When subjecting the efflux mutant to a treatment with SPI001 alone, a significant reduction in 
the number of viable cells was detected when using 50 µM or higher. Remarkably, SPI001 
and SPI002, when administered at 100 µM, were as potent as ofloxacin on stationary phase 
cells of the efflux mutant. When the same treatment was performed on the wild-type strain, no 
decrease was visible at all. Taken together, these data show that, because of the low 
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permeability of wild-type P. aeruginosa cells, more compound is needed to achieve the 
desired effect. 
 
 
Figure 6.14: Effect of SPI001 and SPI002 on S. aureus. A. Anti-persistence and B. bactericidal effect was 
evaluated by treating stationary phase cultures for 5 hours with a combination of rifampicin (Rif) and 
compound or the compound alone, respectively. After treatment, cells were washed, diluted and plated on 
solid medium to determine the number of surviving cells. Data points represent the average of three 
independent repeats, error bars indicate SEM. *P < 0.1, **P < 0.05 and ***P <0.005.  
 
 
 
 
Figure 6.15: Optimization of persistence assay for the efflux mutant YM64 with ofloxacin. Stationary phase 
cells of wild type and efflux mutant YM64 were treated for 5 hours with increasing concentrations of ofloxacin.  
After treatment, cells were washed, diluted and plated on solid medium. Data points represent the mean of 
three independent repeats, error bars indicate SEM.  
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Figure 6.16 : Effect of SPI001 and SPI002 on efflux mutant. Anti-persistence and the bactericidal effect of A. 
SPI001 and B. SPI002 was evaluated on the wild-type and efflux mutant strain. Stationary phase cells were 
treated for 5 hours with the combination of ofloxacin and compound or compound alone. After treatment, 
cells were washed, diluted and plated on solid medium to determine the number of viable cells. Data points 
correspond to the average of three independent repeats, error bars represent the SEM. *P < 0.05, **P < 0.005 
and ***P < 0.0005. 
 
6.4 Discussion  
In this Chapter, we described the identification of small molecules that significantly reduce 
the persister fraction in combination with the fluoroquinolone ofloxacin compared to 
ofloxacin monotreatment. Based on SAR analysis, the most promising anti-persister 
compounds, named SPI001 and SPI002, were selected for further characterization. We 
showed that these molecules are capable of reducing the persister fraction of P. aeruginosa in 
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combination with two additional clinically used antibiotic classes, and, in addition, have the 
ability to reduce the persister fraction of other relevant Gram-negative and Gram-positive 
pathogens.  
 
6.4.1 Identification and selection of anti-persister molecules 
For the initial selection of promising molecules, the effect was assessed by taking advantage 
of the observed correlation between the number of surviving cells and the lag phase after 
dilution of the surviving cells into fresh growth medium. Based on this screening method, we 
identified 15 different molecules that were able to reduce the persister fraction at least 
fourfold, corresponding to a hit rate of 0.063 %. Independent confirmation experiments by 
viable cell  counts further reduced this rate to 0.021 % which is low in comparison with the 
only other similar screening reported in literature, for which a hit rate of 0.12 % was reported 
(Kim et al., 2011). In this reported screening, chemicals that lowered the persister fraction of 
exponential growing E. coli cells in combination with ampicillin without acting growth 
inhibitory were identified. This difference can be explained by several factors. First of all, it is 
reported that the outer membrane of P. aeruginosa is approximately 100-fold less permeable 
compared to E. coli (Yoshimura & Nikaido, 1982), hereby reducing the number of molecules 
able to enter the bacterial cell to exert their action. This is supported by the observation that, 
when evaluating a collection of previously approved drugs to detect potentiation of the 
tetracycline antibiotic minocycline, the number of molecules showing activity against E. coli 
was seven times higher compared to the ones active against P. aeruginosa (Ejim et al., 2011). 
Secondly, the use of a different start culture, mid-exponential versus stationary phase cultures 
in our set-up respectively, may explain our lower hit rate. For instance, it has been described 
that persisters generated during exponential phase are slow-growing cells rather than non-
growing cells (Balaban et al., 2004) making them more susceptible than non-growing cells. 
Furthermore, we previously showed that persisters formed during exponential phase 
conditions are more prone to resuscitation by which they regain susceptibility against 
antibacterial agents (Kristine Stepanyan, unpublished data). Lastly, the likely difference in 
composition of the used small-molecule collections probably affects the number of molecules 
identified.  
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Of the 15 selected compounds, only five were retained after analysis by viable cell counting. 
Additionally, after dose-response analysis, no correlation between the screening method and 
the viable cell counting experiments was detected for some of the compounds. The most 
striking example is provided by CIM056268, for which no effect on the persister fraction at 
all was detected by viable cell evaluation. Since treatment of the cells is carried out in exactly 
the same way, the difference in result is caused by factors inherently embedded in the 
evaluation method used to estimate the effect on persistence. Possibly, treatment with these 
compounds inhibit specific cellular pathways delaying regrowth after dilution of the surviving 
population in fresh medium. This results in the observation of a longer lag phase, without 
actually affecting the number of surviving cells. This hypothesis can be examined by treating 
isolated ofloxacin-tolerant persisters with compound or DMSO, dilute cells into fresh growth 
medium and monitor regrowth with viable cell counting. 
In addition, molecules that in combination with ofloxacin result in the survival of more cells 
compared to monotreatment with ofloxacin, thus resulting in a shorter lag phase after dilution 
of treated cells into fresh growth medium, were identified during our screening (Appendix B, 
Table B.1). Possibly, these compounds increase the number of viable cells by interfering with 
the bactericidal action of ofloxacin. Alternatively, treatment with these molecules may 
stimulate regrowth of ofloxacin-tolerant cells upon encountering fresh growth medium. 
Unraveling the mode of action of such a persister regrowth-stimulating molecule may provide 
insight into signals or mechanisms implicated in the reversion of the dormant state of 
persisters to antibiotic-susceptible cells. 
 
6.4.2 Combination with other mechanistically distinct antibiotics  
Our screening was carried out by combining compounds with the fluoroquinolone antibiotic 
ofloxacin. It is suggested in literature that the multi-drug tolerant persister population is 
heterogeneous, composed of several subpopulations of persister cells, each represented by 
their own mechanisms of tolerance (Allison et al., 2011b). As a consequence, individual 
persister cells can differ in their tolerance profile, as supported by the observed difference in 
persister fraction upon treatment of a population with distinct classes of antibiotics (Spoering 
& Lewis, 2001; Keren et al., 2004a; Goneau et al., 2014). Approaches have been reported in 
which the susceptibility of persisters cells to one specific antibiotic class can be increased, 
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hereby targeting a specific subpopulation of persister cells (Lu & Collins, 2009; Allison et al., 
2011a; Barraud et al., 2013). In contrast, some molecules have been described which alter 
tolerance of persister cells to multiple antibiotic classes (Kim et al., 2011; Pan et al., 2012).  
Our results show that SPI001 and SPI002 are able to reduce the persister fraction in 
combination with two additional mechanistically different classes of antibiotics. Combination 
of our two selected anti-persister molecules with the aminoglycoside amikacin, which acts by 
inhibiting translation, significantly reduced the persister fraction. The combination with 
SPI001 even resulted in total elimination of the bacterial population after a 5 h treatment. 
Similar results were obtained when combining the anti-persister molecules with the 
cephalosporin antibiotic ceftazidime, acting on cell wall biogenesis. These results indicate 
that our molecules are able to target multiple subpopulations of persisters, making them a 
promising starting point for the development of a future anti-persister therapy. 
Based on these results, the identified anti-persister molecules may act by reverting antibiotic 
tolerance of the persister cells after which they are killed by the antibiotic present in the 
growth medium or, alternatively, by killing the persister cells itself. In literature, examples of 
both strategies were reported. For instance, the molecule 3-[4-(4-methoxyphenyl) piperazin-1-
yl] piperidin-4-yl biphenyl-4-carboxylate (C10) wakes up persister cells (Kim et al., 2011), 
while the synthetic quorum-sensing inhibitor (Z)-4-bromo-5-(bromomethylene)-3-
methylfuran-2(5H)-one (BF8) has been described to revert multidrug tolerance in P. 
aeruginosa and E. coli strains without reverting persisters to growing cells (Pan et al., 2012; 
Pan et al., 2013a; Pan et al., 2013b). On the other hand, the acyldepsipeptide antibiotic 
ADEP4 (Conlon et al., 2013) and the anti-pseudomonal artilysin Art-175 (Briers et al., 
2014a) were shown to directly kill persister cells.  
In addition, SPI001 and SPI002, although not bactericidal on P. aeruginosa stationary phase 
cultures, affect viability of growing cells (Figure 6.11). It was reported that E. coli 
exponential phase cells, stationary phase cells and persister cells represent three different 
physiological states (Shah et al., 2006). Therefore, it is possible that the selected anti-persister 
molecules interfere with a process only important in exponential and persister state or that 
stationary phase cells are better protected against the cidal treatment. Non-growing stationary 
phase cells might be less susceptible than growing cells towards the action of our anti-
persister molecules and, in addition, unlike metabolically quiescent persister cells, are able to 
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restore the damage caused by the treatment more quickly. Alternatively, the anti-persister 
molecules may induce non-specific side effects which are only lethal to growing cells.  
 
6.4.3 Effect on other bacterial species 
Although some processes involved in persister formation are shared among different bacterial 
species, such as for example the stringent and oxidative stress response, bacterium-specific 
differences are reported (see Chapter 2). An example is provided by the phenomenon of 
quorum sensing (QS), a process that regulates gene expression based on population density 
through the production and detection of signaling molecules (Waters & Bassler, 2005). This 
process was shown to be involved in the formation of P. aeruginosa persisters (Kayama et al., 
2009; Moker et al., 2010; Que et al., 2013), while it does not seem to play a role in the 
formation of persisters in E. coli (Lewis, 2007).  
Therefore, we investigated the effect of SPI001 and SPI002 in combination with a 
conventional antibiotic against other clinically relevant bacterial species. SPI001 and SPI002 
both reduced the persister fraction of the Gram-negatives E. coli and S. Typhimurium and of 
the Gram-positive S. aureus. Based on these results, we conclude that SPI001 and SPI002 act 
on a process involved in persister formation or interfere with a process essential for viability 
or maintenance of the antibiotic tolerant state which is shared among the tested bacteria.  
While SPI001 and SPI002 did not affect viability of P. aeruginosa stationary phase cultures, 
these anti-persister molecules act bactericidal on stationary phase cultures of E. coli, S. 
Typhimurium and S. aureus. Possibly, the high intrinsic resistance of P. aeruginosa compared 
to other Gram-negatives (Breidenstein et al., 2011) prevents the bactericidal action of SPI001 
and SPI002. This is supported by the observation that stationary phase cultures of a P. 
aeruginosa efflux mutant are indeed susceptible to the bactericidal action of the anti-persister 
molecules (Figure 6.16). 
 
6.4.4 Conclusion 
We identified small-molecules belonging to three chemically distinct classes that, when 
combined with a conventional antibiotic, significantly reduce the persister fraction of P. 
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aeruginosa. Based on SAR analysis, the two most promising compounds were selected for 
further characterization. The anti-persister effect is not restricted to a specific antibiotic class 
nor to a specific bacterial species. These data strongly support the potential of these molecules 
to serve as a starting point for the development of an anti-persister therapy. A logical next 
step in the functional analysis of these anti-persister molecules would consist in unraveling 
their mode of action (see next Chapter).  
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Chapter 7 
Detailed examination of biological activity and mode 
of action of the anti-persister molecule SPI00114 
 
7.1 Introduction 
Pseudomonas aeruginosa is one of the dominant bacteria present in the lungs of cystic 
fibrosis (CF) patients (Zhao et al., 2012). Often, these infections become chronic thereby 
continuously damaging the lung which ultimately leads to respiratory failure (Folkesson et al., 
2012). When comparing clonal P. aeruginosa isolates from early and late stages of chronic 
infections, a 100-fold increase in persister cells was observed, which provides evidence for a 
causal relationship between the presence of persister cells and the recalcitrant nature of 
infections in the CF lung (Mulcahy et al., 2010). In addition, persisters provide a reservoir of 
viable cells within the host, increasing the probability of acquiring additional resistance 
mechanisms by horizontal gene transfer or mutation, thereby contributing to the development 
of multidrug resistant strains (Cohen et al., 2013). Therefore, targeting persisters will not only 
greatly help in clearing infections but also in preventing development of resistance. 
Currently no molecular targets are available for rational development of an anti-persister 
therapy. Therefore, we used a top-down approach to identify small molecules that specifically 
act on persister cells. A medium-throughput screening was carried out for compounds that, in 
combination with the clinically used antibiotic ofloxacin, reduce the persister fraction of P. 
aeruginosa. We showed that the identified compounds can eliminate an entire bacterial 
culture in combination with mechanistically distinct antibiotic classes. Furthermore, they also 
exhibited activity against other Gram-negative pathogens such as Escherichia coli and 
Salmonella. Typhimurium and against the Gram-positive bacterium Staphylococcus aureus 
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 Analysis of transcriptome data described in this Chapter was performed by Dr. Carolina Fierro (KU Leuven) 
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(Chapter 6). In this Chapter, one of those compounds, named SPI001, is examined in more 
detail. Here, we evaluate the effect of SPI001 on several P. aeruginosa clinical isolates and 
examine its combination spectrum in more detail. Furthermore, its mode of action is studied 
both at the cellular and genetic level.  
 
7.2 Experimental procedures 
Bacterial strains, media and growth conditions. Strains were grown in 1:20 Trypticase Soy 
Broth (TSB) at 37 °C. For solidified medium, TSB was supplemented with 1.5 % agar. The 
following antibiotics and antiseptics were used: ofloxacin, amikacin, ceftazidime, polymyxin 
B, hexachlorophene, acriflavine hydrochloride and ferric chloride. Concentrations are 
indicated in the text. All chemicals were purchased from Sigma unless indicated otherwise. 
Strains are listed in Table 7.1, clinical P. aeruginosa isolates were kindly provided by Prof. 
Françoise van Bambeke (Université Catholique de Louvain).  
Minimal inhibitory concentration (MIC) determination. MIC values were determined as 
described before (see Chapter 4) using 1:20 TSB as a growth medium. The lowest antibiotic 
concentration resulting in the absence of bacterial growth was considered as the MIC. 
Persistence assay. Determination of the number of persisters was carried out as described in 
Chapter 6.  
Statistical analysis. Statistical analysis was carried out as described in Chapter 6.  
Treatment of isolated persister cells. Persister cells were isolated as described previously 
with minor modifications (Pan et al., 2012). Stationary phase cells were treated for 5 hours 
with ofloxacin (10 µg mL-1). These conditions were previously optimized as higher ofloxacin 
concentrations or increased incubation times do not lead to a further reduction of the number 
of surviving cells. The surviving persisters were washed twice with a 0.85 % NaCl solution 
(4750 rpm, 15 minutes, 4 °C). These isolated persister cells were used for treatment as 
described in the text. After treatment, the sample was washed twice with 0.85 % NaCl (6000 
rpm, 10 minutes, 4 °C) and divided into three parts. The first aliquot was diluted and plated 
out to determine the number of surviving colony forming units (CFU). The second and third 
aliquot were treated for 5 hours with water and ofloxacin respectively to determine the 
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number of persister cells that regained sensitivity to ofloxacin. Next, cells were washed, 
diluted and plated on solid medium in order to quantify the number of viable cells. 
 
Table 7.1: strains used in this Chapter 
Strain Descriptiona Source or reference  
P. aeruginosa PA14 Wild type, KmR Lee et al. (2006) 
P. aeruginosa PAO1 Wild type Dieter Haas (ETH) 
P. aeruginosa YM64 mexAB-oprM::FRT, mexXY::FRT,  
mexCD-oprJ::FRT, mexEF-oprN::FRT 
Morita et al. (2001) 
P. aeruginosa BE136 Clinical isolate bronchus Pirnay et al.(2002) 
P. aeruginosa PA1255 Clinical isolate CF lung Françoise van Bambeke 
(UCL) 
P. aeruginosa AA249 Clinical isolate burn wound Pirnay et al.  (2002) 
P. aeruginosa BU004 Clinical isolate throat Pirnay et al. (2002) 
P. aeruginosa BR642 Clinical isolate bed pan Pirnay et al. (2002) 
P. aeruginosa PA1256 Clinical isolate CF lung Françoise van Bambeke 
(UCL) 
E. coli SX43∆mutS K-12 MG1655 lacZ::tsr-venus; mutS::KmR Toon Swings (KU Leuven) 
 
Synthesis of small unilamellar vesicles (SUV). SUV composed of 1,2-dioleoyl-sn-glycero-
3-phosphoethanolamine (DOPE)/ 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac -glycerol) 
(DOPG) and 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC)/cholesterol representing 
bacterial and eukaryotic cell membranes respectively were prepared. All lipids were 
purchased from Avanti-Polar Lipids, Inc. Lipids, DOPE/DOPG (4:1 molar ratio) or 
DOPC/cholesterol (1:1 molar ratio) were mixed in dichloromethane, after which the solvent 
was removed by drying the sample using a flow of nitrogen gas followed by a three hour 
incubation in a excicator. Next, the lipid micelles were hydrated by adding a 50 mM 
carboxyfluorescein solution (50 mM carboxyfluorescein in HEPES/NaOH buffer, pH 7.4-7.5) 
and stirred with a glass stirrer. The lipid suspension was incubated at room temperature for 15 
hours in a dark environment. The following day, the suspension was sonicated at 0 °C for 45 
minutes. The SUV and free carboxyfluorescein were separated by exclusion chromatography 
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on a Sephadex G-75 column (diameter 2 cm, height 60 cm), using a 5 mM HEPES solution 
(pH 7.4) as eluent.  
Determination of SUV concentration. The SUV concentration was determined by 
measuring the total fraction of inorganic phosphate. First, the organic phosphate was 
completely ashed as follows: a drop of magnesium nitrate solution was added to a SUV 
aliquot after which it was taken to dryness by heating the sample in a flame. Next, the total 
amount of inorganic phosphate was determined as described by Ames (1966). Briefly, a 10 % 
ascorbic acid: 0.42 % ammonium molybdate solution (1:6 v/v) was added to the sample and 
incubated for 20 minutes at 45 °C after which absorbance was measured at 820 nm. 
Ammonium molybdate was solubilized in 1N H2SO4 The readings were proportional to 
phosphate concentrations to an optical density of at least 1.8, 0.01 µmol of inorganic 
phosphate results in an absorbancy of 0.260.  
Leakage assay. The phospholipid concentration is kept constant throughout the experiments 
([DOPE+DOPG] or [DOPC+cholesterol] = 25 µM). SUV were treated with increasing 
compound concentrations, keeping the final dimethyl sulfoxide (DMSO) concentration at 1 % 
(v:v). After rapid and vigorous stirring, the time-course of fluorescence change corresponding 
to carboxyfluorescein release was recorded at 515 nm, with λexc 490 nm, for 15 minutes. The 
percentage of released carboxyfluorescein at time t was determined by: 
% carboxyfluorescein = (Ft - F0)/(FT – F0) x 100 % 
With: F0 = intensity of fluorescence of the liposomes in absence of peptide; Ft = intensity of 
fluorescence at time t in the presence of peptide; FT  = intensity of fluorescence after liposome 
destruction by adding 50 µL 10 % Triton X-100 in water.  
Sample preparation and RNA sequencing. Overnight cultures were diluted 100-fold into 
fresh 1:20 TSB medium and grown until late-exponential phase (OD595 = 0.2). Next, cells 
were treated for 15 minutes with 50 µM SPI001, 50 µM of the inactive analogue CIM056276 
(see Figure 6.6), further referred to as SPI006, or 1 % DMSO. RNA sampling, isolation and 
assessment of RNA integrity, quantity and purity was carried out as described before (see 
Chapter 4). For each strain, RNA isolation was done in triplicate. To deplete ribosomal RNA 
sequences, the samples were treated with the Ribo-Zero™ rRNA Removal Kit for Gram-
Chapter 7                                 Detailed examination of biological activity and mode of action of SPI001 
135 
 
 
negative bacteria (Epicentre) according to the manufacturer’s instructions. Preparation of the 
library followed by RNA sequencing was performed by GeneCore, EMBL, Heidelberg, 
Germany.  
Transcriptome data analysis. Raw RNA-Seq data were evaluated with FastQC for quality 
control. Only one of the nine samples (cells treated with SPI006) showed a bias in its base 
content along the whole read length. Multivariate analysis performed with the mpm R 
package (Wouters et al., 2003) and hierarchical clustering of samples indicated that the 
sample largely differed from the rest and it was removed from subsequent analyses. Genomic 
alignments of reads were performed with Bowtie2 using P. aeruginosa UCBPP-PA14 
genome as reference (NC_008463.1). Raw counts for gene expression were obtained with 
HTSeq-count (no strain-specific option and union mode to count for overlapping features). 
Differential expression between treated and control samples was done with DESeq2 (Anders 
& Huber, 2010; Love et al., 2014) using a False Discovery Rate threshold of 5%. The list of 
differentially expressed genes was further refined by keeping log2 fold-changes above 1. For 
further analysis of genes affected upon treatment with the anti-persister molecule SPI001, 
genes differentially expressed under the inactive compound treatment were removed. Gene 
expression values for plotting were obtained using the regularized log-transformation in the 
DESeq2 package. Gene expression values were mean centered and variance rescaled before 
visualization with heatmaps. Functional annotation of results was performed using KEGG 
pathways and KEGG modules. PseudoCAP functional classes and Gene Ontology annotation 
were obtained from www.pseudomonas.com (Winsor et al., 2011). Since the functional 
annotation for the UCBPP-PA14 strain is more limited than for the PAO1 strain, we finally 
used the PAO1 gene annotation and transferred it to UCBPP-PA14 strain using orthology 
relations from the OMA browser (Altenhoff et al., 2011). 
Network analysis. Pseudomonas functional interactions were obtained from STRING 
database (Jensen et al., 2009). Only gene-gene interactions with a minimum reliability score 
of 0.8 were retained. A deregulated network was extracted by selecting interactions in which 
both genes are differentially expressed in the presence of the active compound. Network 
visualization was done with Cytoscape (Smoot et al., 2011). 
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7.3 Results 
7.3.1 Effect of SPI001 on Pseudomonas aeruginosa clinical isolates 
Until now, the anti-persister effect of SPI001 had only been tested on the P. aeruginosa lab 
strain PA14, a human clinical isolate (Rahme et al., 1995). To assess if SPI001 is also active 
against other clinical isolates, previously exposed to different in vivo conditions, we obtained 
P. aeruginosa isolates from different sampling sites (Table 7.2).  
  
Table 7.2: Clinical P. aeruginosa strains and their characteristics. Source and collection information is given 
with information regarding serotype (Sero), siderophore type (pyoverdine type, PVD), presence of exoS/exoU 
and oprD allele code based on data published by Pirnay et al. (2009).  
Strain Source Treatment 
concentration 
 (µg mL-1) 
Am     Of      Cf 
Resistance* Sero PVD exoS/ 
exoU 
oprD** 
BE136 bronchus 100 100 250 / 3 IIa exoU A110 
PA1255 CF lung 100 10 250 / / / / / 
AA249 burn wound 500 100 250 Am, Of, Cf, IPM, 
MEM, ATM & Cp 
NT I exoS B107  
(DOM) 
BU004 throat 100 100 250 / NT I exoS C106 
BR642 bed pan 100 100 250 / 1 I exoU A103 
PA1256 CF lung 100 10 250 / / / / / 
* Based on data of Kristine Stepanyan and Pirnay et al. (2002) which were compared to EUCAST 
values15. Am, amikacin; ATM, aztreonam; Cf, ceftazidime; Cp, ciprofloxacin; IPM, imipenem; MEM, 
meropenem; Of,ofloxacin 
**DOM, defective oprD mutation 
 
Stationary phase cells were treated for 5 hours with an antibiotic or a combination of 
antibiotic and 200 µM SPI001. Based on MIC-testing carried out in our research group (data 
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of Kristine Stepanyan, not shown), antibiotic concentrations that only allowed survival of 
persister cells were determined. After treatment, cells were washed, diluted and plated on 
solid medium. The lab strains PA14 and PAO1 were included as reference. The results are 
shown in Figure 7.1. The majority of isolates tested was extremely susceptible to the 
combination of ofloxacin and SPI001 resulting in complete eradication of the bacterial 
population. Treatment of PA1255 and AA249 resulted in a ~15 and ~90 times lower persister 
fraction respectively compared to the ofloxacin monotreatment. Combination of SPI001 with 
the cephasloporin ceftazidime decreased the persister fraction at least ~150-fold of all clinical 
isolates tested. The best result was obtained with the CF lung isolate PA1256, where 
combination of ceftazidime with SPI001 resulted in a ~7900 times lower fraction compared to 
treatment with only the antibiotic. Finally, combining SPI001 with the aminoglycoside 
amikacin also significantly decreased the persister fraction compared to monotreatment. 
However, for clinical isolates AA249 and BU004 and the lab strain PAO1, no persister 
fraction was observed after treatment with the aminoglycoside amikacin.  
 
 
Figure 7.1: Effect of SPI001 in combination with clinically used antibiotics on P. aeruginosa clinical isolates. 
Stationary phase cells were treated for 5 hours with ofloxacin (Of) or amikacin (Am) alone or combined with 
SPI001. After treatment, cells were washed, diluted and plated on solid medium to determine the surviving 
cells. To test the combination of ceftazidime (Cf) with SPI001, dividing cells were treated for 5 hours. Data 
points represent the mean of three independent repeats, error bars represent standard error of the mean 
(SEM). Black and white bars represent the result after monotreatment and combination treatment (the 
indicated antibiotic and SPI001) respectively. *P < 0.05, **P < 0.005 and *** P < 0.0005. ND, not detectable.  
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Aminoglycosides are an important class of antibiotics frequently used as treatment of P. 
aeruginosa infections. In order to evaluate the effect of SPI001 in combination with other 
aminoglycosides on these strains, the experimental conditions were optimized using 
gentamicin and tobramycin (data not shown). Unfortunately, it was not possible to obtain a 
stable persister fraction in this experimental setup.  
 
7.3.2 Combination spectrum of SPI001 
To further characterize the combination spectrum of SPI001, Phenotype MicroArrays 
(Biolog) were used. These arrays contain 240 different compounds, supplied in four different 
concentrations that target specific cellular pathways16. To avoid confusion, these compounds 
will be further referred to as ‘Biolog compounds’. The goal was to identify Biolog 
compounds that, in combination with SPI001, reduce the number of surviving cells compared 
to treatment with the Biolog compound alone. To lower the amount of SPI001 needed for the 
initial screening of these Phenotype MicroArrays, the P. aeruginosa efflux mutant YM64 was 
used, which is more sensitive towards SPI001 (see Section 6.3.4.3). Subsequent confirmatory 
experiments were carried out using the PA14 wild-type strain.  
The screening method is based on the correlation between the number of surviving cells and 
the duration of the lag phase (see Section 6.3.1). Essentially, the lower the numbers of 
surviving cells, the longer it takes for this remaining bacterial population to yield visible 
growth after dilution into fresh growth medium. For practical reasons, treatment time was 
prolonged and stationary phase cells were treated for 24 hours. Regrowth was monitored by 
measuring the optical density (595 nm) at successive time points by using a microplate reader 
(BioTek® Synergy HT Multi-Mode Microplate Reader). 
 
7.3.2.1 Optimization of screening conditions 
To determine the dilution factor of treated cells, a first experiment was carried out in which 
stationary phase cultures were treated with increasing amounts of ofloxacin (0-5 µg mL-
1)(MIC value of ofloxacin on YM64 = 0.04 µg mL-1). After treatment, cells were diluted 100- 
                                               
16
 www.biolog.com/products-static/phenotype_microbial_cells_use.php 
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or 1000-fold into fresh medium and regrowth was monitored. Lower dilutions were not taken 
into consideration to avoid effects of residual ofloxacin on regrowth. Since differences in 
regrowth were more obvious after a 100-fold dilution of the treated cells, this factor was 
chosen for further experiments (Figure 7.2).  
Treatment of stationary YM64 cultures with 5 µg mL-1 ofloxacin prevented regrowth of the 
100 and 1000-fold diluted surviving population. A 100-fold dilution of the antibiotic leaves a 
residual concentration of ofloxacin above the MIC value, which possibly explains the lack of 
regrowth of the surviving population. However, a 1000-fold dilution brings the residual 
ofloxacin concentration back to a level below the determined MIC value. Therefore, it seems 
that a 24 h treatment of stationary phase cells with 5 µg mL-1 ofloxacin allows survival of a 
very low number of cells of which regrowth cannot be detected within 28 hours. This is in 
disagreement with results obtained after a five hour treatment of YM64 stationary phase cells 
(Section 6.3.4.3). Here, addition of 5 µg mL-1 ofloxacin or higher leaves a stable persister 
fraction of approximately 0.01 % which corresponds to 1 x 105 cells mL-1. 
 
 
Figure 7.2: Optimization of dilution factor after treatment. Stationary phase cells were treated for 24 hours 
with increasing concentrations of ofloxacin (0 – 5 µg mL
-1
, as indicated by the different symbols). After 
treatment, cells were 100- or 1000-fold diluted into fresh growth medium and regrowth was monitored by 
measuring optical density (595 nm). 
 
The concentration of antibacterial agent present in these Phenotype Microarrays is unknown. 
To determine the optimal concentration of SPI001 to identify combination effects, the 
following experiment was carried out. Stationary phase cells were treated with ofloxacin (0-5 
µg mL-1) and 0, 25, 50 or 100 µM of SPI001 (MIC value of SPI001 on YM64 = 50 µM) for 
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24 hours after which the cells were diluted 100-fold into fresh medium to monitor regrowth. 
The results are given in Figure 7.3. As expected, treatment with 5 µg mL-1 ofloxacin 
prevented regrowth within 28 hours. Combination with 25 µM SPI001 prevented regrowth 
when cells were simultaneously treated with 1 µg mL-1 ofloxacin. When 50 or 100 µM 
SPI001 was administered together with ofloxacin, regrowth was only detected for cells treated 
with SPI001 in combination with the lowest ofloxacin concentration tested. Based on these 
data, a concentration of 50 µM SPI001 was selected. 
 
 
Figure 7.3: Optimization of SPI001 concentration. Stationary phase cells were treated for 24 hours with 
increasing concentrations of ofloxacin (as indicated by the symbols) combined with 0, 25, 50 or 100 µM SPI001. 
After treatment, cells were 100-fold diluted into fresh growth medium and regrowth was monitored by 
measuring optical density (595 nm).  
 
7.3.2.2 Screening 
Screening of the Phenotype Microarrays was carried out using conditions as described above, 
regrowth was monitored for 32 hours. Several Biolog compounds were identified that, in 
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combination with SPI001, reduced the number of surviving cells compared to the 
corresponding monotreatment. Clinically relevant Biolog compounds identified in our assay 
are listed in Table 7.3. Among these compounds, the fluoroquinolone ofloxacin and several 
aminoglycosides were detected. In the previous Chapter, we showed that SPI001 completely 
eliminates the bacterial culture in combination with these classes of antibiotics, hereby 
confirming our screening procedure.  
 
Table 7.3: Biolog compounds identified during the screening 
Class Identified Biolog compounds 
Antibiotics  
     Fluoroquinolones ofloxacin 
     Aminoglycosides amikacin, neomycin, gentamicin, paromomycin, sisomicin, 
tobramycin 
     Polymyxins polymyxin B 
     Tetracyclines doxycycline 
     Peptidyl transferase thiamphenicol 
     Aminonucleosides puromycin 
  
Antiseptics ferric chloride, acriflavine, proflavine, hexachlorophene 
 
 
Others lidocaine, atropine, pridinol 
 
For further experiments we selected two interesting classes of identified Biolog compounds. 
The first one is represented by the polymyxin antibiotics for which polymyxin B was 
identified during our experiment. This class of antibiotics acts by disrupting the outer and 
inner membrane of Gram-negative bacteria (as reviewed by Falagas et al. (2010)). As shown 
in Figure 7.4, combination of SPI001 with the highest concentration of polymyxin B available 
in the Phenotype Microarrays significantly affects regrowth of the treated bacterial culture. 
Secondly, the identified Biolog compounds comprised several antiseptics (Figure 7.5). One of 
them is acriflavine, an antiseptic used for skin and mucous membranes (Kumar et al., 2012). 
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Again, only combination of SPI001 with the highest concentration available in the Phenotype 
Microarrays significantly affects regrowth of the treated bacterial culture (Figure 7.4).  
 
 
 
Figure 7.4: Effect of SPI001 in combination with selected Biolog compounds. Stationary phase cells were 
treated overnight with a combination of 50 µM SPI001 and four different concentrations of Biolog compound 
(designated by [1] to [4]). After treatment, cells were diluted 100-fold into fresh growth medium and growth 
was monitored by measuring optical density at fixed time points. As the effect is mainly visible upon treatment 
with the two highest concentrations ([3] and [4]) of the Biolog compound, these treatment regimens are shown 
in different colors. 
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Commercial preparations are often mixtures with proflavine, which was also identified during  
our screen. Here, the highest proflavine concentration present in the Phenotype Microarrays 
completely prevented regrowth when administered alone. However, a significant difference 
was detected between cells treated with the second highest concentration of proflavine alone 
or combined with SPI001 (Figure 7.4). For further experiments acriflavine hydrochloride, a 
mixture of acriflavine and proflavine, was purchased. A third antiseptic identified was 
hexachlorophene, which is widely used in drug and cosmetic products and is reported to be 
mainly active against Gram-positive bacteria. A combination of SPI001 with the two highest 
concentrations present in the Phenotype Microarrays completely eliminated regrowth (Figure 
7.4). The last antiseptic identified is ferric chloride, which is used to protect wounds from 
infection. When the highest concentration of ferric chloride was combined with SPI001, no 
regrowth was observed (Figure 7.4). The result of the other Biolog compounds listed in Table 
7.3 are available in Appendix B, Figure B.4.  
 
 
Figure 7.5: Chemical structures of the antiseptics proflavine, acriflavine and hexachlorophene.  
 
7.3.2.3 Confirmation of the obtained results 
For confirmatory experiments, we focused on the polymyxin antibiotic polymyxin B and the 
identified antiseptics ferric chloride, hexachlorophene and acriflavine hydrochloride. These 
experiments were carried out using the PA14 wild-type strain, the treatment time was reduced 
to 5 hours. In first instance, we evaluated the direct effect on persistence. MIC values of the 
Biolog compounds were determined (data not shown) and cells were treated with 10 X MIC 
combined with 200 µM SPI001 after which the number of viable cells was assessed. Based on 
earlier experiments carried out in our group, treating cells with 10 X MIC ensures survival of 
the antibiotic-insensitive persisters only. Treatment of stationary phase cells with a 
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combination of 6.25 µg mL-1 polymyxin B and 200 µM of SPI001 for 5 hours completely 
eliminated the bacterial population (Figure 7.6) further underlining the broad application 
range of SPI001. However, treatment with 10 X MIC of the three selected antiseptics did not 
yield a detectable persister fraction upon monotreatment (data not shown). Possibly, 
potentiating effects of SPI001 on lower concentrations of antiseptic were detected in the 
initial screening of the Phenotype Microarrays.  
 
 
Figure 7.6: Effect of SPI001 in combination with polymyxin B. Stationary phase cells were treated for 5 hours 
with the combination polymyxin B (6.25 µg mL
-1
) and DMSO (1 %) or with the combination polymyxin B (6.25 
µg mL
-1
 ) and 200 µM SPI001. After treatment, cells were washed, diluted and plated on solid medium to 
determine the number of viable cells. The experiment was independently repeated three times. Data points 
represent the mean, error bars indicate SEM. ND, not detectable.  
 
To assess these possible potentiating effects, we tested different concentrations of the three 
antiseptics in combination with 200 µM SPI001 by monitoring regrowth of the treated 
stationary phase cultures after dilution in fresh medium. Results show that combination of 
SPI001 with MIC or sub-MIC concentrations of the antiseptics clearly delayed growth 
compared to monotreatment (Figure 7.7A). Next, plate counting experiments were carried out 
using sub-MIC (0.5 X MIC) concentrations of the respective antiseptics to confirm the 
observed effects. The results show that the bactericidal effect of acriflavine hydrochloride on 
stationary phase cells was potentiated upon addition of SPI001, hereby lowering the active 
concentration of antiseptic needed to obtain complete elimination of the bacterial population. 
However, the combination of hexachlorophene or ferric chloride with SPI001 did not result in 
a statistically significant difference in the number of surviving cells compared to 
monotreatment with the antiseptic (Figure 7.7B). 
Chapter 7                                 Detailed examination of biological activity and mode of action of SPI001 
145 
 
 
 
 
Figure 7.7: Effect of SPI001 in combination with antiseptics. A. Stationary phase cells of PA14 WT were treated 
overnight with a combination of Biolog compound (used concentrations (µg mL
-1
) are indicated in the figure 
legend) and 200 µM SPI001. After treatment, cells were 100-fold diluted into fresh growth medium and 
regrowth was monitored by measuring optical density at fixed time points. B. Stationary phase cells were 
treated for 5 hours with a combination of antiseptic and 200 µM SPI001. After treatment, cells were washed, 
diluted and plated on solid medium to determine the number of viable cells. Each experiment was 
independently repeated three times. Data points represent the mean, error bars indicate SEM. For this 
experiment, 31.25 µg mL
-1
 acriflavine hydrochloride (0.5 X MIC), 312.5 µg mL
-1
 ferric chloride (0.5 X MIC) and 25 
µg mL
-1
 hexachlorophene (0.5 X MIC) was used respectively. *P < 0.05.  
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7.3.3 SPI001 kills persister cells in the absence of antibiotics 
To investigate whether SPI001 can also reduce the persister fraction when not administered 
simultaneously with ofloxacin, the following experiment was carried out. P. aeruginosa 
stationary phase cells were treated with ofloxacin (10 µg mL-1) or water. After 5 or 24 hours, 
200 µM SPI001 or 1 % DMSO was added and the number of CFU was monitored over time 
(Figure 7.8B and C). For comparison, stationary phase cells were treated for 72 hours with 
SPI001 or with the combination of ofloxacin and SPI001 (Figure 7.8A). For each experiment, 
complete eradication of the bacterial population was achieved within 24 hours after addition 
of SPI001. These results indicate that SPI001 can be administered separately from ofloxacin, 
hereby broadening treatment options. Although no bactericidal effect was detected when 
treating stationary phase cultures for 5 hours with SPI001 (see Chapter 6, Figure 6.6), this 
compound acts bactericidal upon increased treatment time (Figure 7.8). 
 
 
Figure 7.8: Effect of SPI001 on ofloxacin treated stationary cultures. A. Stationary phase cells were treated for 
72 hours with SPI001 or the combination of ofloxacin and SPI001. B. stationary phase cells were first treated 
with ofloxacin or water for 5 or C. 24 hours after which SPI001 was added to the culture. During treatment the 
number of viable cells was determined at 24, 48 and 72 hours. Data points represent the average of three 
independent repeats, error bars indicate SEM. Statistical significance for the cidal effect of SPI001 on stationary 
phase cells on the different time points is displayed, with *P < 0.05, **P < 0.005 and ***P < 0.0005.   
 
Based on these results, we can conclude that SPI001 may act in two different ways. One 
possibility is that SPI001 is capable of waking up the persister cells, hereby rendering them 
sensitive to the bactericidal action of ofloxacin present in the growth medium. Secondly, 
SPI001 could kill the persister cells directly. To distinguish between those two possibilities, 
persister cells were isolated and treated separately with 1 % DMSO, 10 µg mL-1 ofloxacin, 
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200 µM SPI001 or the combination ofloxacin and SPI001. After treatment, samples were 
divided into three aliquots. The first one was diluted and plated on solid medium to evaluate 
the effect of treatment. The second and third aliquot was treated for 5 hours with water and 
ofloxacin respectively. This allowed us to determine the fraction of cells that regained 
sensitivity towards ofloxacin. Treatment of isolated persisters with 200 µM SPI001 almost 
completely eliminated all cells, in contrast to the persister cells that had been subjected to an 
ofloxacin treatment. This result shows that SPI001 is capable of killing persister cells directly 
(Figure 7.9A).  
The persister fraction slightly decreases upon treatment with ofloxacin compared to treatment 
with DMSO. Manipulation of the persister cells during the washing steps seems to sensitize a 
small fraction of persisters which are killed by ofloxacin present in the sample. This is 
supported by the results shown in Figure 7.9B. Therefore, it was evaluated whether treatment 
of persister cells in spent medium reduces the reversion of a small fraction persisters into 
ofloxacin-sensitive cells. However, again a small fraction of persister cells regained 
sensitivity towards ofloxacin (data not shown). Upon testing of the SPI001 treated persister 
cells for regained sensitivity towards ofloxacin, no cells were detected after control treatment 
with water. Likely, the low number of persisters cells surviving the treatment with SPI001 
were washed away before plating out the ofloxacin and water treatment respectively. 
 
 
Figure 7.9: SPI001 kills persister cells. Persister cells were isolated and treated for 5 hours with 1 % DMSO, 10 
µg mL
-1
 ofloxacin, 200 µM SPI001 or a combination of ofloxacin and SPI001. After treatment, the sample was 
divided into three parts and A. the first aliquot was diluted and plated on solid medium to determine the 
number of surviving persister cells. B. the second and third aliquots were treated for 5 hours with water and 
ofloxacin respectively. Data points correspond to the mean of three independent repeats, error bars represent 
SEM. *P < 0.05, **P < 0.005. ND, not detectable. 
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7.3.4 SPI001 induces membrane damage 
Our results indicate that SPI001 is able to kill persister cells. Theoretically, in vitro, this can 
be achieved by interfering with processes essential to maintain viability (see Chapter 2). One 
such target, frequently proposed as suitable for killing dormant cells, is membrane integrity 
(Hurdle et al., 2011). To investigate whether this might explain the observed anti-persister 
effect, we tested whether SPI001 is able to disrupt lipid bilayers that mimick the Gram-
negative inner membrane. In addition, the membrane disrupting capacity of SPI001 was tested 
on SUV representing eukaryotic cell membranes. Additional analogues, representing small 
molecules with or without bactericidal and/or anti-persister activity, were included in this 
analysis as controls (Table 7.4). 
 
Table 7.4: Overview of chemical analogues used in the carboxyfluorescein leakage assay. Persistence and 
bactericidal effect and MIC values on the PA14 wild type strain are shown 
Analogue Persistence effect Bactericidal effect MIC (µM) 
SPI001 (CIM056271) Yes No 200 
SPI003 (CIM056263) No No >200 
SPI004 (CIM056273) No Yes 200 
SPI005 (CIM056307) Yes No 100 
 
SUV were treated with increasing concentrations of compound for 15 minutes. Every minute, 
carboxyfluorescein leakage was monitored by measuring absorbance at 515 nm. For all 
samples, the maximum value was reached within a few minutes, therefore only the 
measurement at 15 minutes is shown. As a negative and positive control of the bacterial 
model, ofloxacin and polymyxin B were included (Figure 7.10). In line with our expectation, 
ofloxacin did not induce any leakage while polymyxin B caused leakage at relatively low 
concentrations. The maximum level of leakage was reached at a polymyxin B/lipid molar 
ratio of 0.11 which corresponds to a polymyxin B concentration of 2 µg mL-1 (Figure 7.10A). 
SPI003, an analogue displaying no bactericidal or anti-persistence effect, did not cause 
significant leakage in either the bacterial or eukaryotic system. Addition of SPI004, which 
displays a bactericidal but not a persister effect, caused leakage in both models. SPI005, an 
analogue which is capable of reducing the persister fraction in combination with ofloxacin 
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without displaying a bactericidal effect on stationary phase cells, induced significant leakage 
in the bacterial and eukaryotic system. However, leakage caused in the eukaryotic system is 
lower compared to the bacterial model. These data suggest that compounds affecting the 
persister fraction induce leakage in both system, but to a lesser extent in the eukaryotic model, 
while compounds that are bactericidal cause maximum damage in both systems. When testing 
the membrane disrupting capacity of SPI001, the lipid bilayer was disrupted in both in vitro 
models. The in vivo effect, however, seems to differ as no cytotoxicity was observed on 
human embryonic kidney 293 cells (LD50 > 200 µM) (Hugo Klaassen, personal 
communication). 
 
 
Figure 7.10: Carboxyfluorescein leakage assay. A. SUV representing the bacterial membrane were treated with 
increasing concentrations of ofloxacin (negative control) and polymyxin B (positive control). B. SUV 
representing bacterial or C. eukaryotic membranes were treated with SPI001 and three other chemical 
analogues. After 15 minutes, absorbance was measured. Data points represent the average of three 
independent repeats, error bars indicate SEM.  
 
7.3.5 SPI001 spontaneous resistant mutants 
Generation and analysis of spontaneous resistant mutants (SRM) provides insight in 
resistance mechanisms (Srinivas et al., 2010; Mistry et al., 2013). Here, we seek to isolate 
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SRM that are resistant to the growth inhibitory effect of SPI001. By additionally testing the 
SRM for their sensitivity towards the anti-persistence effect of SPI001, information is 
obtained on the causative correlation between the bactericidal and anti-persistence effect of 
SPI001 in P. aeruginosa.  
P. aeruginosa YM64 cells (5 x 108, 1 x 109 and 5 x 109 cells as determined by plate counting) 
were plated on solid 1:20 TSB growth medium containing 4 and 5 times the MIC of SPI001 
respectively. After three weeks of incubation at 37 °C, no colonies were detected.  
To increase the probability of SRM development, an E. coli mutS mutant was used. This 
mutant was extensively characterized in our research group and has a 65-fold increased 
mutation rate compared to the corresponding wild-type strain (Toon Swings, personal 
communication). The MIC of SPI001 against this strain was determined (MIC value = 50 
µM) and subsequently, 5 x 109 cells were plated on solid medium containing 2.5 or 4 times 
the MIC of SPI001. However, after three weeks of incubation at 37 °C, no SRM were formed.  
 
7.3.6 Transcriptome analysis of cells exposed to SPI001 
To assess the change in gene expression upon addition of SPI001 to growing cells, a 
transcriptome analysis was carried out. P. aeruginosa PA14 wildtype growing cells were 
treated with respectively SPI001, the inactive analogue SPI006 or the solvent DMSO for 15 
minutes. A concentration of 50 µM (0.25 X MIC) was used since this causes no significant 
effect on viability of the cells, while a clear effect on growth was detected (Figure 7.11).  
In total, 316 and 39 genes were differentially expressed (log2 fold change ≥ 1) upon treatment 
of growing cells with SPI001 and SPI006 respectively. 19 genes were differentially expressed 
upon treatment with both compounds and were removed from the list of genes differentially 
expressed upon treatment with SPI001. Because of the high number of genes affected upon 
treatment with SPI001, we based our analysis on the identification of functionally related 
processes targeted by different genes. For this end, a functional interaction network was 
constructed based on interactions in which both partners (genes) were differentially expressed 
in cells treated with SPI001. These sub-networks were annotated using KEGG pathways and 
KEGG modules, PseudoCAP functional classes and Gene Ontology annotation and are shown 
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in Figure 7.12. Interaction clusters that consisted of only two genes or that could not be 
classified into one or more functional categories were excluded for further analysis. The 
obtained network consisted of 88 genes and 404 interactions and resulted in 10 network 
clusters. Genes belonging to each of the 10 sub-network are displayed in Table 7.5.  
 
 
Figure 7.11: Evolution of viability and growth of cells treated with SPI001, SPI006 or DMSO. Stationary phase 
cells were diluted 100-fold into fresh medium. At OD595 = 0.2 (time 0 hours in the figure), cells were treated 
with 50 µM SPI001, 50 µM SPI006 or 1 % DMSO after which A. the number of viable cells and B. growth was 
monitored by counting viable cells and measuring optical density at 595 nm using an automated plate reader 
respectively. Data points correspond to the mean of three independent repeats. Error bars represent SEM. 
Samples for RNA isolation were taken 15 minutes after treatment start (indicated by an arrow). 
 
Expression of genes belonging to the first seven sub-networks was upregulated. Sub-networks 
1, 2 and 3 contain genes with a function in antibiotic resistance. Genes included in the first 
two sub-networks encode constituents of two different efflux pumps, supportive of active 
efflux of SPI001. Sub-network 3 contains genes belonging to the arnBCADTEF-PA3559 
operon, playing a role in conferring tolerance upon sensing cationic antimicrobial peptides by 
modifying the lipid A moiety of lipopolysaccharide (LPS). These data suggest a cationic 
nature of SPI001. In addition to antibiotic resistance mechanisms, genes with a role in 
oxidative stress protection are upregulated (sub-network 6). Furthermore, increased 
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expression of genes mainly involved in fatty acid degradation was detected (sub-network 4), 
suggesting a high amount of available fatty acids upon treatment of cells with SPI001. Also 
genes classified into the functional group ‘Ribosome’ are upregulated, which indicates an 
increased translation rate in SPI001-treated cells. Lastly, expression of a few genes with a role 
in ‘Glycine, serine and threonine metabolism’ was increased.  
Expression of genes belonging to sub-networks 8, 9 and 10 was downregulated upon 
treatment with SPI001. These sub-networks contain genes involved in a type VI secretion 
system, phenazine biosynthesis and protein secretion and motility & attachment respectively, 
pointing to downregulation of non-essential processes.  
 
Table 7.5: Genes differentially expressed (log2 fold change ≥ 1) upon treatment with SPI001 for each sub-
network 
Gene number Gene name Product name and/or function Fold change 
(log2) 
UPREGULATED SUBNETWORKS 
Sub-network 1: Multidrug resistance 
PA14_60820 oprJ outer membrane protein OprJ 2.39 
PA14_60850 mexC multidrug efflux RND membrane fusion 
protein 
2.91 
PA14_60860 nfxB transcriptional regulator NfxB 2.54 
    
Sub-network 2: Transport of small molecules;  Antibiotic resistance and susceptibility 
PA14_23520  MFS transporter 1.04 
PA14_23530 mdr secretion protein 1.12 
PA14_68110  transcriptional regulator 1.16 
PA14_68120 opmG outer membrane protein 1.03 
PA14_68130 emrA multidrug resistance protein 1.15 
PA14_68140 emrB drug efflux transporter 1.04 
    
Sub-network 3: Amino sugar and nucleotide sugar metabolism 
PA14_18350 fmt or arnA bifunctional UDP-glucuronic acid 
decarboxylase/UDP-4-amino-4-deoxy-L-
arabinose formyltransferase 
1.13 
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Table 7.5 - continued 
Gene number Gene name Product name and/or function Fold change 
(log2) 
PA14_18360 pmrF or 
arnC 
glycosyl transferase family protein 1.39 
PA14_18370 arnB UDP-4-amino-4-deoxy-L-arabinose-
oxoglutarate aminotransferase 
1.28 
 
PA14_38350 galU UTP-glucose-1-phosphate 
uridylyltransferase 
1.06 
PA14_38360 ugd nucleotide sugar dehydrogenase 1.00 
    
Sub-network 4: Valine, leucine and isoleucine degradation; Fatty acid degradation; Butanoate 
metabolism 
PA14_01620 aptA beta alanine--pyruvate transaminase 2.27 
PA14_06600  acyl-CoA dehydrogenase 2.43 
PA14_06640  acyl-CoA dehydrogenase 2.70 
PA14_13090  acyl-CoA thiolase 1.83 
PA14_18140 mmsB 3-hydroxyisobutyrate dehydrogenase -1.02 
PA14_25080 fadB multifunctional fatty acid oxidation 
complex subunit alpha 
2.14 
PA14_25090 fadA 3-ketoacyl-CoA thiolase 2.33 
PA14_25840  electron transfer flavoprotein-ubiquinone 
oxidoreductase 
1.80 
PA14_25860 etfB electron transfer flavoprotein subunit beta 1.29 
PA14_25880 etfA electron transfer flavoprotein subunit alpha 1.11 
PA14_41950  enoyl-CoA hydratase 1.37 
PA14_42080 fadB 3-hydroxyacyl-CoA dehydrogenase 1.02 
PA14_42090  acetyl-CoA acetyltransferase 1.09 
PA14_66350  acyl-CoA dehydrogenase 1.15 
PA14_66840 phaC2 poly(3-hydroxyalkanoic acid) synthase 2 -1.07 
    
Sub-network 5: Ribosome 
PA14_08720 rplK 50S ribosomal protein L11 1.13 
PA14_08730 rplA 50S ribosomal protein L1 1.24 
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Table 7.5 - continued 
Gene number Gene name Product name and/or function Fold change 
(log2) 
PA14_08740 rplJ 50S ribosomal protein L10 1.35 
PA14_08750 rplL 50S ribosomal protein L7/L12 1.17 
PA14_08860 rplD 50S ribosomal protein L4 1.05 
PA14_08870 rplW 50S ribosomal protein L23 1.12 
PA14_08880 rplB 50S ribosomal protein L2 1.02 
PA14_08890 rpsS 30S ribosomal protein S19 1.01 
PA14_08900 rplV 50S ribosomal protein L22 1.02 
PA14_08910 rpsC 30S ribosomal protein S3 1.00 
PA14_08920 rplP 50S ribosomal protein L16 1.07 
PA14_08930 rpmC 50S ribosomal protein L29 1.07 
PA14_08940 rpsQ 30S ribosomal protein S17 1.11 
PA14_08950 rplN 50S ribosomal protein L14 1.14 
PA14_08960 rplX 50S ribosomal protein L24 1.16 
PA14_08970 rplE 50S ribosomal protein L5 1.14 
PA14_08980 rpsN 30S ribosomal protein S14 1.02 
PA14_09000 rplF 50S ribosomal protein L6 1.00 
PA14_09010 rplR 50S ribosomal protein L18 1.12 
PA14_09020 rpsE 30S ribosomal protein S5 1.00 
PA14_17060 rpsB 30S ribosomal protein S2 1.10 
PA14_17070 tsf elongation factor Ts 1.18 
PA14_23330 rpsA 30S ribosomal protein S1 1.13 
PA14_65150 rplI 50S ribosomal protein L9 1.12 
PA14_67260  histidine/phenylalanine ammonia-lyase -1.46 
PA14_67280 proW ABC transporter permease -1.02 
PA14_67300 prfoX ABC transporter substrate-binding protein -1.46 
PA14_67560 typA GTP-binding protein TypA 1.19 
PA14_67600 glnA glutamine synthetase 1.04 
PA14_71650 aspA aspartate ammonia-lyase 1.71 
    
Sub-network 6: Adaptation, Protection  
PA14_27220 ohr organic hydroperoxide resistance protein 1.26 
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Table 7.5 - continued 
Gene number Gene name Product name and/or function Fold change 
(log2) 
PA14_27520 gpo glutathione peroxidase 3.38 
PA14_27530  MarR family transcriptional regulator 2.66 
    
Sub-network 7: Glycine, serine and threonine metabolism  
PA14_32985 gcvH2 glycine cleavage system protein H 2.99 
PA14_33000 gcvP2 glycine dehydrogenase 2.46 
PA14_33010 glyA2 serine hydroxymethyltransferase 1.73 
    
DOWNREGULATED SUBNETWORKS 
Sub-network 8: Type VI secretion system 
PA14_33990  ClpA/B-type protease -1.60 
PA14_34010 hsiG3* hypothetical protein -1.67 
PA14_34030 hcp3* hypothetical protein -1.60 
PA14_34050 hsiC3* hypothetical protein -1.64 
PA14_34070 hsiB3* hypothetical protein -1.49 
PA14_34080 lip3* hypothetical protein -1.38 
PA14_34100 hsiJ3* hypothetical protein -1.35 
PA14_34110  dotU3* hypothetical protein -1.29 
PA14_34130 icmF3* hypothetical protein -1.44 
    
Sub-network 9: Phenazine biosynthesis 
PA14_09440 phzE1 phenazine biosynthesis protein PhzE -1.44 
PA14_39880 phzG2 pyridoxamine 5'-phosphate oxidase -1.85 
PA14_39945 phzC2 phenazine biosynthesis protein PhzC -2.00 
PA14_39960 phzB2 phenazine biosynthesis protein -1.46 
PA14_39970 phzA2 phenazine biosynthesis protein -1.99 
    
Sub-network 10: Protein secretion/export apparatus; Motility & Attachment 
PA14_55780  two-component sensor -1.21 
PA14_55790  hypothetical protein -1.42 
PA14_55850  pilus assembly protein -1.24 
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Table 7.5 - continued 
Gene number Gene name Product name and/or function Fold change 
(log2) 
PA14_55860  hypothetical protein -1.48 
PA14_55880  hypothetical protein -1.81 
PA14_55890 cpaF2 type II secretion system protein -1.55 
PA14_55900  hypothetical protein -1.22 
PA14_55920  type II secretion system protein -1.93 
PA14_55930  pilus assembly protein -1.85 
*As described in Lesic et al. (2009) 
 
7.4 Discussion  
In this Chapter, we aimed to further characterize the anti-persister compound SPI001 towards 
its activity on clinical isolates and its combination spectrum with chemical agents. 
Furthermore, experiments were conducted to unravel the mode of action of SPI001, which 
will greatly help to gain insight into the persistent state and to develop more targeted therapies 
in the future.  
 
7.4.1 Biological activity of SPI001 
Depending on the site of infection, P. aeruginosa encounters different stresses related to the 
host environment. In addition, for each type of infection, different treatment regimens are 
recommended17. This results in isolates specifically adapted to the conditions experienced 
during infection and subsequent treatment. Therefore, we tested the activity of SPI001, in 
combination with conventional antibiotics, on clinical isolates obtained from different 
environments. The results show that SPI001 is active against all isolates tested, making it a 
good starting point for the development of an anti-persister therapy.  
 
                                               
17
 http://www.uzleuven.be/antibioticagids/ 
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Figure 7.12: Differentially expressed genes mapped on the functional interaction network STRING. Dark blue and red coloured circles represent genes that are 
either down- or upregulated upon treatment with SPI001 (log2 fold change ≥ 1), respectively. The annotated sub-networks are numbered, gene names or PA14 
gene numbers are shown. 
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To further characterize the combination possibilities of SPI001, we performed synergy testing 
with 240 different compounds that target specific cellular pathways18. Although several β-
lactams are present in the Phenotype MicroArrays, none of them was picked up in our 
experiment. This class of antibiotics is only active against fast-growing cells (Tuomanen et 
al., 1986), explaining their inactivity on the stationary phase cultures used in our experimental 
set-up. The fluoroquinolone ofloxacin and several protein synthesis inhibiting antibiotics were 
picked up (Table 7.3). This confirms our previously obtained results (see Section 6.3.4), 
namely that combination of SPI001 with ofloxacin and the aminoglycoside amikacin perform 
better compared to monotreatment with antibiotics. Interestingly, the antibiotic polymyxin B 
which exerts membrane damage, was also identified during this screening. Polymyxin B 
belongs to the polymyxins, a class of antibiotics abandoned as systemic therapy in the 
seventies because of toxicity. However, they are increasingly used nowadays as a last-line 
antibiotic for the treatment of multi-drug resistant Gram-negative bacteria such as P. 
aeruginosa (Vaara, 2010). Several studies are ongoing to develop less toxic and/or more 
potent polymyxin derivatives (Vaara, 2013).  
In addition, we identified several antiseptics of which the activity improved upon 
simultaneous administration with SPI001. When confirming these results at the level of a 
decrease of CFUs using plate counts, only the combination of SPI001 with acriflavine 
hydrochloride showed improved activity over monotreatment with the antiseptic. Acriflavine 
is used as a 0.1 % antiseptic solution for wound treatment, although it has been reported to 
cause skin irritation (Leelavathi et al., 2011). Administration together with SPI001 lowers the 
active concentration of acriflavine needed, potentially diminishing the side effects associated 
with the use of this topical antiseptic.  
Two other antiseptics, hexachlorophene and ferric chloride, were identified. However, the 
observed effect evaluated by monitoring regrowth of treated cells was not confirmed when 
assessing the effect with viable cell counting (Figure 7.7). The reason for this discrepancy is 
at present unclear.  
 
                                               
18
 www.biolog.com/products-static/phenotype_microbial_cells_use.php 
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7.4.2 Mode of action of SPI001 
SPI001 is able to exert membrane damage at relatively low concentrations. At a SPI001/lipid 
molar ratio of 1, which corresponds to a SPI001 concentration of 25 µM (= 1/8 X MIC value), 
50 % leakage is achieved in SUVs. For comparison, 50 % leakage by polymyxin B is induced 
at 1 µg mL-1 (1.6 X MIC). Disruption of the lipid bilayer by SPI001 was detected in both the 
bacterial and eukaryotic model. SPI005, a chemical analogue that, just like SPI001, displays 
an anti-persistence effect but no bactericidal effect on stationary phase cells, caused less 
leakage in the eukaryotic system as compared to the bacterial model. Bacteria contain anionic 
phospholipids in their membranes while the eukaryotic ones are composed of neutrally 
charged components (Epand & Epand, 2009) as reflected in our phospholipid models. 
Possibly, SPI005 requires the negative charge present in the bacterial model to exert its 
membrane disrupting capacity. The ability of SPI001 to disrupt lipid bilayers provides a 
plausible explanation for the cidal effect on persister cells. The antibiotic tolerance of 
persister cells is typically attributed to their metabolic quiescent, dormant state in which the 
antibiotic targets are less active (Wood et al., 2013). However, the lipid bilayer remains 
vulnerable to membrane-disrupting agents.  
To analyze transcriptional changes induced upon exposure of growing cells to SPI001, an 
RNA-Seq experiment was performed. Network analysis showed that several genes involved 
in antibiotic resistance were upregulated. First of all, the expression of genes encoding two 
different efflux pumps was increased, indicating that SPI001 is actively extruded. Genes 
encoding the efflux pump MexCD-OprJ are upregulated (sub-network 1). This efflux pump is 
inactive under standard laboratory conditions but it was shown that expression is induced by 
membrane-acting agents (Fraud et al., 2008). Genes encoding a second multidrug efflux 
pump, EmrAB-OpmG, were also upregulated (sub-network 2). This efflux pump is not yet 
characterized in P. aeruginosa but the genes show homology to the ones of the E. coli 
EmrAB-TolC efflux pump (Tanabe et al., 2009). This efflux pump was shown to confer 
resistance to hydrophobic toxins in E. coli (Lomovskaya & Lewis, 1992). Secondly, ugd and 
arnA-C, genes involved in a tolerance conferring pathway, were upregulated (sub-network 3). 
They are involved in synthesis of undecaprenol-phosphate-linked 4-amino-4-deoxy-L-
arabinose (L-Ara4N). This molecule serves as a carrier of L-Ara4N which is added to the LPS 
component lipid A as a response to cationic peptide stress. In this way, the negative charge of 
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LPS is reduced, conferring increased tolerance against cationic peptides such as for instance 
polymyxin B (Moskowitz et al., 2004). Other genes upregulated in response to SPI001 
exposure include those involved in oxidative degradation of fatty acids (sub-network 4). Fatty 
acid degradation in P. aeruginosa occurs by repetition of a sequence of four reactions which 
shortens the fatty acid by two carbon atoms in each round. The successive steps are carried 
out by an acyl CoA dehydrogenase, an enoyl CoA hydratase, a 3-hydroxyacyl COA 
dehydrogenase and a thiolase respectively (Yuan et al., 2012). Upregulation of fatty acid 
degradation may point to the high abundance of free fatty acids, possibly resulting from 
membrane damage. The latter may lead to oxidative stress (Dominguez-Cuevas et al., 2006), 
explaining the upregulation of genes involved in oxidative stress tolerance (sub-network 6). 
The largest functional group of upregulated genes, sub-network 5, contains members 
encoding 50S and 30S ribosomal proteins. In general, upregulation of ribosomal proteins 
mostly results from treatment with a protein synthesis inhibitor (Davies et al., 2006). 
However, if SPI001 acts on protein synthesis, additional changes are expected such as 
changes in genes involved in amino acid biosynthesis or heat shock genes (Davies et al., 
2006; Morita et al., 2014). Therefore, we hypothesize that upregulation of these ribosomal 
proteins is necessary to support production of the gene products encoded by the upregulated 
genes such as those involved in efflux pumps and fatty acid metabolism. 
A number of genes, belonging to non-essential processes, are downregulated. Likely, shutting 
down these non-essential processes saves energy which can be used to counteract the stress 
experienced during treatment with SPI001. Sub-network 8 contains genes encoding proteins 
of the third type VI secretion system of P. aeruginosa, also named HSI-III. So far, only the 
function of the first type VI secretion system is understood, and is involved in bacterial 
competition and pathogenesis (Filloux et al., 2008). Also expression of genes involved in 
motility and biosynthesis of phenazines are downregulated. These results are also indicative 
of downregulation of virulence, another advantage of treatment with SPI001 (see Section 
1.4.3.1). 
Based on our results, it is likely that SPI001 acts by disrupting the membrane. One of the 
mechanisms P. aeruginosa uses to gain tolerance against membrane-acting agents is by active 
extrusion of the compound (Ramos et al., 2002). This may explain the absence of SRM 
formed after exposure of the efflux mutant to SPI001. The P. aeruginosa mutant lacks 4 
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major efflux pumps (Morita et al., 2001), including MexCD-OprJ which was implicated in 
tolerance against membrane-acting agents (Fraud et al., 2008). However, when treating E. 
coli with SPI001, no SRM were formed either. Possibly, several mutations need to 
accumulate to decrease susceptibility against SPI001. Therefore, a more gradual evolution 
experiment may be more successful to obtain SRM against SPI001.   
 
7.5 Concluding remarks 
In this Chapter, we showed that SPI001 is active against different clinical isolates and acts in 
combination with a variety of antibiotics and antiseptics, hereby further increasing its 
potential as anti-persister molecule. Furthermore, it was shown that SPI001 likely acts by 
disrupting membranes, which provides a plausible explanation for its cidal action on persister 
cells. Experiments to confirm the proposed mode of action are needed. In addition, 
assessment of the combination therapy under more in vivo like conditions will shed more light 
on the potential of SPI001 as a supplement to conventional antibiotic therapy.  
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Chapter 8 
General conclusions and perspectives  
 
Pseudomonas aeruginosa is an opportunistic pathogen, causing severe infections in (partially) 
immunocompromised persons. On top of its considerable intrinsic resistance, this bacterium is 
able to acquire additional resistance mechanisms which can lead to development of strains 
resistant to nearly all available antibiotics (Breidenstein et al., 2011). However, even in the 
absence of resistance, infections are often difficult to eradicate. One of the major factors held 
responsible for the refractory nature of such infections is the presence of persister cells 
(Mulcahy et al., 2010; Fauvart et al., 2011). These antibiotic tolerant cells comprise a small 
fraction of a genetically heterogeneous population which survives the cidal effect of 
antibacterial agents. Once the antibiotic pressure drops, persisters are able to start growing 
again and form a susceptible population, hereby causing relapse of infection. In this way, the 
presence of the infecting strain in the human body is maintained, increasing the probability of 
developing resistance against the used antibiotic treatment (Cohen et al., 2013). Targeting 
persisters provides a good strategy to prevent relapse of infection, avoiding development of 
chronic infections which negatively affect the outcome of patients.  
Design of a rational treatment strategy is difficult since the mechanisms underlying 
persistence in P. aeruginosa are not yet understood. Hence, a screen for mutants displaying an 
altered persister fraction was carried out in our research group previously (De Groote et al., 
2009). In this thesis, we followed up on this research by studying the newly identified gene 
dnpA, which represents a possible target for the rational design of an anti-persister strategy. 
Since several mechanisms underlie the formation and/or maintenance of persister cells, 
development of a rational anti-persister therapy is challenging. In a second part we used a top-
down approach to identify anti-persister molecules which can be used in combination with 
conventional antibiotics, providing a potential starting point for development of an anti-
persister strategy.  
Chapter 8                                                                                      General conclusions and perspectives 
164 
 
8.1 The newly identified persistence gene dnpA 
In a first part of this thesis, the previously uncharacterized persistence gene, which we named 
dnpA (de-N-acetylase involved in persistence; gene locus PA14_66140/PA5002), was studied. 
Our results show that dnpA is a bona fide persistence gene since fluoroquinolone tolerance of 
a dnpA mutant is strongly reduced both in planktonic culture and in a biofilm model whereas 
overexpression of dnpA in the wild-type strain increases the persister fraction. dnpA is part of 
the conserved lipopolysaccharide (LPS) core oligosaccharide biosynthesis gene cluster, 
however, no obvious role in LPS biosynthesis could be demonstrated. Possibly, DnpA is 
responsible for minor LPS modifications which are not detected by the LPS profiling 
methodology used here, such as for example changes in the acetylation state of LPS (Slauch 
et al., 1995). Alternatively, DnpA could be involved in monitoring the bacterium’s 
environment. It was reported that the gene upstream of dnpA, PA14_66150, is involved in 
sensing cationic antimicrobial peptides which leads to the induction of the LPS modification 
operon arnBCADTEF-PA3559 (Jochumsen et al., 2011). The latter is responsible for adding 
L-Ara4N to lipid A, hereby decreasing the susceptibility to cationic peptides (Moskowitz et 
al., 2004). Since PA66150-dnpA is conserved as one unit in all of the genomes analyzed 
(Figure 4.4), it is possible that dnpA, together with PA14_66150, has a role in monitoring LPS 
biosynthesis/assembly or outer membrane physiology (Jochumsen et al., 2011). This is 
supported by our transcriptome analysis, which indicated that DnpA affects the expression of 
genes involved in cell surface-associated processes. In support of these results we showed that 
DnpA is anchored within the inner membrane with C-terminal part, which includes the 
catalytic domain, located at the cytoplasmic side of the membrane. As such, DnpA is 
perfectly located to fulfill a role in membrane-associated processes. The dnpA mutant did not 
show an altered susceptibility towards polymyxin B, indicating that dnpA may be involved in 
other surface-related processes. No difference was seen between LPS profiles or outer 
membrane fractions of wild-type and dnpA mutant cells. This does not exclude minor 
modifications of membrane proteins or changes in membrane composition itself. For instance, 
as a follow-up study, the structure of LPS extracted from both wild type and dnpA mutant can 
be evaluated (Choudhury et al., 2005) as well as fatty acid and polar lipid composition.  
How exactly persistence can be regulated by sensing the extracellular environment remains 
unknown. One possibility is provided by the phenomenon known as contact dependent 
growth inhibition (CDI), in which bacteria regulate their growth rate by cell contact (as 
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reviewed by Ruhe et al. (2013)). In Escherichia coli, this mechanism is regulated by a two-
partner secretion system in which a ß-barrel protein exports a toxin across the outer 
membrane. Upon contact with the target cell via a receptor, the toxin is cleaved and 
translocated into the target cells where it decreases the proton motive force leading to 
cessation of growth. Also in stationary phase cultures, a form of CDI was observed 
(Lemonnier et al., 2008). CDI expression is activated at high cell densities when cell-cell 
contact is more common (Lemonnier et al., 2008; Ruhe et al., 2013), showing similarities 
with the kinetics of persister formation in which the persister level starts increasing in mid-to 
late-exponential phase (Keren et al., 2004a).  
Based on sequence analysis, we predicted that DnpA is a de-N-acetylase, acting on a yet 
unidentified substrate. Site-directed mutagenesis suggests that this enzymatic activity is 
essential for DnpA-mediated persistence. In the future, more information about the putative 
substrate specificity of DnpA could be obtained using a glycan array (Blixt et al., 2004). 
Based on the obtained results, biochemical in vitro activity can be tested in more detail as 
described in Deli et al. (2010). Here, deacetylation is quantified using the molecule 
fluorescamine, which becomes fluorescent upon binding the free amino groups resulting from 
enzymatic de-N-actylase activity. In addition, it has been shown that activity of other 
members of the PIG-L family can be inhibited by small molecules, without affecting human 
PIG-L members (de Macedo et al., 2003; Metaferia et al., 2007; Gammon et al., 2010). The 
inhibitory effect of existing inhibitory molecules can be tested in vitro, followed by evaluation 
of its effect on whole cells. Lastly, since multiple mechanisms seem to be involved in the 
formation of persister cells, it should be tested whether absence of dnpA (activity) is sufficient 
to obtain more effective eradication of the infecting population in vivo.  
 
8.2 The anti-persister molecule SPI001 
In a second part of this thesis we identified and characterized the promising anti-persister 
molecule SPI001 in detail. This small molecule is able to strongly reduce the persister fraction 
of P. aeruginosa lab strains and several different clinical isolates in combination with 
mechanistically different classes of antibiotics. Moreover, this compound was also able to 
reduce the persister fraction of other clinically relevant bacteria such as E. coli, S. 
Typhimurium and Staphylococcus aureus. Taken together, SPI001 has the potential to be 
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developed into an anti-persister therapy. An important factor for further development is its 
activity in an in vivo infection model. Currently, a first experiment (carried out by Valerie 
Defraine, in collaboration with Prof. Françoise van Bambeke, UCL) in which activity of 
SPI001 in combination with ofloxacin is tested on P. aeruginosa infected human THP-1 cells, 
showed promising results. In contrast to monotreatment with ofloxacin, the combination of 
ofloxacin with SPI001 is able to completely eradicate the infecting P. aeruginosa cells 
without significantly affecting the viability of the eukaryotic cells (unpublished results). A 
next step would be to test this combination therapy in a more complex in vivo infection 
model. Since persisters play an important role in chronic infections, it is important to assess 
the anti-persister therapy in a chronic infection model, of which only a few are available. A 
first model is represented by the chronic P. aeruginosa mouse airway infection model. Here, 
the mouse lung pathology resembles that of chronically infected CF patients (Facchini et al., 
2014). A second model is the S. aureus mediated deep-seated thigh infection model in 
neutropenic mice which resembles a chronic infection in immunocompromised patients 
(Conlon et al., 2013). A third possibility is provided by the S. Typhimurium intragastric 
mouse infection model, in which the presence of antibiotic-tolerant populations was shown 
upon treatment with ciprofloxacin, causing relapse of infection after discontinuation of 
antibiotic therapy (Kaiser et al., 2014).  
Currently, a relatively high concentration of SPI001 is needed to reduce the persister fraction 
in vitro. It is unlikely that such high concentrations can be reached within the infected tissues 
upon systemic application. Future steps may involve optimization of the SPI001 structure to 
enhance activity. A recent research paper points to the possibility to optimize each separate 
part of a molecule to obtain the most potent variant, as performed in the case of the anti-
mycobacterial 4‑aminoquinolone piperidine amides (Naik et al., 2014). P. aeruginosa is also 
known to infect surgical sites and burn wounds (Altoparlak et al., 2004; ECDC, 2013). This 
makes SPI001 a potential candidate for use as topical agent, allowing much higher compound 
concentrations at the site of infection (Kaye, 2000; Spann et al., 2003). P. aeruginosa is also 
able to form biofilms on indwelling devices such as catheters and endotracheal tubes giving 
rises to severe infections (Bouza et al., 2004; Gil-Perotin et al., 2012; Cole et al., 2014). For 
intravascular catheter-related infections, SPI001 can be used in the so called ‘antibiotic lock 
therapy’ (ALT) in which very high concentrations of antibiotic are left within the catheter 
(Mermel et al., 2009). As SPI001 likely acts on the bacterial membrane, it would also be an 
excellent candidate for coating the surface of indwelling devices (Zelichenko et al., 2013). As 
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is the case with ALT, high concentrations of the coated agent can be reached, circumventing 
possible concentration-related problems of SPI001. 
In this thesis, we showed that SPI001 likely acts by inducing membrane damage by disrupting 
the lipid bilayer, causing leakage of carboxyfluorescein encapsulated in SUV. However, some 
membrane-acting agents can exert their action without disrupting the lipid bilayer. Examples 
include peptides or molecules that incorporate into the membrane and cause depolarization 
(Eun et al., 2012) or delocalize peripheral membrane proteins (Wenzel et al., 2014). To 
further confirm our hypothesis, the membrane damaging effect should be tested on whole 
cells, for example by a potassium leakage assay (Wenzel et al., 2014). In addition, it has been 
shown that membrane disrupting properties rely on the composition of the lipid bilayer, which 
is different among Gram-positive and Gram-negative bacteria (Randall et al., 2013). 
Therefore, the membrane-disrupting hypothesis should also be tested on Gram-positive 
bacteria. In addition, it would also be interesting to test the activity on Mycobacterium. It was 
shown that the inner membrane is unusually rich in diacyl phosphatidylinositol dimannosides, 
creating a bilayer environment with very low fluidity, which possibly has an impact on the 
activity of SPI001 (Bansal-Mutalik & Nikaido, 2014).    
Overall, our screening identified a very promising compound which in combination with 
conventional antibiotics leads to more potent treatment of bacterial populations. Therefore, it 
might be useful to screen other libraries for similar compounds. However, some limitations 
and drawbacks are associated with the used screening method. First of all, quantification of 
the effect on persistence is influenced by effects on the regrowth of the treated cultures. 
Viable cell counting experiments remain the most accurate way to assess the number of 
persisters although they are time consuming. Secondly, only 200 compounds could be 
screened in 24 hours, making compound discovery a slow process. To increase throughput, 
the use of a metabolic dye seems a good alternative. This strategy was reported in literature in 
the search of potentiators of antifungals (Lafleur et al., 2013). Compounds that lower the 
metabolic activity are also identified while they do not necessarily affect the number of 
surviving persister cells. Therefore, plate counting experiments, in first instance by spot 
plating, remain necessary to confirm the observed effect.  
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8.3 Concluding remarks 
This work has contributed to the characterization of dnpA, a newly identified persistence gene 
in P. aeruginosa which affects persister levels both in free-living and biofilm state. Although 
the mechanism is not yet fully understood, it seems that dnpA affects surface-associated 
processes, which represents a novel mechanism underlying antibiotic tolerance. Future 
experiments will reveal if targeting this specific gene significantly reduces persistence in vivo. 
In addition, we identified a very promising anti-persister compound acting in combination 
with different classes of antibacterial agents and, importantly, showing activity against both 
Gram-negative and Gram-positive pathogens. The work presented in this thesis shows that 
alternative treatment strategies may improve the outcome of current treatments. General 
awareness of the pressing need for new antibiotics has increased over the last years and action 
is being undertaken both at the governmental level and in industry. For instance, the European 
government initiated several initiatives in the framework of Horizon 2020 to support 
identification and further development of new antibacterial agents19. Also, important 
pharmaceutical companies like Roche are re-investing into antibacterial research20. Overall, 
there is hope to find new antibacterials which can be used in improved treatment strategies to 
keep ahead of the threat posed by infectious diseases. 
 
                                               
19
 http://ec.europa.eu/programmes/horizon2020/ 
20
 http://www.nature.com/nrd/journal/v13/n3/pdf/nrd4273.pdf 
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Addendum I  
Identification and characterization of an anti-
pseudomonal dichlorocarbazol derivative displaying 
anti-biofilm activity21 
 
I.1 Contribution of authors to the experimental work 
Screening of the compound library was carried out by V. Liebens, W. J. Knapen and T. 
Swings. Evaluation of growth inhibition on bacterial free-living and biofilm cultures was 
conducted by H. P. Steenackers and S. Robijns (Escherichia coli and Porphyromonas 
gingivalis), A. Lippell and A. J. O’Neill (Staphylococcus aureus and Staphylococcus 
epidermidis), E. Gerits and S. Beullens (Pseudomonas aeruginosa). Microscopic experiments 
described in this Chapter were performed by A. Krona and M. Lövenklev, cell viability assays 
were carried out by M. Veber and M. Fröhlich. 
 
I.2 Introduction  
P. aeruginosa is an opportunistic pathogen that primarily infects cystic fibrosis (CF) patients 
and immunocompromised individuals such as HIV and burn wound patients but also 
frequently causes nosocomial infections (Kerr & Snelling, 2009). Up to 80 % of CF patients 
get infected by this pathogen, making it one of the dominant bacteria in the CF lung. Mostly, 
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(2014). Identification and characterization of an anti-pseudomonal dichlorocarbazol derivative displaying anti-
biofilm activity. Bioorganic & Medicinal Chemistry Letters, 24, 5404-5408.   
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P. aeruginosa establishes a chronic infection in the CF airway that significantly contributes to 
the mortality of these patients (Folkesson et al., 2012). In addition, according to a recent 
report from the European Centre for Disease Prevention and Control, P. aeruginosa is 
responsible for 8.9 % of all nosocomial infections in Europe, making this pathogen one of the 
leading causes of healthcare-associated infections (ECDC, 2013). P. aeruginosa infections are 
extremely difficult to treat with currently available antibacterials. This is primarily due to 
significant intrinsic resistance, caused by low permeability of the outer cell membrane 
(Strateva & Yordanov, 2009). Additionally, P. aeruginosa has a remarkable capacity to 
acquire additional resistance mechanisms. This has led to development of resistance towards 
all available classes of antibiotics (Breidenstein et al., 2011) resulting in rapidly rising rates of 
(multi)drug resistance (Obritsch et al., 2004). The number of new antibiotics in the 
pharmaceutical pipeline active against P. aeruginosa is very limited (Bassetti et al., 2011; 
Pendleton et al., 2013) underlining the pressing need for the development of new 
antipseudomonal agents. In this Chapter, the identification and characterization of a promising 
new anti-pseudomonal small molecule is described  
 
I.3 Experimental procedures 
Bacterial and human cell culture conditions. Pseudomonas strains, E. coli TG1 and 
Staphylococcus species were grown in 1:20 Trypticase Soy Broth (TSB) at 37 °C, shaking at 
200 rpm. P. gingivalis was cultured statically in an anaerobic jar (H2/CO2/N2; 5:5:90 %, 
Anoxomat AN2OP, Mart® Microbiology BV, Drachten, The Netherlands) at 37 °C. For 
solidified medium, 1.5 % agar was added. Strains used in this Chapter are listed in Table I.1. 
Osteoblasts and mesenchymal stromal cells were cultured in Advanced DMEM, 10 % FBS, 
1x GlutaMAX, 0.05 mg mL-1 gentamicin. Microvascular endothelial cells were grown in 
Medium 131, Microvascular Growth Supplement, 0.05 mg mL-1 gentamicin (all from Gibco, 
Carlsbad, CA, USA). Human aortic endothelial cells were cultured in M200 medium with 
Low serum growth supplement (Gibco, Carlsbad, CA). 
Small-molecule library and compound storage. See Chapter 6.  
Minimal inhibitory concentration (MIC) determination. MIC values were determined as 
described before (Chapter 4). The lowest antibiotic concentration resulting in the absence of 
bacterial growth was considered as the MIC. 
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Table I.1: Bacterial strains used in this Chapter 
Strain Descriptiona Source or reference  
P. aeruginosa PA14 Wild type, KmR Lee et al. (2006) 
P. aeruginosa YM Wild type Morita et al. (2001) 
P. aeruginosa YM64 mexAB-oprM::FRT, mexXY::FRT,  
mexCD-oprJ::FRT, mexEF-oprN::FRT 
Morita et al. (2001) 
E. coli TG1 Wild type, [F' traD36 proAB lacZ  
∆M15] supE thi-1 ∆(lac-proAB)  
∆(mcrB-hsdSM)5(rK - mK - 
Carter et al. (1985)  
S. aureus SH1000 Functional rsbU derivative of 8325-4  
rsbU+ (wild type strain cured of prophages) 
O’Neill et al.(2010); 
Horsburgh et al.(2002)  
S. epidermidis RP62A Wild type, ATCC 35984 ATCC 
P. gingivalis  Wild type, ATCC 33277 ATCC  
aKmR, kanamycin resistant 
 
Biofilm inhibition assay. To assess inhibition of biofilm formation, the Calgary biofilm 
device (Nunc-Immuno TSP, VWR International) was used. Bacterial cells from an overnight 
culture were diluted 1:200 (P. aeruginosa), 1:100 (E. coli and Staphylococcus species) or 1:10 
(P. gingivalis) into fresh growth medium. Biofilms were allowed to form for 24 h (P. 
aeruginosa, E. coli and Staphylococcus species) or 72 h (P. gingivalis) on the polystyrene 
pegs and were quantified by crystal violet staining. The lowest concentration that completely 
prevented biofilm formation was considered the minimal biofilm inhibitory concentration 
(MBIC).
 
For E. coli and P. gingivalis, MBIC90 (concentration with 90 % biofilm inhibition) 
values were calculated. Prevention of Staphylococcus biofilm growth was quantified by 
determining the lowest concentration of compound that completely inhibits biofilms from 
seeding fresh growth medium as described previously (Miller et al., 2005; Ooi et al., 2010).  
Biofilm eradication assay. P. aeruginosa stationary phase cells were 200-fold diluted and 
biofilms were allowed to form on polystyrene pegs as described above. 24 h old biofilms were 
subjected to treatment with different concentrations of compound during 24 h at 37 °C. 
Subsequently, biofilm cells were recovered by means of sonication after which the number of 
surviving cells was determined by plate counting (Harrison et al., 2010).  
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Microscopic evaluation of biofilms. Overnight P. aeruginosa cultures were diluted into fresh 
TSB to 1 x 105 cells mL-1 and transferred to a 6-well plate containing a titanium disc and 0, 10 
and 32.5 µM of compound, respectively. Subsequently, biofilms were allowed to form for 19 
h at 37 °C with agitation. Biofilm formation was analyzed using confocal laser scanning 
microscopy (CLSM, Leica TCS SP5). In addition, viability of the cells was examined by the 
LIVE/DEAD®BacLightTM viability kit (Molecular Probes). Each sample was analyzed in 
triplicate. During CLSM evaluation, 25 digital images were taken with X-Y scan a few µm 
above the surface plane with an HCX PL APO CS objective with 63 times magnification and 
numerical aperture 1.20. The thickness of the optic sections was 577 nm at full width half 
maximum and image size of the micrographs was 2048 x 2048. Image analysis was performed 
in Mathlab to calculate the fraction of live and dead bacteria.  
Cell viability assay. Cell viability of human osteoblasts, bone marrow derived mesenchymal 
stem cells and microvascular endothelial cells was tested with trypan blue staining according 
to the ISO 10993-5 standard. Briefly, cells were seeded at 2 × 104 cells cm-2 to 96-well plates, 
and were exposed in four replicates to different conditions. Afterwards, the cell culture 
medium was removed and 1:3 of trypan blue in DMEM medium was added to the culture for 
three minutes. Dead (blue) and live (transparent) cells in two visual fields were counted in 
each of four wells.  
Tube formation assay. The surface of 24-well plates was coated with 250 µL of phenol-red 
free Matrigel (Becton Dickinson, Bedford, MA) per well and human aortic endothelial cells 
were seeded at 2 × 104 cells cm-2. Cells were grown in different conditions as indicated in the 
text. Four hours after seeding of the cells, 9 random phase-contrast digital images per 
treatment were taken with a digital camera (DS-Fi1, Nikon, Tokyo, Japan) using a 10 x 
objective lens. Tube-like structures were analyzed with ImageJ software 
(http://rsbweb.nih.gov/ij/) and the average tube length per field was calculated. 
 
I.4 Results and Discussion 
I.4.1 Screening for anti-pseudomonal compounds 
To identify novel anti-pseudomonal compounds, we conducted a medium-throughput 
screening of a small compound library comprising 23909 commercially available diverse 
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compounds. Overnight P. aeruginosa PA14 cultures (Table I.1) were diluted into fresh 1:20 
TSB and transferred to a 96-well plate containing a single compound per well at a final 
concentration of 20-50 µM. After 24 h of incubation at 37 °C with agitation, growth inhibition 
was evaluated by measuring culture turbidity. Compounds that caused > 90 % growth 
inhibition were selected and retested (fresh sample), after which the most promising 
compound, 1-(sec-butylamino)-3-(3, 6-dichloro-9H-carbazol-9-yl) propan-2-ol, designated as 
compound 1 (Figure I.1), was selected for further characterization.  
 
 
Figure I.1: Schematic structure of compound 1. 
 
I.4.2 Structure-activity relationship analysis 
In order to analyze the structural determinants important for pseudomonal growth inhibitory 
activity of 1, commercially available chemical analogues of 1 were obtained (compounds 2-8, 
Figure I.2). The MIC of these compounds was determined against P. aeruginosa grown in 
1:20 TSB (Table I.2). The lowest compound concentration resulting in the absence of 
bacterial growth was considered as the MIC. None of the tested analogs showed better 
antibacterial activity against P. aeruginosa compared to the original hit compound 1 (MIC of 
50 µM). The minimal bactericidal concentration (concentration resulting in absence of 
bacterial regrowth after dilution in Mueller-Hinton Broth (MHB)) of 1 against P. aeruginosa 
is 50 µM, indicating that this compound acts bactericidal.  
The MIC of 1 against a P. aeruginosa efflux mutant YM64 (Table I.1) lacking all four major 
mex operons for multidrug efflux pumps (Morita et al., 2001) is 12.5 µM, which is 
significantly lower as compared to its corresponding wild-type strain YM (MIC of 50 µM). 
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This result indicates that 1 probably has to cross the P. aeruginosa outer membrane to exert 
its action. 
 
Table I.2: Minimal inhibitory concentration (MIC) for N-alkylated 3, 6- dihalogeno-carbazoles against P. 
aeruginosa PA14 
 
 
 
 
 
 
 
 
Figure I.2: Schematic structure of N-alkylated 3, 6-dihalogenocarbazoles represented by numbers 2-8.  
 
I.4.3 Further characterization of 1 
I.4.3.1  Effect on P. aeruginosa clinical isolates 
The susceptibility of several clinical isolates obtained from CF and non-CF patients towards 1 
was tested. These strains were as susceptible towards 1 as the wild-type strain used in our 
Compound MIC (µM) 
1 50 
2 50-100 
3 >200  
4 50-100 
5 100-400 
6 50-200 
7 200-400 
8 50-100  
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study (Table I.3). In addition, isolates resistant towards specific clinically used antibiotics did 
not show cross-resistance towards 1. These results indicate that 1 is active against strains 
adapted to in vivo conditions, including antibiotic treatment regimes.  
 
Table I.3: Minimal inhibitory concentration (MIC) of 1 on P. aeruginosa clinical isolates obtained from cystic 
fibrosis (CF) and non-CF patients. These strains were kindly provided by Prof. Françoise van Bambeke 
(Université Catholique de Louvain).  
Clinical isolate Resistance profile*  MIC 1 (µM) 
 
  
Non-CF isolates   
PA08 ticarcillin 50-100 
PA53 ticarcillin 50 
PA129 piperacillin 50-100 
PA346 ticarcillin, piperacillin 50-100 
PA424 ticarcillin 50-100 
   
 
  
CF isolates   
PA1250 ticarcillin, cefepime 50 
PA1255 ticarcillin, piperacillin, ceftazidime, cefepime 50-100 
PA1256 / 25-50 
PA1270 / 50 
PA1271 ticarcillin 50-100 
*Based on EUCAST values. 
 
I.4.3.2  Effect on P. aeruginosa biofilms 
In vivo, P. aeruginosa is well known to form biofilms, multicellular structures of cells 
embedded in a self-produced extracellular matrix (Honda, 2011; Romling & Balsalobre, 
2012). The bacterial cells residing in these biofilms are significantly less susceptible to 
antibiotics and host defenses. This complicates treatment and often leads to chronic and 
recurrent infections (Costerton et al., 1999; Romling & Balsalobre, 2012). We assessed 
whether 1 is capable of preventing biofilm formation in vitro as described in Experimental 
procedures. The result shows that 1 completely prevents biofilm formation of P. aeruginosa at 
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50 µM (Table I.4). To further evaluate the effect of 1 on biofilm formation on clinically 
relevant implant material, the formation of P. aeruginosa biofilms on smooth titanium discs 
(10 mm diameter, 2 mm thick) in the presence of 1 was investigated. The results show that 1 
is capable of preventing biofilm formation of P. aeruginosa, already at a concentration of 10 
µM. The total area fraction, defined as the percentage of surface covered by bacteria, was 
reduced by approximately 50 % upon addition of 1. Biofilms formed on the titanium discs in 
the presence of 1 comprised a greater proportion of dead cells within the biofilm compared to 
the control experiment. This was most evident at the highest concentration of 1 (32.5 
µM)(Figure I.3). Taken together, these microscopy results clearly show that 1 prevents 
biofilm formation of P. aeruginosa on titanium discs.  
Next, we tested the capability of 1 to eradicate mature biofilms of P. aeruginosa grown on 
polystyrene pegs using the Calgary biofilm device. Treatment of biofilms with 12.5 µM or 
higher concentrations of 1 resulted in a drastic decrease of viable cells within the biofilm, 
which demonstrates the capability of 1 to eradicate biofilms (Figure I.4). These data suggest a 
biofilm-specific effect of 1 in P. aeruginosa. 
 
I.4.3.3  Effect on other pathogens 
The effect of 1 was subsequently evaluated on the inhibition of growth and biofilm formation 
of other clinically relevant bacteria listed in Table I.1. The MIC and MBIC values were 
determined as described above. E. coli, S. aureus and S. epidermidis were selected as they are 
frequently involved in biofilm-associated infections (Romling & Balsalobre, 2012). 
Additionally, the efficacy of 1 was evaluated on the obligate anaerobic pathogen P. gingivalis, 
which plays an important role in the initiation of periodontitis, a biofilm-associated infection 
of the gum eventually leading to tooth loss (Darveau et al., 2012). Results shown in Table I.4 
indicate that 1 is capable of inhibiting both planktonic and biofilm growth of other clinically 
important Gram-negative bacteria such as E. coli and P. gingivalis at concentrations well 
below those active against P. aeruginosa. Furthermore, 1 has a bacteriostatic and biofilm 
inhibitory effect on both Gram-positive S. aureus and S. epidermidis strains. The capability of 
1 to target a wide range of bacterial species makes it a potential starting point for the 
development of a novel broad-spectrum antibiotic. A previous, unrelated screening campaign 
identified 1 as a candidate antifungal (Thevissen et al., 2009). Growth-inhibiting activity 
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against bacterial as well as fungal pathogens could indicate that 1 targets an essential cellular 
process that is conserved among both prokaryotic and eukaryotic microbes. 
 
 
Figure I.3: CLSM analysis of biofilm inhibitory effect of 1. A. Representative CLSM micrographs of P. 
aeruginosa treated with 1. The extent of the titanium surface that is covered by bacteria in a thin optical 
section at full width half maximum is shown after treatment with 0 and 32.5 µM of 1. Live cells were stained 
with CYTO
®
9 (green) and dead cells were stained with propidium iodide (red). Scale bar = 5 µm. Each sample 
was analyzed in triplicate. B. Compound 1 reduces the total area fraction and proportion of viable cells of P. 
aeruginosa biofilms covering titanium discs. After 19 h of growth in the presence of compound 1 (0, 10 and 
32.5 µM), the discs were analyzed with CLSM. The proportion of viable (black) and dead (light grey) cells is 
indicated in the graphs. This experiment was repeated independently 3 times, error bars represent standard 
error of the mean (SEM).  
 
 
 
Figure I.4: Compound 1 eradicates P. aeruginosa biofilms. 24 h old biofilms of P. aeruginosa were subjected to 
a 24 h treatment with different concentrations of 1. Subsequently, biofilm cells were disrupted by sonication, 
diluted and plated out after which the number of surviving cells was determined. This experiment was 
repeated independently three times, error bars represent SEM. The number of CFU peg
-1
 in the control sample 
was normalized to 100 % and corresponds to 4.62 x 10
5
. The relative number of CFU peg
-1
 is indicated above 
each bar. 
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Table I.4: Minimal inhibitory concentration (MIC) and minimal biofilm inhibitory concentration (MBIC) of 1 
against P. aeruginosa, E. coli, S. aureus, S. epidermidis and P. gingivalis strains 
Strain MIC 1 (µM) MBIC
 
1
 
(µM) Growth medium 
P.aeruginosa     
   PA14 50  50 1:20 TSB 
YM 50 NDa 1:20 TSB 
    YM64 12.5 NDa 1:20 TSB 
E. coli TG1 12.5 6b  1:20 TSB 
S. aureus SH1000 25 25  MHB 
S. epidermidis RP62A 25  25 MHB 
P. gingivalis ATCC 33277 12.5  13.8b  1:20 TSB 
aND: not determined; bMBIC90  
 
I.4.4 Effect of 1 on cell viability 
As limited human cellular toxicity is an important feature for a compound with such a broad 
spectrum of action, the toxicity of 1 was evaluated on several human cell types. While two 
hours of exposure to 12.5 µM of 1 resulted in > 80 % viability for osteoblasts and 
mesenchymal stem cells, these conditions were lethal to microvascular endothelial cells (data 
not shown). However, the tube formation potential of aortic endothelial cells was not 
negatively affected (Figure I.5), indicating that more differentiated endothelial cells in the 
tube-assembled stage are less susceptible to the potential toxic effects of 1 compared to 
endothelial cells in the non-assembled stage in monolayer culture. The observed difference 
could also be due to the use of different types of endothelial cells in the two assays, as 
endothelial cells from different sources are functionally different and could therefore behave 
differently. Moreover, various carbazoles have previously been shown to possess low cellular 
toxicity at 80-100 µM (Sunthitikawinsakul et al., 2003), pointing to the possibility to further 
develop 1 into a non-toxic novel antipseudomonal biofilm drug and a broad-spectrum 
antibacterial and antifungal agent. 
 
I.5 Conclusion 
We identified 1, a non-toxic N-alkylated 3, 6-dihalogenocarbazol displaying anti-
pseudomonal activity both on planktonic and biofilm cultures. Furthermore, 1 inhibits growth 
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of several other clinically important pathogens making 1 an interesting starting point for 
development of a broad-spectrum agent. 
 
 
Figure I.5: Tube formation potential of endothelial cells is not affected by 1. Human endothelial cells were 
cultured in M200 medium with low serum growth supplement (ENDO) in the presence of 0.5 % dimethyl 
sulfoxide (DMSO) (control treatment), 0.05 % phenol (positive cytotoxic control) or 12.5 µM of 1 for 4 hours. A. 
Representative photographs and. B. average tube length are shown for each condition. The average tube 
length is not inhibited by 1, whereas 0.05 % phenol causes negative effect on tube formation (* P < 0.05).  
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Appendix A 
Optimization of DnpA overexpression for large-scale 
purification 
 
A.1 Introduction  
Based on its deduced amino acid sequence, DnpA is a member of the PIG-L or LmbE-like 
superfamily (Pfam PF02585). All eukaryotic members studied so far play a role in the 
synthesis of glycosylphosphatidylinositol, a glycolipid that anchors proteins at the cell surface 
(Nakamura et al., 1997; Sharma et al., 1997; Smith et al., 1997; Watanabe et al., 1999; Viars 
et al., 2014). In bacteria, characterized PIG-L members are involved in different unrelated 
pathways as discussed in Chapter 4. These proteins share a catalytic site containing a number 
of conserved residues that are essential for enzymatic activity. Multiple sequence alignment of 
DnpA and all biochemically characterized members of this PIG-L family reveals that the 
critical residues of the active site are intact in DnpA. Therefore, we predict that DnpA acts as 
a de-N-acetylase, probably acting on N-acetylglucosamine residues of a yet unknown 
substrate. Evaluation of the persistence effect of mutant dnpA alleles, predicted to completely 
lack de-N-acetylase activity, led to contradictory results. Therefore, in order to answer the 
question if the predicted de-N-acetylase activity of DnpA is important in fluoroquinolone 
tolerance, data on biochemical activity are needed. For in vitro experiments, high amounts of 
purified DnpA are needed. In this Chapter, we describe the optimization of conditions for 
DnpA overexpression.  
 
A.2 Experimental procedures 
Strains and growth conditions. Escherichia coli strains were cultured in Luria-Bertani (LB) 
broth at 37 °C, for solidified medium 1.5 % agar was added. Following antibiotics were used: 
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kanamycin (45 µg mL-1) and chloramphenicol (35 µg mL-1). Strains and plasmids used in this 
study are listed in Table A.1.  
 
Table A.1: Plasmids and strains used in this Chapter 
Strain or plasmid  Description*  Reference/source 
Strains   
E. coli TOP10 F-mcrA ∆(mrr-hsdRMS-mcrBC) 
ϕ80lacZ∆M15 ∆lacX74 deoR recA1 
araD139 ∆(ara-leu)7697 galU galK 
Invitrogen 
E. coli BL21–Codon Plus (DE3)-RP F– ompT hsdS(rB– mB–) dcm+ TetR gal 
λ(DE3) endA Hte [argU proL CmR]  
 
Stratagene 
E. coli ROSETTA 2(DE3)pLysS F- ompT hsdSB(rB- mB-) gal dcm (DE3) 
pLysSRARE2 (CmR) 
Novagen 
 
  
Plasmids   
pET24a(+) pBR322, T7 promotor, KmR, C-terminal 
His6-tag 
Novagen 
pET28a(+) pBR322, T7 promotor, KmR, N-terminal 
His6-tag 
Novagen 
pET24a(+)-dnpA-N pET plasmid encoding N-terminal His6-
tagged DnpA 
This work 
pET24a(+)-dnpA-NT pET plasmid encoding truncated (AA 1-
43) N-terminal His6-tagged DnpA 
This work 
pET28a(+)-dnpA-C pET plasmid encoding C-terminal His6-
tagged DnpA 
This work 
pET28a(+)-dnpA-CT pET plasmid encoding truncated (AA 1-
43) C-terminal His6-tagged DnpA 
This work 
*TetR: tetracycline resistance; CmR: chloramphenicol resistance; KmR: kanamycin resistance 
 
Construction of His6-tagged DnpA. For optimization of expression, plasmids encoding 
different forms of His6-tagged DnpA were constructed. For the construction of N-terminal 
His6-tagged DnpA, amplification was carried out by using primer couples SPI5285-5286, 
SPI5285-5287 with purified genomic DNA as a template. The PCR fragments were XhoI-
HindIII cloned into pET28a(+), in frame with the His6-tag present in this plasmid. 
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Construction of C-terminal His6-tagged DnpA was achieved by using primer couples 
SPI5367-5369 and SPI5368-5369. The resulting PCR fragments were cloned into pET24a(+) 
using XhoI-HindIII, in frame with the His6-tag present on the plasmid. Primers SPI5367 and 
SPI5368 contain a start codon and a ribosome binding site (RBS). All constructs were 
confirmed by sequencing. Subsequently, the plasmids were introduced into E. coli BL21–
Codon Plus (DE3)-RP by means of transformation. For sequences of the primers see Table 
A.2.  
 
Table A.2: Primers used in this Chapter 
Primer name Sequence* Description 
SPI5285 CACCAAGCTTGCGCACGCAAGCAG Reverse primer for construction of N-
terminal His6-tagged dnpA 
SPI5286 ACTCCTCGAGTCACGCCTCCCCAT Forward primer for construction of full 
length N-terminal His6-tagged dnpA 
SPI5288 CACCAAGCTTTGGCCCTGTGGGTC 
 
Reverse primer for construction of 
truncated N-terminal His6-tagged dnpA 
SPI5367 ACTCAAGCTTAATAATTTTGTTTAA
CTTTAAGAAGGAGATATACATATG
AGCGCACGCAAGCAGCAGTTGCTC
AAGCGTCATCGACGC 
Reverse primer for construction of full 
length C-terminal His6-tagged dnpA. 
Contains RBS and a start codon. 
SPI5368 ACTCAAGCTTAATAATTTTGTTTAA
CTTTAAGAAGGAGATATACATATG
GTGGCCCTGTGGGTCGCCCACGAA
GCC 
Reverse primer for construction of 
truncated C-terminal His6-tagged dnpA. 
Contains RBS and a start codon. 
SPI5369 CACCCTCGAGCGCCTCCCCATCCA
GCGACTC 
Forward primer for construction of C-
terminal His6-tagged dnpA 
*Restriction sites are indicated in bold; the start codon is underlined 
 
Purification of total protein fraction on small scale. Overnight cultures were diluted 100-
fold into LB medium and incubated at 37 °C while shaking at 200 rpm. After three hours of 
growth, cultures were induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 
the indicated time after which 1 mL of culture was harvested by centrifugation (13 000 rpm, 1 
minute, 4 °C). The resulting cell pellet was stored overnight at – 80 °C. The next day, the 
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pellet was resuspended in native lysis buffer (10 mM imidazole, 50 mM NaH2PO4, 300 mM 
NaCl, pH 8.0) and treated with lysozyme for 30 minutes. Soluble proteins were separated 
from the cell debris by centrifugation (13 000 rpm, 10 minutes, 4 °C). The remaining pellet 
was resuspended in an isovolume of denaturating lysis buffer (100 mM NaH2PO4, 10 mM 
Tris/HCl, 8 M Urea, pH 8.0). The presence of DnpA-His6 in each fraction was analyzed by 
western hybridization. 
Purification of total protein fraction on large scale. Overnight cultures were diluted 100-
fold into LB medium and incubated at 37 °C while shaking at 200 rpm. After three hours of 
growth, cultures were induced with 1 mM IPTG overnight at 22 °C. Thereafter, the cells were 
harvested by centrifugation (4750 rpm, 20 minutes, 4 °C). The resulting cell pellet was stored 
overnight at – 80 °C. Next, the pellet was resuspended in native lysis buffer and treated with 
lysozyme (Sigma) for 30 minutes at 37 °C. To increase yields, cells were further disrupted by 
means of sonication. Next, samples were treated with Benzonase Nuclease (Sigma) in order to 
digest nucleic acids. Finally, proteins were separated from cell debris by centrifugation (9250 
rpm, 25 minutes, 4 °C). The presence of DnpA-His6 was verified by western hybridization. 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis analysis (SDS-PAGE) 
analysis. An aliquot of each protein sample was mixed with NuPAGE LDS Sample Buffer 
and Reducing Agent and incubated at 70 °C for 10 minutes. The samples were loaded onto a 
NuPAGE Novex 12 % Bis-Tris MiniGel (Invitrogen), using a MOPS-based  running buffer 
(50 mM MOPS, 50 mM Tris, 1 mM EDTA, 0.1 % SDS (w/v), pH 7.7). Visualization of the 
proteins was carried out by incubating the protein gel in a Coomassie blue solution for 30 
minutes, followed by a destaining procedure (destaining solution: 45 % methanol (v/v), 7 % 
acetic acid (v/v)) until the desired background was reached.  
Western blotting and hybridization. Proteins were transferred from a NuPAGE Novex 12 
% Bis-Tris MiniGel (Invitrogen) to a polyvinylidene fluoride membrane using an XCell II 
Blot Module (Invitrogen) using CAPS buffer (10 mM CAPS, 10 % methanol (v/v), pH 11.0) 
as a transfer buffer. Successful transfer was verified by Coomassie blue staining of the protein 
gel. Western hybridization was performed using a monoclonal anti-His6 antibody solution 
(Roche) and Anti-Mouse IgG Alkaline Phosphatase Conjugated antibodies (Sigma) as a 
primary and secondary antibody, respectively.  
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A.3 Results 
A.3.1 Optimization of DnpA overexpression using E. coli BL21–Codon Plus (DE3)-
RP as a host strain 
To optimize overexpression of DnpA, small-scale experiments were carried out. DnpA is 
predicted to possess a single transmembrane helix which anchors the protein into the bacterial 
inner membrane (see Chapter 5). Therefore, in addition to the full length allele, a truncated 
version which lacks the first 43 N-terminal amino acids was constructed, including part of the 
predicted transmembrane domain. For each of these alleles, two different forms were 
constructed. One of them contains an N-terminal His6-tag, the other one is C-terminally 
tagged with His6. For these experiments, E. coli BL21–Codon Plus (DE3)-RP was used as a 
host strain. This strain contains extra copies of genes encoding tRNAs that recognize the 
arginine codons AGA and AGG and the proline codon CCC, respectively. Translation of 
heterologous proteins from GC-rich genomes such as Pseudomonas aeruginosa is most 
frequently restricted by these tRNAs.22 
Overnight cultures were diluted 100-fold into LB medium and incubated at 37 °C while 
shaking at 200 rpm. After three hours, cells were induced with 1 mM IPTG during 1, 2, 3 and 
4 hours at 22 °C. Next, cells were harvested by centrifugation after which the total protein 
fraction was purified as described in Experimental procedures. As shown in Figure A.1 most 
His6-tagged protein was detected in the soluble fraction when overexpressing the allele 
encoding full length DnpA containing a C-terminal His6-tag. Therefore, further optimization 
was carried out using the pET28a(+)-dnpA-C construct.  
To increase the amount of DnpA in the soluble fraction, induction at 16 °C was tested. In 
addition, phenylmethylsulfonyl fluoride was added to all lysis buffers to prevent protein 
degradation by proteases. As a control, an E. coli strain overexpressing the obgE-venus-His6 
allele was taken along in these experiments. ObgE-Venus-His6 is known to occur both in the 
soluble and insoluble fraction, but sufficient amount of the protein is present in the soluble 
fraction to ensure successful purification (Natalie Verstraeten, personal communication). 
Overnight cultures were diluted 100-fold into LB medium and incubated at 37 °C while 
shaking at 200 rpm. After three hours, cells were induced with 1 mM IPTG during 4, 8, 52 
                                               
22
 www.genomics.agilent.com/article.jsp?pageId=484 
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and 68 hour at 16 °C. Next, cells were harvested by centrifugation after which the total 
protein fraction was purified as described in Experimental procedures. Equal volumes of all 
protein samples were loaded on the protein gel. As shown in Figure A.2, DnpA is mostly 
present in the insoluble fraction.  
 
 
Figure A.1: Detection of DnpA-His6 after overexpression in E. coli BL21–Codon Plus (DE3)-RP cells. Western 
hybridization analysis of soluble and insoluble total protein fractions after 1, 2, 3 and 4 hours of induction of E. 
coli BL21–Codon Plus (DE3)-RP cells overexpressing A. full length N-terminal His6-tagged DnpA (theoretical MW 
of 57.67 kDa) B. truncated N-terminal His6-tagged DnpA (theoretical MW of 52.94 kDa) C. full length C-terminal 
His6-tagged DnpA (theoretical MW of 54.51 kDa) and D. truncated C-terminal His6-tagged DnpA (theoretical 
MW of 49.78 kDa). Equal volumes of each fraction were evaluated. Analysis was carried out with an anti-His6 
primary antibody. Lane 1: Precision Plus Protein Kaleidoscope Standards (Bio-Rad); lane 2, 4, 6 and 8: insoluble 
protein fraction; lane 3, 5, 7 and 9: soluble protein fraction after 1, 2, 3 and 4 hours of induction respectively. 
For clarity, the order of the lanes of protein gels B and C was switched. 
 
 
 
Figure A.2: Detection of DnpA-His6 and ObgE-Venus-His6 after overexpression in E. coli BL21–Codon Plus 
(DE3)-RP cells. Western hybridization analysis of soluble and insoluble total protein fractions after 4, 28, 52 and 
68 hours of induction of E. coli BL21–Codon Plus (DE3)-RP cells overexpressing full length C-terminal His6-
tagged DnpA (theoretical MW of 54.51 kDa) or ObgE-Venus-His6 (theoretical MW of 75.48 kDa). Equal volumes 
of each fraction were evaluated. Analysis was carried out with an anti-His6 primary antibody. Lane 1 & 10: 
Precision Plus Protein Kaleidoscope Standards (Bio-Rad); lane 2, 6, 11 and 15 represent insoluble protein 
fractions; lane 3,7, 12 and 16 represent soluble protein fractions after 4, 28, 52 and 68 hours induction of full 
length ObgE-Venus-His6 respectively; lane 4, 8, 13 and 17 represent insoluble protein fractions; lane 5,9, 14 and 
18 represent soluble protein fractions after 4, 28, 52 and 68 hours induction of full length C-terminal His6-
tagged DnpA respectively. For clarity, the order of the lanes of the first protein gel was switched.  
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A.3.2 Optimization of DnpA overexpression using E. coli ROSETTA 2(DE3) pLysS 
as a host strain 
When checking the dnpA nucleotide sequence for rare codons23 (Clarke & Clark, 2008), it 
was observed that 1 – 7 % of the gene contains uncommon codons, which could significantly 
influence expression. Therefore, expression of dnpA was checked in an E. coli ROSETTA 2 
(DE3) pLysS host strain. This strain contains tRNAs for seven rare codons (AGA, AGG, 
AUA, CUA, GGA, CCC, and CGG), encoded on a compatible chloramphenicol-resistant 
plasmid. In addition, this strain harbors the plasmid pLysS which expresses T7 lysozyme. 
This enzyme further suppresses basal expression of T7 RNA polymerase prior to induction. In 
this way, cells that harbor plasmids encoding a protein that affects cell growth and viability 
are stabilized.24 Additionally, since dnpA encodes a hypothetical inner membrane protein (see 
Chapter 5), overexpression of DnpA possibly destabilizes the inner membrane of the cell. 
Therefore, a very short induction time of 0.5 hours was tested.  
Overnight cultures were diluted 100-fold into LB medium and incubated at 37 °C while 
shaking at 200 rpm. After three hours, cells were induced with 1 mM IPTG during 0.5, 1, 4, 
20 and 28 hours at 16 °C. Total protein fraction was purified as described in Experimental 
procedures. DnpA-His6 was not detected after 0.5 hour of induction, indicating that 
incorporation of DnpA-His6 in the membrane does not significantly affect membrane stability. 
An induction time of 20 hours resulted in the highest amount of DnpA present in the soluble 
fraction (Figure A.3A).  
The three other constructs containing the truncated C- and N-terminal His6-tagged dnpA 
alleles (encoding DnpA-CT and DnpA-NT respectively) and the full length N-terminal His6-
tagged dnpA allele (encoding DnpA-N), were tested for expression under these optimized 
conditions. The corresponding plasmids were introduced into the E. coli ROSETTA 2(DE3) 
pLysS host strain by transformation. Next, expression was evaluated after 20 hours of 
induction at 22 °C. In addition, to evaluate if DnpA-His6 can be purified from the total soluble 
protein fraction by its His6-tag, the “QuickPickTM IMAC” Kit (Bio-Nobile Oy) was used. This 
technique allows purification of His6-tagged proteins on a small scale by means of metal 
affinity. The results, presented in Figure A.3B, show that only overexpression of the allele 
                                               
23
 www.codons.org and www.genscript.com 
24
 www.emdmillipore.com 
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encoding full length C-terminal His6-tagged DnpA results in detectable soluble protein. 
Overexpression of the other dnpA alleles did not yield detectable His6-tagged protein in any of 
the protein fractions, with the exception of a low amount of DnpA-NT present in the insoluble 
fraction. Furthermore, Figure A.3C shows that the His6-tag of DnpA-C-His6 is accessible, 
allowing purification by means of metal affinity.  
These results suggest that the predicted transmembrane helix does not cause any problems 
during overexpression of dnpA. This is in accordance with earlier published data on the PIG-L 
protein from Rattus norvegicus. This protein, which also contains a transmembrane domain, 
was proven to be functional upon overexpression and purification using E. coli host cells 
(Watanabe et al., 1999).  
 
 
 
Figue A.3: Evaluation of overexpression dnpA in E. coli ROSETTA 2(DE3)pLysS cells. A. Western hybridization 
analysis of soluble total protein fractions after 0.5, 1, 4, 20 and 28 hours of induction of E. coli ROSETTA 
2(DE3)pLysS cells overexpressing full length C-terminal His6-tagged DnpA (theoretical MW of 54.51 kDa). Equal 
volumes of each sample were analyzed. Lane 1: Precision Plus Protein Kaleidoscope Standards (Bio-Rad); lane 
2-6 represent soluble protein fractions after 0.5, 1, 4, 20 and 28 hours induction of full length C-terminal His6-
tagged DnpA, respectively. B. Western hybridization analysis of soluble and insoluble total protein fractions 
after 20 hours of induction of E. coli ROSETTA 2(DE3)pLysS cells overexpressing full length N-terminal His6-
tagged DnpA (DnpA-N), truncated N-terminal His6-tagged DnpA (DnpA-NT), full length C-terminal His6-tagged 
DnpA (DnpA-C, theoretical MW of 54.51 kDa) and truncated C-terminal His6-tagged DnpA (DnpA-CT). Equal 
volumes of each fraction were analyzed. Analysis was carried out with an anti-His6 primary antibody. Lane 5: 
Precision Plus Protein Kaleidoscope Standards (Bio-Rad); lane 1, 3, 6 and 8 represent soluble protein fractions; 
lane 2, 4, 7 and 9 represent insoluble fractions after overexpression of dnpA-N, dnpA-NT, dnpA-C and dnpA-CT 
respectively. C. Coomassie blue staining of total soluble protein fractions (lane 1, 3, 6 and 8) and proteins 
purified by metal affinity chromatography (lane 2, 4, 7 and 9) separated by SDS-PAGE after overexpression of 
dnpA-N, dnpA-NT, dnpA-C and dnpA-CT respectively. Lane 5: Precision Plus Protein Kaleidoscope Standards 
(Bio-Rad). 
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A.3.3 Large-scale purification of DnpA-His6 
Next, full length C-terminal His6-tagged DnpA was purified on large scale by using high 
pressure liquid chromatography (HPLC) affinity chromatography using an ÄKTApurifier (GE 
healthcare). Total protein fractions were isolated as described in Experimental procedures and 
loaded onto a HisTrap HP column, washed (wash buffer: 20 mM imidazole, 50 mM 
NaH2PO4, 300 mM NaCl, pH 8.0) and bound recombinant proteins were eluted by 
competition with imidazole (elution buffer: 250 mM imidazole, 50 mM NaH2PO4, 300 mM 
NaCl, pH 8.0). Further purification was carried out by gel filtration using a HiLoad 16/60 
Superdex 200 pg column (GE Healthcare) in a 50 mM NaCl 20 mM Tris buffer (pH 7.2). 
Despite the presence of DnpA-His6 in the soluble protein fraction, it was not possible to retain 
the protein by size exclusion chromatography. Therefore, protein fractions belonging to each 
independent step throughout the purification process were evaluated for the presence of 
DnpA-His6 by western hybridization (Figure A.4). The result shows that DnpA-His6 is present 
in the soluble protein fraction but elutes with the void volume during gel filtration. In 
addition, there was significant loss of DnpA-His6 during the different washing steps. To 
optimize the purification process, a collaboration was started with Prof. Wim Versées 
(Structural Biology Brussels, Vrije Universiteit Brussels, Belgium; Department of Molecular 
and Cellular Interactions, VIB, Belgium). However, no conditions were found that allowed 
successful purification of DnpA-His6.  
 
 
 
Figure A.4: A. Coomassie blue stained protein gel and B. western hybridization of the different protein fractions 
during the isolation and purification process of DnpA-His6 by means of Ni
2+
-chelation HPLC affinity 
chromatography followed by size exclusion chromatography (SEC). Lane 1: Precision Plus Protein Kaleidoscope 
Standards (Bio-Rad); Lane 2-7: total soluble protein fraction, void volume, washing step 1, washing step 2,  
eluate and void volume of SEC, respectively.   
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A.3.4 Optimization of DnpA overexpression using additional truncated constructs 
Meanwhile, the topology of DnpA was determined (see Chapter 5). Based on these results, 
additional alleles encoding His6-tagged DnpA lacking the first 60 and 178 amino acids, 
respectively, were tested. These truncated dnpA alleles were constructed and evaluated by the 
research group of Prof. Wim Versées (Structural Biology Brussels, Vrije Universiteit 
Brussels, Belgium; Department of Molecular and Cellular Interactions, VIB, Belgium). No 
expression was observed using the plasmid encoding DnpA-N178, while low expression was 
obtained with the plasmid encoding DnpAN60 (data not shown) (Wim Versées, personal 
communication).  
 
A.4 Conclusion  
In this Chapter, we optimized conditions for DnpA overexpression using different host strains 
and dnpA alleles. Good expression was obtained with the full length C-terminal His6-tagged 
DnpA. However, during large scale purification, the protein eluted with the void volume 
during gel filtration. Several other forms of DnpA, lacking one or two transmembrane 
segments, were constructed and tested. One of those forms, DnpAN60, showed promising 
results although further optimization is needed to increase expression levels.  
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Table B.1: Effect of compounds that in combination with ofloxacin increase the number of surviving cells. The 
number of cells upon treatment was determined based on the correlation between the number of cells and the 
duration of the lag phase after dilution of the treated cells into fresh growth medium. The relative fold increase 
in surviving cells was calculated as described in Chapter 6. The experiment was repeated independently three 
times.  
Plate  Well Relative fold increase in surviving cells  SEM* 
208 C2 263.82 23.52 
182 D10 4.40 0.54 
171 F5 5.57 0.40 
141 G10 665.96 263.56 
84 F3 89.98 21.14 
81 H2 60.10 19.41 
81 F6 15.78 3.28 
80 G1 83.25 8.09 
80 B1 14.50 3.93 
79 C2 15.70 11.36 
75 B4 500.11 60.17 
70 A2 2.52 0.51 
65 F10 11.09 1.22 
56 D2 11.16 2.91 
56 E2 5.61 0.53 
55 E6 83.14 15.54 
51 G2 10.11 3.06 
50 A10 3.56 0.70 
50 D10 3.54 0.85 
15 D7 6.16 0.45 
13 A3 4.45 1.00 
4 H6 134.75 21.98 
4 F10 113.36 11.24 
3 D5 11.81 1.33 
*SEM, standard error of the mean 
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Figure B.1: Bactericidal effect of chemical analogues (continued).  
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Continued Figure B.1: Bactericidal effect of chemical analogues (continued). 
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Continued Figure B.1: Bactericidal effect of chemical analogues (continued). 
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Continued Figure B.1: Bactericidal effect of chemical analogues. Stationary phase cells were treated for 5 
hours with compound (0.78 – 200 µM). After treatment, samples were 100-fold diluted into fresh Trypticase 
Soy Broth (TSB) growth medium and incubated in an automated plate reader in order to obtain separate 
growth curves for each sample. Based on the duration of the lag phase of each individual growth curve, the 
number of surviving cells was estimated. Data points represent the relative reduction in number of cells 
compared to treatment with only DMSO.   
Appendix B                                                                                                 Additional Tables and Figures 
196 
 
 
 
 
 
 
Figure B.2: Effect on persistence of all chemical analogues (continued) 
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Continued Figure B.2: Effect on persistence of all chemical analogues (continued).  
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Continued Figure B.2: Effect on persistence of all chemical analogues (continued). 
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Continued Figure B.2: Effect on persistence of all chemical analogues in combination with ofloxacin. 
Stationary phase cells were treated for 5 hours with a combination of ofloxacin (10 µg mL-1) and compound 
(0.78 – 200 µM). After treatment, samples were 100-fold diluted into fresh TSB growth medium and incubated 
in an automated plate reader in order to obtain separate growth curves for each sample. Based on the duration 
of the lag phase of each individual growth curve, the number of surviving cells was estimated. Data points 
represent the relative reduction in number of cells compared to treatment with only ofloxacin.   
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Figure B.3: Bactericidal effect of selected analogues on stationary phase cultures. Stationary phase cells were 
treated for 5 hours with compound (0 – 200 µM). After treatment, samples were diluted and plated on solid 
growth medium in order to determine the number of viable cells. Data points represent the relative decrease in 
viable cells.  
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Figure B.4: Effect of SPI001 in combination with selected Biolog compounds (continued) 
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Continued Figure B.4: Effect of SPI001 in combination with selected Biolog compounds. Stationary phase cells 
of YM64 were treated overnight with a combination of 50 µM SPI001 and four different concentrations of 
Biolog compound (depicted by [1]-[4]). After treatment, cells were 100-fold diluted into fresh growth medium 
and regrowth was monitored by measuring optical density at fixed time points. 
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